

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/79289 A2

- (51) International Patent Classification⁷: **C07K 14/555**
- (21) International Application Number: **PCT/US01/12191**
- (22) International Filing Date: **13 April 2001 (13.04.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/198,889 **14 April 2000 (14.04.2000)** **US**
- (71) Applicant: **ZYMOGENETICS, INC.** [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (72) Inventors: **THAYER, Edward, C.**; 9701 Sand Point Way NE, #101, Seattle, WA 98115 (US). **HOLLOWAY, James, L.**; 835 Northeast 89th Street, Seattle, WA 98115 (US).
- (74) Agent: **ADAMS, Robyn**; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **HUMAN INTERFERON, ZINF2**

(57) Abstract: Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. To date, five types of interferons have been found in humans: interferon- α , interferon- β , interferon- γ , interferon- ω , and interferon- ϵ . The present invention provides a new form of human interferon, "Zinf2," which has applications in diagnosis and therapy.

WO 01/79289 A2

HUMAN INTERFERON, ZINF2

5

TECHNICAL FIELD

The present invention relates generally to a new cytokine having diagnostic and therapeutic uses. In particular, the present invention relates to a novel
10 interferon, designated "Zinf2," and to nucleic acid molecules encoding Zinf2.

BACKGROUND OF THE INVENTION

Cellular differentiation of multicellular organisms is controlled by
15 hormones and polypeptide growth factors. These diffusable molecules allow cells to communicate with each other and act in concert to form tissues and organs, and to repair and regenerate damaged tissue. Examples of hormones and growth factors include the steroid hormones, parathyroid hormone, follicle stimulating hormone, the interferons, the interleukins, platelet derived growth factor, epidermal growth factor,
20 and granulocyte-macrophage colony stimulating factor, among others.

Hormones and growth factors influence cellular metabolism by binding to receptor proteins. Certain receptors are integral membrane proteins that bind with the hormone or growth factor outside the cell, and that are linked to signaling pathways within the cell, such as second messenger systems. Other classes of receptors are
25 soluble intracellular molecules.

Of particular interest, from a therapeutic standpoint, are the interferons (reviews on interferons are provided by De Maeyer and De Maeyer-Guignard, "Interferons," in *The Cytokine Handbook*, 3rd Edition, Thompson (ed.), pages 491-516 (Academic Press Ltd. 1998), and by Walsh, *Biopharmaceuticals: Biochemistry and*
30 *Biotechnology*, pages 158-188 (John Wiley & Sons 1998)). Interferons exhibit a variety of biological activities, and are useful for the treatment of certain autoimmune diseases, particular cancers, and the enhancement of the immune response against infectious agents, including viruses, bacteria, fungi, and protozoa. The scientific literature reports

six forms of interferon, which have been classified into two major groups. The so-called "type I" interferons include interferon- α , interferon- β , interferon- ω , interferon- δ , and interferon- τ . Recently, a new form of Type I interferon, interferon- ϵ , was discovered. Illustrative human interferon- ϵ proteins comprise the amino acid sequences of SEQ ID NOs:8 and 9. Currently, interferon- γ and one subclass of interferon- α are the only type II interferons.

Type I interferons are thought to be derived from the same ancestral gene, and the type I interferons have retained sufficient similar structure to act by the same cell surface receptor. The α -chain of the human interferon- α/β receptor comprises an extracellular N-terminal domain, which has the characteristics of a class II cytokine receptor. Interferon- γ does not share significant homology with the type I interferons or with the type II interferon- α subtype, but shares a number of biological activities with the type I interferons.

In humans, at least 16 non-allelic genes code for different subtypes of interferon- α , while interferons β and ω are encoded by single genes. Type I interferon genes are clustered in the short arm of chromosome 9. Unlike typical structural human genes, interferon- α , interferon- β , and interferon- ω lack introns. A single gene for human interferon- γ is localized on chromosome 12 and contains three introns. To date, interferon- τ has been described only in cattle and sheep, while interferon- δ has been described only in pigs.

It is believed that all cells may be capable of producing interferons α and β in response to viral infection, double-stranded RNA molecules, growth factors, and cytokines. Normally, however, interferon- α is produced by lymphocytes, macrophages, and monocytes, while interferon- β is synthesized by fibroblasts and some epithelial cells. Interferon- γ is produced by T cells or natural killer cells.

Clinicians are taking advantage of the multiple activities of interferons by using the proteins to treat a wide range of conditions. For example, one form of interferon- α has been approved for use in more than 50 countries for the treatment of medical conditions such as hairy cell leukemia, renal cell carcinoma, basal cell carcinoma, malignant melanoma, AIDS-related Kaposi's sarcoma, multiple myeloma, chronic myelogenous leukemia, non-Hodgkin's lymphoma, laryngeal papillomatosis, mycosis fungoides, condyloma acuminata, chronic hepatitis B, hepatitis C, chronic hepatitis D, and chronic non-A, non-B/C hepatitis. The U.S. Food and Drug Administration has approved the use of interferon- β to treat multiple sclerosis, a chronic disease of the nervous system. Interferon- γ is used to treat chronic granulomatous diseases, in which the interferon enhances the patient's immune response to destroy infectious bacterial, fungal, and protozoal pathogens. Clinical

studies also indicate that interferon- γ may be useful in the treatment of AIDS, leishmaniasis, and lepromatous leprosy.

Although new uses of known interferons may be discovered, a need exists for the provision of new interferons for biopharmaceuticals.

5

BRIEF SUMMARY OF THE INVENTION

The present invention provides a novel interferon, designated "Zinf2." The present invention also provides Zinf2 polypeptides and Zinf2 fusion proteins, nucleic acid molecules encoding such polypeptides and proteins, and methods for using these amino acid and nucleotide sequences.

10

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 is an alignment of the amino acid sequences of the present invention (SEQ ID NO:2 and SEQ ID NO:5) with other interferon amino acid sequences.

15

DESCRIPTION OF THE INVENTION

1. Overview

Prior to the discovery of the novel interferon described herein, the interferon family was believed to be comprised of seven broad classes of molecules. The alpha, omega, beta, delta, and epsilon interferons are all highly related in sequence, while the gamma class is not. Functionally, interferons are characterized by their anti-viral and anti-proliferative responses in cells.

20

Based upon sequence analysis, Zinf2 is proposed to be a member of a distinct class of the Type I interferons. A nucleic acid molecule containing a sequence that encodes a membrane bound Zinf2 has the nucleotide sequence of SEQ ID NO:1. The encoded polypeptide has the amino acid sequence as shown in SEQ ID NO:2. A nucleic acid molecule containing a sequence that encodes a soluble Zinf2 has the nucleotide sequence of SEQ ID NO:4. The encoded polypeptide has the amino acid sequence as shown in SEQ ID NO:5.

25

Thus, the nucleotide sequences of SEQ ID NOs:1 and 4 encode a polypeptide of 198 and 180 amino acids, respectively, as shown in SEQ ID NOs:2 and 5. The signal sequence for Zinf2 can be predicted as comprising amino acid residues 1 to 24 of SEQ ID NOs:2 and 5. A monomer of Zinf2 will have a predicted molecular weight of approximately 23 kD. A homodimer of Zinf2 will have a molecular weight

30
35

stringent wash conditions to a nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of: nucleotides 88 to 594 of SEQ ID NO:1, nucleotides 1 to 594 of SEQ ID NO:1, nucleotides 88 to 540 of SEQ ID NO:4, nucleotides 1 to 540 of SEQ ID NO:4, or the complement thereof. Such nucleic acid molecules include those in which any difference between the amino acid sequence encoded by the nucleic acid molecule and the corresponding amino acid sequence of either SEQ ID NO:2 is due to a conservative amino acid substitution.

The present invention further provides isolated nucleic acid molecules, comprising the nucleotide sequence of nucleotides 88 to 594 of SEQ ID NO:1, isolated nucleic acid molecules comprising the nucleotide sequence of nucleotides 1 to 594 of SEQ ID NO:1, isolated nucleic acid molecules comprising the nucleotide sequence of nucleotides 88 to 540 of SEQ ID NO:4, isolated nucleic acid molecules comprising the nucleotide sequence of nucleotides 1 to 540 of SEQ ID NO:4, and isolated nucleic acid molecules comprising the nucleotide sequence of SEQ ID NOs:1 or 4.

The present invention also provides vectors and expression vectors comprising such nucleic acid molecules, recombinant host cells comprising such vectors and expression vectors, and recombinant viruses comprising such expression vectors. These expression vectors and recombinant host cells can be used to prepare Zinf2 polypeptides. In addition, the present invention provides pharmaceutical compositions, comprising a pharmaceutically acceptable carrier and at least one of such an expression vector or recombinant virus.

The present invention further contemplates antibodies and antibody fragments that specifically bind with Zinf2 polypeptides. Such antibodies include polyclonal antibodies, murine monoclonal antibodies, humanized antibodies derived from murine monoclonal antibodies, and human monoclonal antibodies. Examples of antibody fragments include $F(ab')_2$, $F(ab)_2$, Fab' , Fab , Fv , $scFv$, and minimal recognition units.

The present invention further includes compositions comprising a carrier and a peptide, polypeptide, or antibody described herein. For example, the composition can be a pharmaceutical composition, and the carrier can be a pharmaceutically acceptable carrier.

The present invention also provides methods for detecting the presence of Zinf2 RNA in a biological sample, comprising the steps of :

(a) contacting a Zinf2 nucleic acid probe under hybridizing conditions with either (i) test RNA molecules isolated from the biological sample, or (ii) nucleic acid molecules synthesized from the isolated RNA molecules, wherein the probe has a nucleotide sequence comprising a portion of the nucleotide sequence

of approximately 46 kD. These predicted molecular weights do not include the extra mass that may be contributed by carbohydrate chains.

Zinf2 is a helical cytokine in the interferon class. As such, the polypeptide is characterized by four helices in an up-up-down-down bundle with an extra helix formed by the loop between the third and fourth helices. Thus, helix E in the interferon class corresponds to helix D in the non-interferon class of four helix bundle cytokines. Table 4 describes structural features of human Zinf2.

A Zinf2 polypeptide having the amino acid sequence of SEQ ID NO:2 may contain at least one disulfide bond. There is also are cysteine residues which may participate in an intermolecular disulfide bond with another Zinf2 monomer.

Motif analysis of 55 interferon family members from various species has revealed a few residues that appear to be immutable throughout the family. It is expected that disrupting any one of these residues will inactivate the function of any interferon, including Zinf2. In reference to SEQ ID NO:2, these residues are Cys²⁰, Cys²⁴, Cys⁵⁰, Gln⁸³, Gln⁸⁴, Gln¹⁰², Gln¹⁰³, Cys¹¹⁰, Leu¹³⁸, Cys¹⁴⁶, and Ala¹⁴⁷. Gln⁸³ and Gln⁸⁴ are polar residues on a highly exposed location of helix B and are predicted to be involved in receptor binding. Leu¹³⁸, and Ala¹⁴⁷ have side chains pointing into the core of the structure, and are predicted to be essential for protein structural stability.

As described below, the present invention provides isolated polypeptides having an amino acid sequence that is at least 70% identical to a reference amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:2, (b) amino acid residues 25 to 198 of SEQ ID NO:2, (c) the amino acid sequence of SEQ ID NO:5, and (d) amino acid residues 25 to 180 of SEQ ID NO:5, wherein the isolated polypeptide specifically binds with an antibody that specifically binds with a polypeptide consisting of the amino acid sequence of SEQ ID NO:2. The present invention also provides isolated polypeptides having an amino acid sequence that is at least 80%, or at least 90%, identical to one of amino acid sequences (a) - (d). Examples of such polypeptides include polypeptides comprising the amino acid sequence of SEQ ID NO:2.

The present invention also contemplates isolated polypeptides comprising a first amino acid sequence consisting of amino acid residues 25 to 198 of SEQ ID NO:2, or consisting of amino acid residues 25 to 180 of SEQ ID NO:5, as well as polypeptides that further comprise a signal secretory sequence that resides in an amino-terminal position relative to the first amino acid sequence, wherein the signal secretory sequence comprises amino acid residues 1 to 24 of the amino acid sequence of SEQ ID NO:2.

The present invention also includes variant human Zinf2 polypeptides, wherein the amino acid sequence of the variant polypeptide shares an identity with the amino acid sequence of SEQ ID NOs:2 and 5 selected from the group consisting of at least 70% identity, at least 80% identity, at least 90% identity, at least 95% identity, or greater than 95% identity, and wherein any difference between the amino acid sequence of the variant polypeptide and the amino acid sequence of SEQ ID NO:2 is due to one or more conservative amino acid substitutions.

Illustrative polypeptides comprise an amino acid sequence selected from the group consisting of: amino acid residues 30 to 40 of SEQ ID NO:2, amino acid residues 41 to 75 of SEQ ID NO:2, amino acid residues 76 to 92 of SEQ ID NO:2, amino acid residues 30 to 92 of SEQ ID NO:2, amino acid residues 93 to 99 of SEQ ID NO:2, amino acid residues 100 to 110 of SEQ ID NO:2, amino acid residues 111 to 124 of SEQ ID NO:2, amino acid residues 125 to 139 of SEQ ID NO:2, amino acid residues 140 to 149 of SEQ ID NO:2, amino acid residues 150 to 169 of SEQ ID NO:2, amino acid residues 170 to 198 of SEQ ID NO:2, amino acid residues 180 to 198 of SEQ ID NO:2, and amino acid residues 170 to 180 of SEQ ID NO:5. Additional exemplary polypeptides include polypeptides comprising an amino acid sequence of 15, 20, or 30 contiguous amino acid residues of the following amino acid sequences within SEQ ID NOs:2 and 5: amino acid residues 30 to 92, amino acid residues 76 to 110, amino acid residues 100 to 139, amino acid residues 111 to 149, amino acid residues 125 to 169, and amino acid residues 150 to 198 of SEQ ID NO:2, and amino acid residues 150 to 180 of SEQ ID NO:5. Additional examples include polypeptides consisting of an amino acid sequence selected from the group consisting of: amino acid residues 30 to 40 of SEQ ID NO:2, amino acid residues 41 to 75 of SEQ ID NO:2, amino acid residues 76 to 92 of SEQ ID NO:2, amino acid residues 30 to 92 of SEQ ID NO:2, amino acid residues 93 to 99 of SEQ ID NO:2, amino acid residues 100 to 110 of SEQ ID NO:2, amino acid residues 111 to 124 of SEQ ID NO:2, amino acid residues 125 to 139 of SEQ ID NO:2, amino acid residues 140 to 149 of SEQ ID NO:2, amino acid residues 150 to 169 of SEQ ID NO:2, amino acid residues 170 to 198 of SEQ ID NO:2, amino acid residues 180 to 198 of SEQ ID NO:2, and amino acid residues 170 to 180 of SEQ ID NO:5.

The polypeptides described herein can further comprise an affinity tag.

The present invention also contemplates isolated nucleic acid molecules that encode a Zinf2 polypeptide, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs:3 or 6, (b) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NOs:2 or 5, and (c) a nucleic acid molecule that remains hybridized following

selected from the group consisting of SEQ ID NO:1, and the complement of SEQ ID NO:1, and

(b) detecting the formation of hybrids of the nucleic acid probe and either the test RNA molecules or the synthesized nucleic acid molecules,

5 wherein the presence of the hybrids indicates the presence of *Zinf2* RNA in the biological sample.

In addition, the presence of *Zinf2* polypeptide in a biological sample can be detected by methods that comprise the steps of (a) contacting the biological sample with an antibody, or an antibody fragment, that specifically binds with a polypeptide
10 having the amino acid sequence of either SEQ ID NO:2, wherein the contacting is performed under conditions that allow the binding of the antibody or antibody fragment to the biological sample, and (b) detecting any of the bound antibody or bound antibody fragment.

The present invention also provides kits for detecting *Zinf2* nucleic acid
15 molecules or *Zinf2* polypeptides. For example, a kit for detection of *Zinf2* nucleic acid molecules may comprise a container that comprises a nucleic acid molecule, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of nucleotides 88 to 594 of SEQ ID NO:1, (b) a nucleic acid molecule comprising the complement of the nucleotide
20 sequence of nucleotides 88 to 594 of SEQ ID NO:1, (c) a nucleic acid molecule comprising the nucleotide sequence of nucleotides 88 to 540 of SEQ ID NO:4, (d) a nucleic acid molecule comprising the complement of the nucleotide sequence of nucleotides 88 to 540 of SEQ ID NO:4, (e) a nucleic acid molecule comprising the nucleotide sequence of nucleotides 541 to 594 of SEQ ID NO:1, (f) a nucleic acid
25 molecule comprising the complement of the nucleotide sequence of nucleotides 541 to 594 of SEQ ID NO:1, and (g) a nucleic acid molecule that is a fragment of (a) through (f) consisting of at least eight nucleotides. Such kits may further comprise a second container that comprises one or more reagents capable of indicating the presence of the nucleic acid molecule. A kit for detection of *Zinf2* polypeptide may comprise a
30 container that comprises an antibody, or an antibody fragment, that specifically binds with a polypeptide having the amino acid sequence of SEQ ID NO:2 or 5.

The present invention also contemplates isolated nucleic acid molecules comprising a nucleotide sequence that encodes a *Zinf2* secretion signal sequence and a nucleotide sequence that encodes a biologically active polypeptide, wherein the *Zinf2*
35 secretion signal sequence comprises an amino acid sequence of residues 1 to 24 of SEQ ID NO:2. Illustrative biologically active polypeptides include Factor VIIa, proinsulin, insulin, follicle stimulating hormone, tissue type plasminogen activator, tumor necrosis

factor, interleukin, colony stimulating factor, interferon, erythropoietin, and thrombopoietin. Moreover, the present invention provides fusion proteins comprising a Zinf2 secretion signal sequence and a polypeptide, wherein the Zinf2 secretion signal sequence comprises an amino acid sequence of residues 1 to 24 of SEQ ID NO:2.

5 The present invention also contemplates anti-idiotypic antibodies, or anti-idiotypic antibody fragments, that specifically bind with an anti-Zinf2 antibody or antibody fragment. Certain anti-idiotypic antibodies, or anti-idiotypic antibody fragments, possesses anti-viral activity or anti-proliferative activity.

 The present invention further includes methods of inhibiting a viral
10 infection of cells, comprising the step of administering a composition comprising Zinf2 to the cells. For example, the composition can be a pharmaceutical composition, which is administered in a therapeutically effective amount to a subject, which has a viral infection. *In vivo* treatment of a viral infection can provide at least one physiological effect selected from the group consisting of decreased viral titer, decreased detectable
15 viral antigen, and increased anti-viral antibody titer.

 The present invention also includes methods of inhibiting the proliferation of tumor cells, comprising the step of administering a composition comprising Zinf2 to the tumor cells. In an *in vivo* approach, the composition is a pharmaceutical composition, administered in a therapeutically effective amount to a
20 subject, which has a tumor. Such *in vivo* administration can provide at least one physiological effect selected from the group consisting of decreased number of tumor cells, decreased metastasis, decreased size of a solid tumor, and increased necrosis of a tumor.

 The present invention further includes methods of treating a
25 lymphoproliferative disorder in a subject, comprising the step of administering a therapeutically effective amount of pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises Zinf2. Illustrative lymphoproliferative disorders include B-cell lymphoma, chronic lymphatic leukemia, and acute lymphatic leukemia.

30 The present invention also provides fusion proteins comprising a Zinf1 polypeptide moiety. Such fusion proteins can further comprise an immunoglobulin moiety. An exemplary immunoglobulin moiety is a human immunoglobulin heavy chain constant region.

35 These and other aspects of the invention will become evident upon reference to the following detailed description. In addition, various references are identified below and are incorporated by reference in their entirety.

2. Definitions

In the description that follows, a number of terms are used extensively.
5 The following definitions are provided to facilitate understanding of the invention.

As used herein, "nucleic acid" or "nucleic acid molecule" refers to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and
10 fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (*e.g.*, α -enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties
15 and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of
20 modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogous of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate,
25 phosphoramidate, and the like. The term "nucleic acid molecule" also includes so-called "peptide nucleic acids," which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.

The term "complement of a nucleic acid molecule" refers to a nucleic
30 acid molecule having a complementary nucleotide sequence and reverse orientation as compared to a reference nucleotide sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

The term "contig" denotes a nucleic acid molecule that has a contiguous stretch of identical or complementary sequence to another nucleic acid molecule.
35 Contiguous sequences are said to "overlap" a given stretch of a nucleic acid molecule either in their entirety or along a partial stretch of the nucleic acid molecule.

The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons as compared to a reference nucleic acid molecule that encodes a polypeptide. Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (*i.e.*, GAU and GAC triplets each encode Asp).

The term "structural gene" refers to a nucleic acid molecule that is transcribed into messenger RNA (mRNA), which is then translated into a sequence of amino acids characteristic of a specific polypeptide.

An "isolated nucleic acid molecule" is a nucleic acid molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes a growth factor that has been separated from the genomic DNA of a cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the genome of an organism. A nucleic acid molecule that has been isolated from a particular species is smaller than the complete DNA molecule of a chromosome from that species.

A "nucleic acid molecule construct" is a nucleic acid molecule, either single- or double-stranded, that has been modified through human intervention to contain segments of nucleic acid combined and juxtaposed in an arrangement not existing in nature.

"Linear DNA" denotes non-circular DNA molecules having free 5' and 3' ends. Linear DNA can be prepared from closed circular DNA molecules, such as plasmids, by enzymatic digestion or physical disruption.

"Complementary DNA (cDNA)" is a single-stranded DNA molecule that is formed from an mRNA template by the enzyme reverse transcriptase. Typically, a primer complementary to portions of mRNA is employed for the initiation of reverse transcription. Those skilled in the art also use the term "cDNA" to refer to a double-stranded DNA molecule consisting of such a single-stranded DNA molecule and its complementary DNA strand. The term "cDNA" also refers to a clone of a cDNA molecule synthesized from an RNA template.

A "promoter" is a nucleotide sequence that directs the transcription of a structural gene. Typically, a promoter is located in the 5' non-coding region of a gene, proximal to the transcriptional start site of a structural gene. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites, TATA sequences, CAAT sequences, differentiation-specific elements (DSEs; McGehee *et al.*, *Mol. Endocrinol.* 7:551 (1993)), cyclic AMP response elements (CREs), serum response elements (SREs; Treisman, *Seminars in Cancer Biol.* 1:47

(1990)), glucocorticoid response elements (GREs), and binding sites for other transcription factors, such as CRE/ATF (O'Reilly *et al.*, *J. Biol. Chem.* 267:19938 (1992)), AP2 (Ye *et al.*, *J. Biol. Chem.* 269:25728 (1994)), SP1, cAMP response element binding protein (CREB; Loeken, *Gene Expr.* 3:253 (1993)) and octamer factors (see, in general, Watson *et al.*, eds., *Molecular Biology of the Gene*, 4th ed. (The Benjamin/Cummings Publishing Company, Inc. 1987), and Lemaigre and Rousseau, *Biochem. J.* 303:1 (1994)). If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. Repressible promoters are also known.

A "core promoter" contains essential nucleotide sequences for promoter function, including the TATA box and start of transcription. By this definition, a core promoter may or may not have detectable activity in the absence of specific sequences that may enhance the activity or confer tissue specific activity.

A "regulatory element" is a nucleotide sequence that modulates the activity of a core promoter. For example, a regulatory element may contain a nucleotide sequence that binds with cellular factors enabling transcription exclusively or preferentially in particular cells, tissues, or organelles. These types of regulatory elements are normally associated with genes that are expressed in a "cell-specific," "tissue-specific," or "organelle-specific" manner.

An "enhancer" is a type of regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.

"Heterologous DNA" refers to a DNA molecule, or a population of DNA molecules, that does not exist naturally within a given host cell. DNA molecules heterologous to a particular host cell may contain DNA derived from the host cell species (*i.e.*, endogenous DNA) so long as that host DNA is combined with non-host DNA (*i.e.*, exogenous DNA). For example, a DNA molecule containing a non-host DNA segment encoding a polypeptide operably linked to a host DNA segment comprising a transcription promoter is considered to be a heterologous DNA molecule. Conversely, a heterologous DNA molecule can comprise an endogenous gene operably linked with an exogenous promoter. As another illustration, a DNA molecule comprising a gene derived from a wild-type cell is considered to be heterologous DNA if that DNA molecule is introduced into a mutant cell that lacks the wild-type gene.

A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides."

A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell.

5 Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

A peptide or polypeptide encoded by a non-host DNA molecule is a "heterologous" peptide or polypeptide.

10 An "integrated genetic element" is a segment of DNA that has been incorporated into a chromosome of a host cell after that element is introduced into the cell through human manipulation. Within the present invention, integrated genetic elements are most commonly derived from linearized plasmids that are introduced into the cells by electroporation or other techniques. Integrated genetic elements are passed
15 from the original host cell to its progeny.

A "cloning vector" is a nucleic acid molecule, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell. Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites that allow insertion of a nucleic acid molecule in a determinable fashion
20 without loss of an essential biological function of the vector, as well as nucleotide sequences encoding a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance.

An "expression vector" is a nucleic acid molecule encoding a gene that is
25 expressed in a host cell. Typically, an expression vector comprises a transcription promoter, a gene, and a transcription terminator. Gene expression is usually placed under the control of a promoter, and such a gene is said to be "operably linked to" the promoter. Similarly, a regulatory element and a core promoter are operably linked if the regulatory element modulates the activity of the core promoter.

30 A "recombinant host" is a cell that contains a heterologous nucleic acid molecule, such as a cloning vector or expression vector. In the present context, an example of a recombinant host is a cell that produces Zinf2 from an expression vector. In contrast, Zinf2 can be produced by a cell that is a "natural source" of Zinf2, and that lacks an expression vector.

35 "Integrative transformants" are recombinant host cells, in which heterologous DNA has become integrated into the genomic DNA of the cells.

A "fusion protein" is a hybrid protein expressed by a nucleic acid molecule comprising nucleotide sequences of at least two genes. For example, a fusion protein can comprise at least part of a Zinf2 polypeptide fused with a polypeptide that binds an affinity matrix. Such a fusion protein provides a means to isolate large quantities of Zinf2 using affinity chromatography.

The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule termed a "ligand." This interaction mediates the effect of the ligand on the cell. Receptors can be membrane bound, cytosolic or nuclear; monomeric (*e.g.*, thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (*e.g.*, PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor). Membrane-bound receptors are characterized by a multi-domain structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. In certain membrane-bound receptors, the extracellular ligand-binding domain and the intracellular effector domain are located in separate polypeptides that comprise the complete functional receptor.

In general, the binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell, which in turn leads to an alteration in the metabolism of the cell. Metabolic events that are often linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids.

The term "secretory signal sequence" denotes a nucleotide sequence that encodes a peptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

An "isolated polypeptide" is a polypeptide that is essentially free from contaminating cellular components, such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. Typically, a preparation of isolated polypeptide contains the polypeptide in a highly purified form, *i.e.*, at least about 80% pure, at least about 90% pure, at least about 95% pure, greater than 95% pure, or greater than 99% pure. One way to show that a particular protein preparation contains an isolated polypeptide is by the appearance of a single band following sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of the protein preparation and Coomassie Brilliant Blue staining of the gel. However, the term "isolated" does not

exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

The term "expression" refers to the biosynthesis of a gene product. For example, in the case of a structural gene, expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.

The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a polypeptide encoded by a splice variant of an mRNA transcribed from a gene.

As used herein, the term "immunomodulator" includes cytokines, stem cell growth factors, lymphotoxins, co-stimulatory molecules, hematopoietic factors, and synthetic analogs of these molecules.

The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of less than 10^9 M^{-1} .

An "anti-idiotypic antibody" is an antibody that binds with the variable region domain of an immunoglobulin. In the present context, an anti-idiotypic antibody binds with the variable region of an anti-Zinf2 antibody, and thus, an anti-idiotypic antibody mimics an epitope of Zinf2. Certain Zinf2 anti-idiotypic antibodies have anti-viral or anti-proliferative activity.

An "antibody fragment" is a portion of an antibody such as F(ab')_2 , F(ab)_2 , Fab' , Fab , and the like. Regardless of structure, an antibody fragment binds with the same

antigen that is recognized by the intact antibody. For example, an anti-Zinf2 monoclonal antibody fragment binds with an epitope of Zinf2.

The term "antibody fragment" also includes a synthetic or a genetically engineered polypeptide that binds to a specific antigen, such as polypeptides consisting of the light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("scFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

A "chimeric antibody" is a recombinant protein that contains the variable domains and complementary determining regions derived from a rodent antibody, while the remainder of the antibody molecule is derived from a human antibody.

"Humanized antibodies" are recombinant proteins in which murine complementarity determining regions of a monoclonal antibody have been transferred from heavy and light variable chains of the murine immunoglobulin into a human variable domain.

As used herein, a "therapeutic agent" is a molecule or atom which is conjugated to an antibody moiety to produce a conjugate which is useful for therapy. Examples of therapeutic agents include drugs, toxins, immunomodulators, chelators, boron compounds, photoactive agents or dyes, and radioisotopes.

A "detectable label" is a molecule or atom which can be conjugated to an antibody moiety to produce a molecule useful for diagnosis. Examples of detectable labels include chelators, photoactive agents, radioisotopes, fluorescent agents, paramagnetic ions, or other marker moieties.

The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a polyhistidine tract, protein A (Nilsson *et al.*, *EMBO J.* 4:1075 (1985); Nilsson *et al.*, *Methods Enzymol.* 198:3 (1991)), glutathione S transferase (Smith and Johnson, *Gene* 67:31 (1988)), Glu-Glu affinity tag (Grussenmeyer *et al.*, *Proc. Natl. Acad. Sci. USA* 82:7952 (1985)), substance P, FLAG peptide (Hopp *et al.*, *Biotechnology* 6:1204 (1988)), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford *et al.*, *Protein Expression and Purification* 2:95 (1991). Nucleic acid molecules encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

A "naked antibody" is an entire antibody, as opposed to an antibody fragment, which is not conjugated with a therapeutic agent. Naked antibodies include both polyclonal and monoclonal antibodies, as well as certain recombinant antibodies, such as chimeric and humanized antibodies.

5 As used herein, the term "antibody component" includes both an entire antibody and an antibody fragment.

An "immunoconjugate" is a conjugate of an antibody component with a therapeutic agent or a detectable label.

10 As used herein, the term "antibody fusion protein" refers to a recombinant molecule that comprises an antibody component and a therapeutic agent. Examples of therapeutic agents suitable for such fusion proteins include immunomodulators ("antibody-immunomodulator fusion protein") and toxins ("antibody-toxin fusion protein").

15 A "tumor associated antigen" is a protein normally not expressed, or expressed at lower levels, by a normal counterpart cell. Examples of tumor associated antigens include alpha-fetoprotein, carcinoembryonic antigen, and Her-2/neu. Many other illustrations of tumor associated antigens are known to those of skill in the art. See, for example, Urban *et al.*, *Ann. Rev. Immunol.* 10:617 (1992).

20 As used herein, an "infectious agent" denotes both microbes and parasites. A "microbe" includes viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganisms. A "parasite" denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms thereof, which are susceptible to immune-mediated clearance or lytic or phagocytic destruction, such as malarial parasites, spirochetes, and the like.

25 An "infectious agent antigen" is an antigen associated with an infectious agent.

30 A "target polypeptide" or a "target peptide" is an amino acid sequence that comprises at least one epitope, and that is expressed on a target cell, such as a tumor cell, or a cell that carries an infectious agent antigen. T cells recognize peptide epitopes presented by a major histocompatibility complex molecule to a target polypeptide or target peptide and typically lyse the target cell or recruit other immune cells to the site of the target cell, thereby killing the target cell.

35 An "antigenic peptide" is a peptide which will bind a major histocompatibility complex molecule to form an MHC-peptide complex which is recognized by a T cell, thereby inducing a cytotoxic lymphocyte response upon presentation to the T cell. Thus, antigenic peptides are capable of binding to an appropriate major histocompatibility complex molecule and inducing a cytotoxic T

cells response, such as cell lysis or specific cytokine release against the target cell which binds or expresses the antigen. The antigenic peptide can be bound in the context of a class I or class II major histocompatibility complex molecule, on an antigen presenting cell or on a target cell.

5 In eukaryotes, RNA polymerase II catalyzes the transcription of a structural gene to produce mRNA. A nucleic acid molecule can be designed to contain an RNA polymerase II template in which the RNA transcript has a sequence that is complementary to that of a specific mRNA. The RNA transcript is termed an "anti-sense RNA" and a nucleic acid molecule that encodes the anti-sense RNA is termed an
10 "anti-sense gene." Anti-sense RNA molecules are capable of binding to mRNA molecules, resulting in an inhibition of mRNA translation.

An "anti-sense oligonucleotide specific for Zinf2" or an "Zinf2 anti-sense oligonucleotide" is an oligonucleotide having a sequence (a) capable of forming a stable triplex with a portion of the Zinf2 gene, or (b) capable of forming a stable duplex
15 with a portion of an mRNA transcript of the Zinf2 gene.

A "ribozyme" is a nucleic acid molecule that contains a catalytic center. The term includes RNA enzymes, self-splicing RNAs, self-cleaving RNAs, and nucleic acid molecules that perform these catalytic functions. A nucleic acid molecule that encodes a ribozyme is termed a "ribozyme gene."

20 An "external guide sequence" is a nucleic acid molecule that directs the endogenous ribozyme, RNase P, to a particular species of intracellular mRNA, resulting in the cleavage of the mRNA by RNase P. A nucleic acid molecule that encodes an external guide sequence is termed an "external guide sequence gene."

The term "variant Zinf2 gene" refers to nucleic acid molecules that
25 encode a polypeptide having an amino acid sequence that is a modification of SEQ ID NO:2. Such variants include naturally-occurring polymorphisms of Zinf2 genes, as well as synthetic genes that contain conservative amino acid substitutions of the amino acid sequence of SEQ ID NO:2. Additional variant forms of Zinf2 genes are nucleic acid molecules that contain insertions or deletions of the nucleotide sequences
30 described herein. A variant Zinf2 gene can be identified by determining whether the gene hybridizes with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, or its complement, under stringent conditions.

Alternatively, variant Zinf2 genes can be identified by sequence comparison. Two amino acid sequences have "100% amino acid sequence identity" if
35 the amino acid residues of the two amino acid sequences are the same when aligned for maximal correspondence. Similarly, two nucleotide sequences have "100% nucleotide sequence identity" if the nucleotide residues of the two nucleotide sequences are the

same when aligned for maximal correspondence. Sequence comparisons can be performed using standard software programs such as those included in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Other methods for comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, *The Internet and the New Biology: Tools for Genomic and Molecular Research* (ASM Press, Inc. 1997), Wu et al. (eds.), "Information Superhighway and Computer Databases of Nucleic Acids and Proteins," in *Methods in Gene Biotechnology*, pages 123-151 (CRC Press, Inc. 1997), and Bishop (ed.), *Guide to Human Genome Computing*, 2nd Edition (Academic Press, Inc. 1998)). Particular methods for determining sequence identity are described below.

Regardless of the particular method used to identify a variant Zinf2 gene or variant Zinf2 polypeptide, a variant gene or polypeptide encoded by a variant gene is functionally characterized by either its anti-viral or anti-proliferative activities, or by the ability to bind specifically to an anti-Zinf2 antibody.

The term "allelic variant" is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

"Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, α -globin, β -globin, and myoglobin are paralogs of each other.

The present invention includes functional fragments of Zinf2 genes. Within the context of this invention, a "functional fragment" of a Zinf2 gene refers to a nucleic acid molecule that encodes a portion of a Zinf2 polypeptide which either (1) possesses an anti-viral or anti-proliferative activity, or (2) specifically binds with an anti-Zinf2 antibody. For example, a functional fragment of a Zinf2 gene described herein comprises a portion of the nucleotide sequence of SEQ ID NO:2, and encodes a polypeptide having either an anti-viral or anti-proliferative activity.

Due to the imprecision of standard analytical methods, molecular weights and lengths of polymers are understood to be approximate values. When such

a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to $\pm 10\%$.

3. *Production of the Human Zinf2 Gene*

5 Nucleic acid molecules encoding a human Zinf2 gene can be obtained by screening a human cDNA or genomic library using polynucleotide probes based upon SEQ ID NO:1. These techniques are standard and well-established.

As an illustration, a nucleic acid molecule that encodes a human Zinf2 gene can be isolated from a human cDNA library. In this case, the first step would be to
10 prepare the cDNA library by isolating RNA from cells or tissue using methods well-known to those of skill in the art. In general, RNA isolation techniques must provide a method for breaking cells, a means of inhibiting RNase-directed degradation of RNA, and a method of separating RNA from DNA, protein, and polysaccharide contaminants. For example, total RNA can be isolated by freezing tissue in liquid nitrogen, grinding the
15 frozen tissue with a mortar and pestle to lyse the cells, extracting the ground tissue with a solution of phenol/chloroform to remove proteins, and separating RNA from the remaining impurities by selective precipitation with lithium chloride (see, for example, Ausubel *et al.* (eds.), *Short Protocols in Molecular Biology*, 3rd Edition, pages 4-1 to 4-6 (John Wiley & Sons 1995) ["Ausubel (1995)"]; Wu *et al.*, *Methods in Gene*
20 *Biotechnology*, pages 33-41 (CRC Press, Inc. 1997) ["Wu (1997)"]).

Alternatively, total RNA can be isolated from a tissue by extracting ground tissue with guanidinium isothiocyanate, extracting with organic solvents, and separating RNA from contaminants using differential centrifugation (see, for example, Chirgwin *et al.*, *Biochemistry* 18:52 (1979); Ausubel (1995) at pages 4-1 to 4-6; Wu
25 (1997) at pages 33-41).

In order to construct a cDNA library, poly(A)⁺ RNA must be isolated from a total RNA preparation. Poly(A)⁺ RNA can be isolated from total RNA using the standard technique of oligo(dT)-cellulose chromatography (see, for example, Aviv and Leder, *Proc. Nat'l Acad. Sci. USA* 69:1408 (1972); Ausubel (1995) at pages 4-11 to 4-
30 12).

Double-stranded cDNA molecules are synthesized from poly(A)⁺ RNA using techniques well-known to those in the art. (see, for example, Wu (1997) at pages 41-46). Moreover, commercially available kits can be used to synthesize double-stranded cDNA molecules. For example, such kits are available from Life
35 Technologies, Inc. (Gaithersburg, MD), CLONTECH Laboratories, Inc. (Palo Alto, CA), Promega Corporation (Madison, WI) and STRATAGENE (La Jolla, CA).

Various cloning vectors are appropriate for the construction of a cDNA library. For example, a cDNA library can be prepared in a vector derived from bacteriophage, such as a λ gt10 vector. See, for example, Huynh *et al.*, "Constructing and Screening cDNA Libraries in λ gt10 and λ gt11," in *DNA Cloning: A Practical Approach Vol. I*, Glover (ed.), page 49 (IRL Press, 1985); Wu (1997) at pages 47-52.

Alternatively, double-stranded cDNA molecules can be inserted into a plasmid vector, such as a PBLUESCRIPT vector (STRATAGENE; La Jolla, CA), a LAMDA GEM-4 (Promega Corp.) or other commercially available vectors. Suitable cloning vectors also can be obtained from the American Type Culture Collection (Manassas, VA).

To amplify the cloned cDNA molecules, the cDNA library is inserted into a prokaryotic host, using standard techniques. For example, a cDNA library can be introduced into competent *E. coli* DH5 cells, which can be obtained, for example, from Life Technologies, Inc. (Gaithersburg, MD).

A human genomic library can be prepared by means well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327). Genomic DNA can be isolated by lysing tissue with the detergent Sarkosyl, digesting the lysate with proteinase K, clearing insoluble debris from the lysate by centrifugation, precipitating nucleic acid from the lysate using isopropanol, and purifying resuspended DNA on a cesium chloride density gradient.

DNA fragments that are suitable for the production of a genomic library can be obtained by the random shearing of genomic DNA or by the partial digestion of genomic DNA with restriction endonucleases. Genomic DNA fragments can be inserted into a vector, such as a bacteriophage or cosmid vector, in accordance with conventional techniques, such as the use of restriction enzyme digestion to provide appropriate termini, the use of alkaline phosphatase treatment to avoid undesirable joining of DNA molecules, and ligation with appropriate ligases. Techniques for such manipulation are well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327).

Nucleic acid molecules that encode a human Zinf2 gene can also be obtained using the polymerase chain reaction (PCR) with oligonucleotide primers having nucleotide sequences that are based upon the nucleotide sequences of the human Zinf2 gene, as described herein. General methods for screening libraries with PCR are provided by, for example, Yu *et al.*, "Use of the Polymerase Chain Reaction to Screen Phage Libraries," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 211-215 (Humana Press, Inc. 1993). Moreover, techniques for using PCR to isolate related genes are described by, for

example, Preston, "Use of Degenerate Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 317-337 (Humana Press, Inc. 1993).

5 Alternatively, human genomic libraries can be obtained from commercial sources such as Research Genetics (Huntsville, AL) and the American Type Culture Collection (Manassas, VA).

 A library containing cDNA or genomic clones can be screened with one or more polynucleotide probes based upon SEQ ID NO:1, using standard methods (see, for
10 example, Ausubel (1995) at pages 6-1 to 6-11).

 Anti-Zinf2 antibodies, produced as described below, can also be used to isolate DNA sequences that encode human Zinf2 genes from cDNA libraries. For example, the antibodies can be used to screen λ gt11 expression libraries, or the antibodies can be used for immunoscreening following hybrid selection and translation
15 (see, for example, Ausubel (1995) at pages 6-12 to 6-16; Margolis *et al.*, "Screening λ expression libraries with antibody and protein probes," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), pages 1-14 (Oxford University Press 1995)).

 As an alternative, a Zinf2 gene can be obtained by synthesizing nucleic acid molecules using mutually priming long oligonucleotides and the nucleotide
20 sequences described herein (see, for example, Ausubel (1995) at pages 8-8 to 8-9). Established techniques using the polymerase chain reaction provide the ability to synthesize DNA molecules at least two kilobases in length (Adang *et al.*, *Plant Molec. Biol.* 21:1131 (1993), Bambot *et al.*, *PCR Methods and Applications* 2:266 (1993), Dillon *et al.*, "Use of the Polymerase Chain Reaction for the Rapid Construction of
25 Synthetic Genes," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 263-268, (Humana Press, Inc. 1993), and Holowachuk *et al.*, *PCR Methods Appl.* 4:299 (1995)).

 The nucleic acid molecules of the present invention can also be synthesized with "gene machines" using protocols such as the phosphoramidite method.
30 If chemically-synthesized double stranded DNA is required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short genes (60 to 80 base pairs) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them. For the production of longer genes (>300 base pairs),
35 however, special strategies may be required, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled in modular form from single-stranded

fragments that are from 20 to 100 nucleotides in length. For reviews on polynucleotide synthesis, see, for example, Glick and Pasternak, *Molecular Biotechnology, Principles and Applications of Recombinant DNA* (ASM Press 1994), Itakura *et al.*, *Annu. Rev. Biochem.* 53:323 (1984), and Climie *et al.*, *Proc. Nat'l Acad. Sci. USA* 87:633 (1990).

5 The sequence of a *Zinf2* cDNA or *Zinf2* genomic fragment can be determined using standard methods. *Zinf2* polynucleotide sequences disclosed herein can also be used as probes or primers to clone 5' non-coding regions of a *Zinf2* gene. Promoter elements from a *Zinf2* gene can be used to direct the expression of heterologous genes in tissues of, for example, transgenic animals or patients treated
10 with gene therapy. The identification of genomic fragments containing a *Zinf2* promoter or regulatory element can be achieved using well-established techniques, such as deletion analysis (see, generally, Ausubel (1995)).

 Cloning of 5' flanking sequences also facilitates production of *Zinf2* proteins by "gene activation," a technique disclosed in U.S. Patent No. 5,641,670.
15 Briefly, expression of an endogenous *Zinf2* gene in a cell is altered by introducing into the *Zinf2* locus a DNA construct comprising at least a targeting sequence, a regulatory sequence, an exon, and an unpaired splice donor site. The targeting sequence is a *Zinf2* 5' non-coding sequence that permits homologous recombination of the construct with the endogenous *Zinf2* locus, whereby the sequences within the construct become
20 operably linked with the endogenous *Zinf2* coding sequence. In this way, an endogenous *Zinf2* promoter can be replaced or supplemented with other regulatory sequences to provide enhanced, tissue-specific, or otherwise regulated expression.

4. Production of *Zinf2* Gene Variants

25 The present invention provides a variety of nucleic acid molecules, including DNA and RNA molecules, that encode the *Zinf2* polypeptides disclosed herein. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules. SEQ ID NO:3 is a degenerate nucleotide sequence that
30 encompasses all nucleic acid molecules that encode the *Zinf2* polypeptide of SEQ ID NO:2. SEQ ID NO:6 is a degenerate nucleotide sequence that encompasses all nucleic acid molecules that encode the *Zinf2* polypeptide of SEQ ID NO:5. Those skilled in the art will recognize that the degenerate sequence of SEQ ID NOs:3 and 6 also provides all RNA sequences encoding SEQ ID NOs:2 and 5, by substituting U for T.
35 Thus, the present invention contemplates *Zinf2* polypeptide-encoding nucleic acid

molecules comprising nucleotides 1 to 594 of SEQ ID NO:1 and nucleotides 1 to 540 of SEQ ID NO:4 and their RNA equivalents.

Table 1 sets forth the one-letter codes used within SEQ ID NOs:3 and 6 to denote degenerate nucleotide positions. "Resolutions" are the nucleotides denoted by a code letter. "Complement" indicates the code for the complementary nucleotide(s). For example, the code Y denotes either C or T, and its complement R denotes A or G, A being complementary to T, and G being complementary to C.

Table 1

Nucleotide	Resolution	Complement	Resolution
A	A	T	T
C	C	G	G
G	G	C	C
T	T	A	A
R	A G	Y	C T
Y	C T	R	A G
M	A C	K	G T
K	G T	M	A C
S	C G	S	C G
W	A T	W	A T
H	A C T	D	A G T
B	C G T	V	A C G
V	A C G	B	C G T
D	A G T	H	A C T
N	A C G T	N	A C G T

The degenerate codons used in SEQ ID NOs:3 and 6, encompassing all possible codons for a given amino acid, are set forth in Table 2.

Table 2

Amino Acid	One Letter Code	Codons	Degenerate Codon
Cys	C	TGC TGT	TGY
Ser	S	AGC AGT TCA TCC TCG TCT	WSN
Thr	T	ACA ACC ACG ACT	ACN
Pro	P	CCA CCC CCG CCT	CCN
Ala	A	GCA GCC GCG GCT	GCN
Gly	G	GGA GGC GGG GGT	GGN
Asn	N	AAC AAT	AAY
Asp	D	GAC GAT	GAY
Glu	E	GAA GAG	GAR
Gln	Q	CAA CAG	CAR
His	H	CAC CAT	CAY
Arg	R	AGA AGG CGA CGC CGG CGT	MGN
Lys	K	AAA AAG	AAR
Met	M	ATG	ATG
Ile	I	ATA ATC ATT	ATH
Leu	L	CTA CTC CTG CTT TTA TTG	YTN
Val	V	GTA GTC GTG GTT	GTN
Phe	F	TTC TTT	TTY
Tyr	Y	TAC TAT	TAY
Trp	W	TGG	TGG
Ter	.	TAA TAG TGA	TRR
Asn Asp	B		RAY
Glu Gln	Z		SAR
Any	X		NNN

One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding an amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequence of SEQ ID NO:2. Variant sequences can be readily tested for functionality as described herein.

Different species can exhibit "preferential codon usage." In general, see, Grantham *et al.*, *Nuc. Acids Res.* 8:1893 (1980), Haas *et al.* *Curr. Biol.* 6:315 (1996), Wain-Hobson *et al.*, *Gene* 13:355 (1981), Grosjean and Fiers, *Gene* 18:199 (1982), Holm, *Nuc. Acids Res.* 14:3075 (1986), Ikemura, *J. Mol. Biol.* 158:573 (1982), Sharp and Matassi, *Curr. Opin. Genet. Dev.* 4:851 (1994), Kane, *Curr. Opin. Biotechnol.* 6:494 (1995), and Makrides, *Microbiol. Rev.* 60:512 (1996). As used herein, the term "preferential codon usage" or "preferential codons" is a term of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino acid (See Table 2). For example, the amino acid threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequence disclosed in SEQ ID NO:3 serves as a template for optimizing expression of polynucleotides in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein.

The present invention further provides variant polypeptides and nucleic acid molecules that represent counterparts from other species (orthologs). These species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species. Of particular interest are Zinf2 polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides. Orthologs of human Zinf2 can

be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses Zinf2 as disclosed herein. Suitable sources of mRNA can be identified by probing northern
5 blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line.

A Zinf2-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using
10 the polymerase chain reaction with primers designed from the representative human Zinf2 sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to Zinf2 polypeptide. Similar techniques can also be applied to the isolation of genomic clones.

Those skilled in the art will recognize that the sequence disclosed in SEQ ID NO:1 represents a single allele of human Zinf2, and that allelic variation and alternative splicing are expected to occur. Allelic variants of this sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the nucleotide sequence shown in SEQ ID
20 NO:1, including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NO:2. cDNA molecules generated from alternatively spliced mRNAs, which retain the properties of the Zinf2 polypeptide are included within the scope of the present invention, as are polypeptides encoded by such
25 cDNAs and mRNAs. Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals or tissues according to standard procedures known in the art.

Within certain embodiments of the invention, the isolated nucleic acid molecules can hybridize under stringent conditions to nucleic acid molecules
30 comprising nucleotide sequences disclosed herein. For example, such nucleic acid molecules can hybridize under stringent conditions to nucleic acid molecules consisting of the nucleotide sequence of SEQ ID NO:1, or a sequence complementary thereto, under "stringent conditions." In general, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined
35 ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.

As an illustration, a nucleic acid molecule encoding a variant Zinf2 polypeptide can be hybridized with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) at 42°C overnight in a solution comprising 50% formamide, 5xSSC (1xSSC: 0.15 M sodium chloride and 15 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution (100x Denhardt's solution: 2% (w/v) Ficoll 400, 2% (w/v) polyvinylpyrrolidone, and 2% (w/v) bovine serum albumin, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA. One of skill in the art can devise variations of these hybridization conditions. For example, the hybridization mixture can be incubated at a higher temperature, such as about 65°C, in a solution that does not contain formamide. Moreover, premixed hybridization solutions are available (e.g., ExpressHyb™ Hybridization Solution from CLONTECH Laboratories, Inc.), and hybridization can be performed according to the manufacturer's instructions.

Following hybridization, the nucleic acid molecules can be washed to remove non-hybridized nucleic acid molecules under stringent conditions, or under highly stringent conditions. Typical stringent washing conditions include washing in a solution of 0.5x - 2x SSC with 0.1% sodium dodecyl sulfate (SDS) at 55 - 65°C. That is, nucleic acid molecules encoding a variant Zinf2 polypeptide remain hybridized, following stringent washing conditions, with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:1 (or its complement), in which the wash stringency is equivalent to 0.5x - 2x SSC with 0.1% SDS at 55 - 65°C, including 0.5x SSC with 0.1% SDS at 55°C, or 2xSSC with 0.1% SDS at 65°C. One of skill in the art can readily devise equivalent conditions, for example, by substituting the SSPE for SSC in the wash solution.

Typical highly stringent washing conditions include washing in a solution of 0.1x - 0.2x SSC with 0.1% sodium dodecyl sulfate (SDS) at 50 - 65°C. In other words, nucleic acid molecules encoding a variant Zinf2 polypeptide remain hybridized, following highly stringent washing conditions, with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:1 (or its complement), in which the wash stringency is equivalent to 0.1x - 0.2x SSC with 0.1% SDS at 50 - 65°C, including 0.1x SSC with 0.1% SDS at 50°C, or 0.2xSSC with 0.1% SDS at 65°C.

The present invention also provides isolated Zinf2 polypeptides that have a substantially similar sequence identity to the polypeptide of SEQ ID NO:2, or its orthologs. The term "substantially similar sequence identity" is used herein to denote polypeptides having 70%, 80%, 90%, 95% or greater than 95% sequence identity to the sequences shown in SEQ ID NO:2, or its orthologs.

The present invention also contemplates Zinf2 variant nucleic acid molecules that can be identified using two criteria: a determination of the similarity between the encoded polypeptide with the amino acid sequence of SEQ ID NO:2, and a hybridization assay, as described above. Such Zinf2 variants include nucleic acid molecules (1) that remain hybridized, following stringent washing conditions, with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:1 (or its complement), in which the wash stringency is equivalent to 0.5x - 2x SSC with 0.1% SDS at 55 - 65°C, and (2) that encode a polypeptide having 70%, 80%, 90%, 95% or greater than 95% sequence identity to the amino acid sequence of SEQ ID NO:2. Alternatively, Zinf2 variants can be characterized as nucleic acid molecules (1) that remain hybridized, following highly stringent washing conditions, with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:1 (or its complement), in which the wash stringency is equivalent to 0.1x - 0.2x SSC with 0.1% SDS at 50 - 65°C, and (2) that encode a polypeptide having 70%, 80%, 90%, 95% or greater than 95% sequence identity to the amino acid sequence of SEQ ID NO:2.

Percent sequence identity is determined by conventional methods. See, for example, Altschul *et al.*, *Bull. Math. Bio.* 48:603 (1986), and Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM 62" scoring matrix of Henikoff and Henikoff (*ibid.*) as shown in Table 3 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as: ([Total number of identical matches]/ [length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences])(100).

Table 3

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	4																			
R	-1	5																		
N	-2	0	6																	
D	-2	-2	1	6																
C	0	-3	-3	-3	9															
Q	-1	1	0	0	-3	5														
E	-1	0	0	2	-4	2	5													
G	0	-2	0	-1	-3	-2	-2	6												
H	-2	0	1	-1	-3	0	0	-2	8											
I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4										
L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-1	-2	-4	7						
S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-2	-1	1	5				
W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of a putative Zinf2 variant. The FASTA algorithm is described by Pearson and Lipman, *Proc. Nat'l Acad. Sci. USA* 85:2444 (1988), and by Pearson, *Meth. Enzymol.* 183:63 (1990).

Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., SEQ ID NO:2 or SEQ ID NO:5) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, *J. Mol. Biol.* 48:444 (1970); Sellers, *SIAM J. Appl. Math.* 26:787 (1974)), which allows for amino acid insertions and deletions. Preferred parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, *Meth. Enzymol.* 183:63 (1990).

FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from three to six, and most preferably, three. The other parameters can be set as: gap opening penalty=10, and gap extension penalty=1.

The present invention includes nucleic acid molecules that encode a polypeptide having a conservative amino acid change, compared with the amino acid sequence of SEQ ID NO:2. That is, variants can be obtained that contain one or more amino acid substitutions of SEQ ID NO:2, in which an alkyl amino acid is substituted for an alkyl amino acid in a Zinf2 amino acid sequence, an aromatic amino acid is substituted for an aromatic amino acid in a Zinf2 amino acid sequence, a sulfur-

containing amino acid is substituted for a sulfur-containing amino acid in a Zinf2 amino acid sequence, a hydroxy-containing amino acid is substituted for a hydroxy-containing amino acid in a Zinf2 amino acid sequence, an acidic amino acid is substituted for an acidic amino acid in a Zinf2 amino acid sequence, a basic amino acid is substituted for a basic amino acid in a Zinf2 amino acid sequence, or a dibasic monocarboxylic amino acid is substituted for a dibasic monocarboxylic amino acid in a Zinf2 amino acid sequence.

Among the common amino acids, for example, a "conservative amino acid substitution" is illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine.

The BLOSUM62 table is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, *Proc. Nat'l Acad. Sci. USA* 89:10915 (1992)). Accordingly, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention. Although it is possible to design amino acid substitutions based solely upon chemical properties (as discussed above), the language "conservative amino acid substitution" preferably refers to a substitution represented by a BLOSUM62 value of greater than -1. For example, an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3. According to this system, preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).

Particular variants of Zinf2 are characterized by having at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or greater than 95% sequence identity to the amino acid sequence of SEQ ID NO:2, wherein the variation in amino acid sequence is due to one or more conservative amino acid substitutions.

Conservative amino acid changes in a Zinf2 gene can be introduced by substituting nucleotides for the nucleotides recited in SEQ ID NO:1. Such "conservative amino acid" variants can be obtained, for example, by oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like (see Ausubel (1995) at pages 8-10 to 8-22; and McPherson (ed.), *Directed Mutagenesis: A Practical Approach* (IRL Press 1991)). The ability of such variants to promote anti-viral or anti-proliferative activity can be determined using

a standard method, such as the assay described herein. Alternatively, a variant Zinf2 polypeptide can be identified by the ability to specifically bind anti-Zinf2 antibodies.

The proteins of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without
5 limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipercolic acid, thiazolidine carboxylic acid, dehydropyrolidine, 3- and 4-methylproline, 3,3-dimethylproline, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-
10 azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of
15 plasmids containing nonsense mutations is typically carried out in a cell-free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See, for example, Robertson *et al.*, *J. Am. Chem. Soc.* 113:2722 (1991), Ellman *et al.*, *Methods Enzymol.* 202:301 (1991), Chung *et al.*, *Science* 259:806 (1993), and Chung *et al.*, *Proc. Nat'l Acad. Sci. USA*
20 90:10145 (1993).

In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti *et al.*, *J. Biol. Chem.* 271:19991 (1996)). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (*e.g.*,
25 phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (*e.g.*, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide *et al.*, *Biochem.* 33:7470 (1994). Naturally occurring amino acid residues can be converted to non-naturally occurring
30 species by *in vitro* chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, *Protein Sci.* 2:395 (1993)).

A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural
35 amino acids may be substituted for Zinf2 amino acid residues.

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis

or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081 (1989), Bass *et al.*, *Proc. Nat'l Acad. Sci. USA* 88:4498 (1991)). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity as disclosed below to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton *et al.*, *J. Biol. Chem.* 271:4699 (1996). The identities of essential amino acids can also be inferred from analysis of homologies with interferon- α , interferon- β , interferon- γ , interferon- δ , interferon- ω , and interferon- τ . The location of Zinf2 receptor binding domains can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos *et al.*, *Science* 255:306 (1992), Smith *et al.*, *J. Mol. Biol.* 224:899 (1992), and Wlodaver *et al.*, *FEBS Lett.* 309:59 (1992). Moreover, Zinf2 labeled with biotin or FITC can be used for expression cloning of Zinf2 receptors.

To date, studies have identified two main receptor binding sites in Type I interferons: one at a high affinity responsible for the binding to the receptor, and another site at lower affinity involved in mediating signal transduction (see, for example, Viscomi, *Biotherapy* 10:59 (1997)). The first site engages Helices A and B, and Loop AB, while the second site engages Helices A and C and Loop DE. Accordingly, mutations can be introduced into Helix C or Loop DE to interfere with Zinf2 receptor signaling. Such a mutant would be expected to bind a Zinf2 receptor without producing a biological effect, and therefore, would have the properties of an Zinf2 antagonist. As shown in Table 4, Helix C and Loop DE are represented by amino acids 100 to 110, and 140 to 149 of SEQ ID NO:2. Another form of Zinf2 antagonist could consist of Helices A and B, and Loop AB of the Zinf2 form described herein (*i.e.*, amino acids 30 to 92 of SEQ ID NO:2).

Table 4

Structural Feature of Human Zinf2	Amino Acid Residues of SEQ ID NO: 2	Nucleotides of SEQ ID NO:1	Amino Acid Residues of SEQ ID NO: 5	Nucleotides of SEQ ID NO:4
Signal sequence	1 – 24	1 – 72	1 – 24	1 – 72
Helix A	30 – 40	88 – 120	30 – 407	88 – 120
AB Loop	41 – 75	121 – 225	41 – 75	121 – 225
Helix B	76 – 92	226 – 276	76 – 92	226 – 276
BC Loop	93 – 99	277 – 297	93 – 99	277 – 297
Helix C	100 – 110	298 – 330	100 – 110	298 – 330
CD Loop	111 – 124	331 – 372	111 – 124	331 – 372
Helix D	125 – 139	373 – 417	125 – 139	373 – 417
DE Loop	140 – 149	418 – 447	140 – 149	418 – 447
Helix E	150 – 169	448 – 507	150 – 169	448 – 507
Membrane Anchor	170 – 198	508 – 594	—	—
“Soluble” C-terminus	—	—	170 – 180	508 – 540

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (*Science* 241:53 (1988)) or Bowie and Sauer (*Proc. Nat'l Acad. Sci. USA* 86:2152 (1989)). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman *et al.*, *Biochem.* 30:10832 (1991), Ladner *et al.*, U.S. Patent No. 5,223,409, Huse, international publication No. WO 92/06204, and region-directed mutagenesis (Derbyshire *et al.*, *Gene* 46:145 (1986), and Ner *et al.*, *DNA* 7:127, (1988)).

Variants of the disclosed Zinf2 nucleotide and polypeptide sequences can also be generated through DNA shuffling as disclosed by Stemmer, *Nature* 370:389 (1994), Stemmer, *Proc. Nat'l Acad. Sci. USA* 91:10747 (1994), and international publication No. WO 97/20078. Briefly, variant DNAs are generated by *in vitro* homologous recombination by random fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using a family of parent DNAs, such as allelic variants or

DNAs from different species, to introduce additional variability into the process. Selection or screening for the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.

5 Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells. Mutagenized DNA molecules that encode biologically active polypeptides, or polypeptides that bind with anti-Zinf2 antibodies, can be recovered from the host cells and rapidly sequenced using modern equipment. These methods
10 allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

The present invention also includes "functional fragments" of Zinf2 polypeptides and nucleic acid molecules encoding such functional fragments. Routine deletion analyses of nucleic acid molecules can be performed to obtain functional
15 fragments of a nucleic acid molecule that encodes a Zinf2 polypeptide. As an illustration, DNA molecules having the nucleotide sequence of SEQ ID NO:1 can be digested with *Bal31* nuclease to obtain a series of nested deletions. The fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for anti-viral or anti-proliferative activity, or for the
20 ability to bind anti-Zinf2 antibodies. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce deletions or stop codons to specify production of a desired fragment. Alternatively, particular fragments of a Zinf2 gene can be synthesized using the polymerase chain reaction.

Studies on the truncation at either or both termini of interferons have
25 been summarized by Horisberger and Di Marco, *Pharmac. Ther.* 66:507 (1995). Moreover, standard techniques for functional analysis of proteins are described by, for example, Treuter *et al.*, *Molec. Gen. Genet.* 240:113 (1993), Content *et al.*, "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in *Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems*, Cantell (ed.), pages 65-72 (Nijhoff 1987), Herschman, "The EGF Receptor," in *Control of Animal Cell Proliferation, Vol. 1*, Boynton *et al.*, (eds.) pages
30 169-199 (Academic Press 1985), Coumailleau *et al.*, *J. Biol. Chem.* 270:29270 (1995); Fukunaga *et al.*, *J. Biol. Chem.* 270:25291 (1995); Yamaguchi *et al.*, *Biochem. Pharmacol.* 50:1295 (1995), and Meisel *et al.*, *Plant Molec. Biol.* 30:1 (1996).

35 The present invention also contemplates functional fragments of a Zinf2 gene that has amino acid changes, compared with the amino acid sequence of SEQ ID NO:2. A variant Zinf2 gene can be identified on the basis of structure by determining

the level of identity with nucleotide and amino acid sequences of SEQ ID NO:1 and 2, as discussed above. An alternative approach to identifying a variant gene on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant Zinf2 gene can hybridize to a nucleic acid molecule having the nucleotide sequence of
5 SEQ ID NO:1, as discussed above.

The present invention also provides polypeptide fragments or peptides comprising an epitope-bearing portion of a Zinf2 polypeptide described herein. Such fragments or peptides may comprise an "immunogenic epitope," which is a part of a protein that elicits an antibody response when the entire protein is used as an
10 immunogen. Immunogenic epitope-bearing peptides can be identified using standard methods (see, for example, Geysen *et al.*, *Proc. Nat'l Acad. Sci. USA* 81:3998 (1983)).

In contrast, polypeptide fragments or peptides may comprise an "antigenic epitope," which is a region of a protein molecule to which an antibody can specifically bind. Certain epitopes consist of a linear or contiguous stretch of amino
15 acids, and the antigenicity of such an epitope is not disrupted by denaturing agents. It is known in the art that relatively short synthetic peptides that can mimic epitopes of a protein can be used to stimulate the production of antibodies against the protein (see, for example, Sutcliffe *et al.*, *Science* 219:660 (1983)). Accordingly, antigenic epitope-bearing peptides and polypeptides of the present invention are useful to raise antibodies
20 that bind with the polypeptides described herein.

Antigenic epitope-bearing peptides and polypeptides preferably contain at least four to ten amino acids, at least ten to fifteen amino acids, or about 15 to about 30 amino acids of SEQ ID NO:2. Such epitope-bearing peptides and polypeptides can be produced by fragmenting a Zinf2 polypeptide, or by chemical peptide synthesis, as
25 described herein. Moreover, epitopes can be selected by phage display of random peptide libraries (see, for example, Lane and Stephen, *Curr. Opin. Immunol.* 5:268 (1993), and Cortese *et al.*, *Curr. Opin. Biotechnol.* 7:616 (1996)). Standard methods for identifying epitopes and producing antibodies from small peptides that comprise an epitope are described, for example, by Mole, "Epitope Mapping," in *Methods in*
30 *Molecular Biology*, Vol. 10, Manson (ed.), pages 105-116 (The Humana Press, Inc. 1992), Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies," in *Monoclonal Antibodies: Production, Engineering, and Clinical Application*, Ritter and Ladyman (eds.), pages 60-84 (Cambridge University Press 1995), and Coligan *et al.* (eds.), *Current Protocols in Immunology*, pages 9.3.1 - 9.3.5
35 and pages 9.4.1 - 9.4.11 (John Wiley & Sons 1997).

Regardless of the particular nucleotide sequence of a variant Zinf2 gene, the gene encodes a polypeptide that is characterized by its anti-viral or anti-proliferative

activity, or by the ability to bind specifically to an anti-Zinf2 antibody. With regard to the activity characteristic, variant Zinf2 genes encode polypeptides which exhibit at least 50%, and preferably, greater than 70, 80, or 90%, of the activity of polypeptide encoded by the human Zinf2 gene described herein.

5 For any Zinf2 polypeptide, including variants and fusion proteins, one of ordinary skill in the art can readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 1 and 2 above. Moreover, those of skill in the art can use standard software to devise Zinf2 variants based upon the nucleotide and amino acid sequences described herein. Accordingly,
10 the present invention includes a computer-readable medium encoded with a data structure that provides at least one of SEQ ID NO:1 and SEQ ID NO:2. Suitable forms of computer-readable media include magnetic media and optically-readable media. Examples of magnetic media include a hard or fixed drive, a random access memory (RAM) chip, a floppy disk, and a ZIP disk. Optically readable media are exemplified
15 by compact discs (*e.g.*, CD-read only memory (ROM), CD-rewritable (RW), and CD-recordable), and digital versatile/video discs (DVD) (*e.g.*, DVD-ROM, DVD-RAM, and DVD+RW).

5. Production of Zinf2 Fusion Proteins

20 Fusion proteins of Zinf2 can be used to express Zinf2 in a recombinant host, and to isolate expressed Zinf2. As described below, particular Zinf2 fusion proteins also have uses in diagnosis and therapy.

One type of fusion protein comprises a peptide that guides a Zinf2 polypeptide from a recombinant host cell. To direct a Zinf2 polypeptide into the secretory pathway of a eukaryotic host cell, a secretory signal sequence (also known as
25 a signal peptide, a leader sequence, prepro sequence or pre sequence) is provided in the Zinf2 expression vector. While the secretory signal sequence may be derived from Zinf2, a suitable signal sequence may also be derived from another secreted protein or synthesized *de novo*. The secretory signal sequence is operably linked to a Zinf2-encoding sequence such that the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the nucleotide sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the nucleotide sequence of interest (see, *e.g.*,
30 Welch *et al.*, U.S. Patent No. 5,037,743; Holland *et al.*, U.S. Patent No. 5,143,830).
35

Although the secretory signal sequence of Zinf2 or another protein produced by mammalian cells (e.g., tissue-type plasminogen activator signal sequence, as described, for example, in U.S. Patent No. 5,641,655) is useful for expression of Zinf2 in recombinant mammalian hosts, a yeast signal sequence is preferred for expression in yeast cells. Examples of suitable yeast signal sequences are those derived from yeast mating pheromone α -factor (encoded by the *MF α 1* gene), invertase (encoded by the *SUC2* gene), or acid phosphatase (encoded by the *PHO5* gene). See, for example, Romanos *et al.*, "Expression of Cloned Genes in Yeast," in *DNA Cloning 2: A Practical Approach*, 2nd Edition, Glover and Hames (eds.), pages 123-167 (Oxford University Press 1995).

In bacterial cells, it is often desirable to express a heterologous protein as a fusion protein to decrease toxicity, increase stability, and to enhance recovery of the expressed protein. For example, Zinf2 can be expressed as a fusion protein comprising a glutathione S-transferase polypeptide. Glutathione S-transferase fusion proteins are typically soluble, and easily purifiable from *E. coli* lysates on immobilized glutathione columns. In similar approaches, a Zinf2 fusion protein comprising a maltose binding protein polypeptide can be isolated with an amylose resin column, while a fusion protein comprising the C-terminal end of a truncated Protein A gene can be purified using IgG-Sepharose. Established techniques for expressing a heterologous polypeptide as a fusion protein in a bacterial cell are described, for example, by Williams *et al.*, "Expression of Foreign Proteins in *E. coli* Using Plasmid Vectors and Purification of Specific Polyclonal Antibodies," in *DNA Cloning 2: A Practical Approach*, 2nd Edition, Glover and Hames (Eds.), pages 15-58 (Oxford University Press 1995). In addition, commercially available expression systems are available. For example, the PINPOINT Xa protein purification system (Promega Corporation; Madison, WI) provides a methods for isolating a fusion protein comprising a polypeptide that becomes biotinylated during expression with a resin that comprises avidin.

Peptide tags that are useful for isolating heterologous polypeptides expressed by either prokaryotic or eukaryotic cells include polyHistidine tags (which have an affinity for nickel-chelating resin), *c-myc* tags, calmodulin binding protein (isolated with calmodulin affinity chromatography), substance P, the RYIRS tag (which binds with anti-RYIRS antibodies), the Glu-Glu tag, and the FLAG tag (which binds with anti-FLAG antibodies). See, for example, Luo *et al.*, *Arch. Biochem. Biophys.* 329:215 (1996); Morganti *et al.*, *Biotechnol. Appl. Biochem.* 23:67 (1996), and Zheng *et al.*, *Gene* 186:55 (1997). Nucleic acid molecules encoding such peptide tags are available, for example, from Sigma-Aldrich Corporation (St. Louis, MO).

The present invention also contemplates that the use of the secretory signal sequence contained in the Zinf2 polypeptides of the present invention to direct other polypeptides into the secretory pathway. A signal fusion polypeptide can be made wherein a secretory signal sequence derived from amino acid residues 1 to 24 of SEQ ID NO:2 is operably linked to another polypeptide using methods known in the art and disclosed herein. The secretory signal sequence contained in the fusion polypeptides of the present invention is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway. Such constructs have numerous applications known in the art. For example, these novel secretory signal sequence fusion constructs can direct the secretion of an active component of a normally non-secreted protein, such as a receptor. Such fusions may be used in a transgenic animal or in a cultured recombinant host to direct peptides through the secretory pathway. With regard to the latter, exemplary polypeptides include pharmaceutically active molecules such as Factor VIIa, proinsulin, insulin, follicle stimulating hormone, tissue type plasminogen activator, tumor necrosis factor, interleukins (*e.g.*, interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, and IL-17), colony stimulating factors (*e.g.*, granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF)), interferons (*e.g.*, interferons- α , β , γ , ω , δ , and τ), the stem cell growth factor designated "S1 factor," erythropoietin, and thrombopoietin. The Zinf2 secretory signal sequence contained in the fusion polypeptides of the present invention is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway. Fusion proteins comprising a Zinf2 secretory signal sequence can be constructed using standard techniques.

Another form of fusion protein comprises a Zinf2 polypeptide and an immunoglobulin heavy chain constant region, typically an F_C fragment, which contains two or three constant region domains and a hinge region but lacks the variable region. As an illustration, Chang *et al.*, U.S. Patent No. 5,723,125, describe a fusion protein comprising a human interferon and a human immunoglobulin Fc fragment. The C-terminal of the interferon is linked to the N-terminal of the Fc fragment by a peptide linker moiety. An example of a peptide linker is a peptide comprising primarily a T cell inert sequence, which is immunologically inert. An exemplary peptide linker has the amino acid sequence: GGSGG SGGGG SGGGG S (SEQ ID NO:7). In this fusion protein, a preferred Fc moiety is a human γ 4 chain, which is stable in solution and has little or no complement activating activity. Accordingly, the present invention contemplates a Zinf2 fusion protein that comprises a Zinf2 moiety and a human Fc

fragment, wherein the C-terminus of the Zinf2 moiety is attached to the N-terminus of the Fc fragment via a peptide linker, such as a peptide consisting of the amino acid sequence of SEQ ID NO:7. The Zinf2 moiety can be a Zinf2 molecule or a fragment thereof.

5 In another variation, a Zinf2 fusion protein comprises an IgG sequence, a Zinf2 moiety covalently joined to the aminoterminal end of the IgG sequence, and a signal peptide that is covalently joined to the aminoterminal of the Zinf2 moiety, wherein the IgG sequence consists of the following elements in the following order: a hinge region, a CH₂ domain, and a CH₃ domain. Accordingly, the IgG sequence lacks a
10 CH₁ domain. The Zinf2 moiety displays a Zinf2 activity, as described herein, such as the ability to bind with a Zinf2 receptor. This general approach to producing fusion proteins that comprise both antibody and nonantibody portions has been described by LaRochelle *et al.*, EP 742830 (WO 95/21258).

Fusion proteins comprising a Zinf2 moiety and an Fc moiety can be
15 used, for example, as an *in vitro* assay tool. For example, the presence of a Zinf2 receptor in a biological sample can be detected using a Zinf2-immunoglobulin fusion protein, in which the Zinf2 moiety is used to target the cognate receptor, and a macromolecule, such as Protein A or anti-Fc antibody, is used to detect the bound fusion protein-receptor complex. Moreover, such fusion proteins can be used to
20 identify agonists and antagonists that interfere with the binding of Zinf2 to its receptor.

In addition, antibody-Zinf2 fusion proteins, comprising antibody variable domains, are useful as therapeutic proteins, in which the antibody moiety binds with a target antigen, such as a tumor associated antigen. Methods of making antibody-cytokine fusion proteins are known to those of skill in the art. For example, antibody fusion
25 proteins comprising an interleukin-2 moiety are described by Boleti *et al.*, *Ann. Oncol.* 6:945 (1995), Nicolet *et al.*, *Cancer Gene Ther.* 2:161 (1995), Becker *et al.*, *Proc. Nat'l Acad. Sci. USA* 93:7826 (1996), Hank *et al.*, *Clin. Cancer Res.* 2:1951 (1996), and Hu *et al.*, *Cancer Res.* 56:4998 (1996). Moreover, Yang *et al.*, *Hum. Antibodies Hybridomas* 6:129 (1995), and Xiang *et al.*, *J. Biotechnol.* 53:3 (1997), describe fusion proteins that
30 include an F(ab')₂ fragment and a tumor necrosis factor alpha moiety. Additional cytokine-antibody fusion proteins include IL-8, IL-12, or Zinf2 as the cytokine moiety (Holzer *et al.*, *Cytokine* 8:214 (1996); Gillies *et al.*, *J. Immunol.* 160:6195 (1998); Xiang *et al.*, *Hum. Antibodies Hybridomas* 7:2 (1996)). Also see, Gillies, U.S. Patent No. 5,650,150.

35 Moreover, using methods described in the art hybrid Zinf2 proteins can be constructed using regions or domains of the inventive Zinf2 in combination with those of other interferon family proteins (*i.e.*, interferon- α , interferon- β , interferon- γ ,

interferon- δ , interferon- ω , interferon- τ , and interferon- ϵ), or heterologous proteins (see, for example, Picard, *Cur. Opin. Biology* 5:511 (1994)). These methods allow the determination of the biological importance of larger domains or regions in a polypeptide of interest. Such hybrids may alter reaction kinetics, binding, constrict or expand the substrate specificity, or alter tissue and cellular localization of a polypeptide, and can be applied to polypeptides of unknown structure. For example Horisberger and DiMarco, *Pharmac. Ther.* 66:507 (1995), describe the construction of fusion protein hybrids comprising different interferon- α subtypes, as well as hybrids comprising interferon- α domains from different species.

Fusion proteins can be prepared by methods known to those skilled in the art by preparing each component of the fusion protein and chemically conjugating them. Alternatively, a polynucleotide encoding both components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein. For example, part or all of a domain(s) conferring a biological function may be swapped between Zinf2 of the present invention with the functionally equivalent domain(s) from another family member, such as interferon- α , interferon- β , interferon- δ , interferon- γ , interferon- ω , or interferon- τ . Such domains include, but are not limited to, the secretory signal sequence, helices A, B, C, D, and E, and loops AB, BC, CD, and DE. Such fusion proteins would be expected to have a biological functional profile that is the same or similar to polypeptides of the present invention or other known interferon family proteins, depending on the fusion constructed. Moreover, such fusion proteins may exhibit other properties as disclosed herein. General methods for enzymatic and chemical cleavage of fusion proteins are described, for example, by Ausubel (1995) at pages 16-19 to 16-25.

The present invention also contemplates chemically modified Zinf2 compositions, in which a Zinf2 polypeptide is linked with a polymer. Typically, the polymer is water soluble so that the Zinf2 conjugate does not precipitate in an aqueous environment, such as a physiological environment. An example of a suitable polymer is one that has been modified to have a single reactive group, such as an active ester for acylation, or an aldehyde for alkylation. In this way, the degree of polymerization can be controlled. An example of a reactive aldehyde is polyethylene glycol propionaldehyde, or mono-(C1-C10) alkoxy, or aryloxy derivatives thereof (see, for example, Harris, *et al.*, U.S. Patent No. 5,252,714). The polymer may be branched or unbranched. Moreover, a mixture of polymers can be used to produce Zinf2 conjugates.

Zinf2 conjugates used for therapy should preferably comprise pharmaceutically acceptable water-soluble polymer moieties. Conjugation of

interferons with water-soluble polymers has been shown to enhance the circulating half-life of the interferon, and to reduce the immunogenicity of the polypeptide (see, for example, Nieforth *et al.*, *Clin. Pharmacol. Ther.* 59:636 (1996), and Monkarsch *et al.*, *Anal. Biochem.* 247:434 (1997)).

5 Suitable water-soluble polymers include polyethylene glycol (PEG), monomethoxy-PEG, mono-(C1-C10)alkoxy-PEG, aryloxy-PEG, poly-(N-vinyl pyrrolidone)PEG, tresyl monomethoxy PEG, PEG propionaldehyde, bis-succinimidyl carbonate PEG, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (*e.g.*, glycerol), polyvinyl alcohol, dextran, 10 cellulose, or other carbohydrate-based polymers. Suitable PEG may have a molecular weight from about 600 to about 60,000, including, for example, 5,000, 12,000, 20,000 and 25,000. A Zinf2 conjugate can also comprise a mixture of such water-soluble polymers.

 One example of a Zinf2 conjugate comprises a Zinf2 moiety and a 15 polyalkyl oxide moiety attached to the *N*-terminus of the Zinf2 moiety. PEG is one suitable polyalkyl oxide. As an illustration, Zinf2 can be modified with PEG, a process known as "PEGylation." PEGylation of Zinf2 can be carried out by any of the PEGylation reactions known in the art (see, for example, EP 0 154 316, Delgado *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems* 9:249 (1992), Duncan and Spreafico, *Clin. Pharmacokinet.* 27:290 (1994), and Francis *et al.*, *Int J Hematol* 68:1 20 (1998)). For example, PEGylation can be performed by an acylation reaction or by an alkylation reaction with a reactive polyethylene glycol molecule. In an alternative approach, Zinf2 conjugates are formed by condensing activated PEG, in which a terminal hydroxy or amino group of PEG has been replaced by an activated linker (see, 25 for example, Karasiewicz *et al.*, U.S. Patent No. 5,382,657).

 PEGylation by acylation typically requires reacting an active ester derivative of PEG with a Zinf2 polypeptide. An example of an activated PEG ester is PEG esterified to *N*-hydroxysuccinimide. As used herein, the term "acylation" includes the following types of linkages between Zinf2 and a water soluble polymer: amide, 30 carbamate, urethane, and the like. Methods for preparing PEGylated Zinf2 by acylation will typically comprise the steps of (a) reacting a Zinf2 polypeptide with PEG (such as a reactive ester of an aldehyde derivative of PEG) under conditions whereby one or more PEG groups attach to Zinf2, and (b) obtaining the reaction product(s). Generally, the optimal reaction conditions for acylation reactions will be determined based upon 35 known parameters and desired results. For example, the larger the ratio of PEG: Zinf2, the greater the percentage of polyPEGylated Zinf2 product.

The product of PEGylation by acylation is typically a polyPEGylated Zinf2 product, wherein the lysine ϵ -amino groups are PEGylated via an acyl linking group. An example of a connecting linkage is an amide. Typically, the resulting Zinf2 will be at least 95% mono-, di-, or tri-pegylated, although some species with higher
5 degrees of PEGylation may be formed depending upon the reaction conditions. PEGylated species can be separated from unconjugated Zinf2 polypeptides using standard purification methods, such as dialysis, ultrafiltration, ion exchange chromatography, affinity chromatography, and the like.

PEGylation by alkylation generally involves reacting a terminal aldehyde derivative of PEG with Zinf2 in the presence of a reducing agent. PEG groups are
10 preferably attached to the polypeptide via a $-\text{CH}_2\text{-NH}$ group.

Derivatization via reductive alkylation to produce a monoPEGylated product takes advantage of the differential reactivity of different types of primary amino groups available for derivatization. Typically, the reaction is performed at a pH that
15 allows one to take advantage of the pKa differences between the ϵ -amino groups of the lysine residues and the α -amino group of the *N*-terminal residue of the protein. By such selective derivatization, attachment of a water-soluble polymer that contains a reactive group such as an aldehyde, to a protein is controlled. The conjugation with the polymer occurs predominantly at the *N*-terminus of the protein without significant modification
20 of other reactive groups such as the lysine side chain amino groups. The present invention provides a substantially homogenous preparation of Zinf2 monopolymer conjugates.

Reductive alkylation to produce a substantially homogenous population of monopolymer Zinf2 conjugate molecule can comprise the steps of: (a) reacting a
25 Zinf2 polypeptide with a reactive PEG under reductive alkylation conditions at a pH suitable to permit selective modification of the α -amino group at the amino terminus of the Zinf2, and (b) obtaining the reaction product(s). The reducing agent used for reductive alkylation should be stable in aqueous solution and preferably be able to reduce only the Schiff base formed in the initial process of reductive alkylation.
30 Preferred reducing agents include sodium borohydride, sodium cyanoborohydride, dimethylamine borane, trimethylamine borane, and pyridine borane.

For a substantially homogenous population of monopolymer Zinf2 conjugates, the reductive alkylation reaction conditions are those which permit the selective attachment of the water soluble polymer moiety to the *N*-terminus of Zinf2.
35 Such reaction conditions generally provide for pKa differences between the lysine amino groups and the α -amino group at the *N*-terminus. The pH also affects the ratio of polymer to protein to be used. In general, if the pH is lower, a larger excess of

polymer to protein will be desired because the less reactive the *N*-terminal α -group, the more polymer is needed to achieve optimal conditions. If the pH is higher, the polymer:Zinf2 need not be as large because more reactive groups are available. Typically, the pH will fall within the range of 3 to 9, or 3 to 6.

5 Another factor to consider is the molecular weight of the water-soluble polymer. Generally, the higher the molecular weight of the polymer, the fewer number of polymer molecules which may be attached to the protein. For PEGylation reactions, the typical molecular weight is about 2 kDa to about 100 kDa, about 5 kDa to about 50 kDa, or about 12 kDa to about 25 kDa. The molar ratio of water-soluble polymer to
10 Zinf2 will generally be in the range of 1:1 to 100:1. Typically, the molar ratio of water-soluble polymer to Zinf2 will be 1:1 to 20:1 for polyPEGylation, and 1:1 to 5:1 for monoPEGylation.

General methods for producing conjugates comprising interferon and water-soluble polymer moieties are known in the art. See, for example, Karasiewicz *et al.*, U.S. Patent No. 5,382,657, Greenwald *et al.*, U.S. Patent No. 5,738, 846, Nieforth
15 *et al.*, *Clin. Pharmacol. Ther.* 59:636 (1996), Monkarsh *et al.*, *Anal. Biochem.* 247:434 (1997)). The present invention also includes anti-Zinf2 antibodies or Zinf2 anti-idiotypic antibodies that comprise a water soluble polymer.

The present invention contemplates compositions comprising a peptide
20 or polypeptide described herein. Such compositions can further comprise a carrier. The carrier can be a conventional organic or inorganic carrier. Examples of carriers include water, buffer solution, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and the like.

Peptides and polypeptides of the present invention comprise at least six,
25 preferably at least nine, and more preferably at least 15 contiguous amino acid residues of SEQ ID NO:2 or 5. For example, polypeptides can comprise at least nine contiguous amino acid residues of the following amino acid sequences: amino acid residues 30 to 40 of SEQ ID NO:2, amino acid residues 41 to 75 of SEQ ID NO:2, amino acid residues 76 to 92 of SEQ ID NO:2, amino acid residues 30 to 92 of SEQ ID NO:2,
30 amino acid residues 100 to 110 of SEQ ID NO:2, amino acid residues 111 to 124 of SEQ ID NO:2, amino acid residues 125 to 139 of SEQ ID NO:2, amino acid residues 140 to 149 of SEQ ID NO:2, amino acid residues 150 to 169 of SEQ ID NO:2, amino acid residues 170 to 198 of SEQ ID NO:2, and amino acid residues 170 to 180 of SEQ ID NO:5. Within certain embodiments of the invention, the polypeptides comprise 20,
35 30, 40, 50, 100, or more contiguous amino acid residues of SEQ ID NO:2. Illustrative polypeptides comprise 20 or 30 contiguous amino acid residues of: amino acid residues 41 to 75 of SEQ ID NO:2, and amino acid residues 30 to 92 of SEQ ID NO:2. Nucleic

acid molecules encoding such peptides and polypeptides are useful as polymerase chain reaction primers and probes.

6. *Production of Zinf2 Polypeptides in Cultured Cells*

5 The polypeptides of the present invention, including full-length polypeptides, functional fragments, and fusion proteins, can be produced in recombinant host cells following conventional techniques. To express a Zinf2 gene, a nucleic acid molecule encoding the polypeptide must be operably linked to regulatory sequences that control transcriptional expression in an expression vector and then, introduced into a host
10 cell. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene which is suitable for selection of cells that carry the expression vector.

 Expression vectors that are suitable for production of a foreign protein in eukaryotic cells typically contain (1) prokaryotic DNA elements coding for a bacterial
15 replication origin and an antibiotic resistance marker to provide for the growth and selection of the expression vector in a bacterial host; (2) eukaryotic DNA elements that control initiation of transcription, such as a promoter; and (3) DNA elements that control the processing of transcripts, such as a transcription termination/polyadenylation sequence. As discussed above, expression vectors can also include nucleotide
20 sequences encoding a secretory sequence that directs the heterologous polypeptide into the secretory pathway of a host cell. For example, a Zinf2 expression vector may comprise a Zinf2 gene and a secretory sequence derived from a Zinf2 gene or another secreted gene.

 Zinf2 proteins of the present invention may be expressed in mammalian
25 cells. Examples of suitable mammalian host cells include African green monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21, BHK-570; ATCC CRL 8544, ATCC CRL 10314), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61; CHO DG44 (Chasin *et al.*, *Som. Cell. Molec.*
30 *Genet.* 12:555 (1986))), rat pituitary cells (GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658).

 For a mammalian host, the transcriptional and translational regulatory
35 signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, in which the regulatory signals are associated with a particular

gene which has a high level of expression. Suitable transcriptional and translational regulatory sequences also can be obtained from mammalian genes, such as actin, collagen, myosin, and metallothionein genes.

Transcriptional regulatory sequences include a promoter region
5 sufficient to direct the initiation of RNA synthesis. Suitable eukaryotic promoters include the promoter of the mouse *metallothionein I* gene (Hamer *et al.*, *J. Molec. Appl. Genet.* 1:273 (1982)), the *TK* promoter of *Herpes* virus (McKnight, *Cell* 31:355 (1982)), the *SV40* early promoter (Benoist *et al.*, *Nature* 290:304 (1981)), the *Rous* sarcoma virus promoter (Gorman *et al.*, *Proc. Nat'l Acad. Sci. USA* 79:6777 (1982)),
10 the cytomegalovirus promoter (Foecking *et al.*, *Gene* 45:101 (1980)), and the mouse mammary tumor virus promoter (see, generally, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland *et al.* (eds.), pages 163-181 (John Wiley & Sons, Inc. 1996)).

Alternatively, a prokaryotic promoter, such as the bacteriophage T3
15 RNA polymerase promoter, can be used to control *Zinf2* gene expression in mammalian cells if the prokaryotic promoter is regulated by a eukaryotic promoter (Zhou *et al.*, *Mol. Cell. Biol.* 10:4529 (1990), and Kaufman *et al.*, *Nucl. Acids Res.* 19:4485 (1991)).

An expression vector can be introduced into host cells using a variety of standard techniques including calcium phosphate transfection, liposome-mediated
20 transfection, microprojectile-mediated delivery, electroporation, and the like. Preferably, the transfected cells are selected and propagated to provide recombinant host cells that comprise the expression vector stably integrated in the host cell genome. Techniques for introducing vectors into eukaryotic cells and techniques for selecting such stable transformants using a dominant selectable marker are described, for example, by Ausubel
25 (1995) and by Murray (ed.), *Gene Transfer and Expression Protocols* (Humana Press 1991).

For example, one suitable selectable marker is a gene that provides resistance to the antibiotic neomycin. In this case, selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems can
30 also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase,
35 which confers resistance to methotrexate. Other drug resistance genes (*e.g.*, hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used. Alternatively, markers that introduce an altered phenotype, such as green

fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means as FACS sorting or magnetic bead separation technology.

5 Zinf2 genes may also be expressed in other higher eukaryotic cells, such as avian, fungal, insect, yeast, or plant cells. The baculovirus system provides an efficient means to introduce cloned Zinf2 genes into insect cells. Suitable expression vectors are based upon the *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV), and contain well-known promoters such as *Drosophila* heat shock protein (hsp) 70 promoter, *Autographa californica* nuclear polyhedrosis virus immediate-early gene promoter (*ie-1*) and the delayed early 39K promoter, baculovirus p10 promoter, 10 and the *Drosophila* metallothionein promoter. A second method of making recombinant baculovirus utilizes a transposon-based system described by Luckow (Luckow, *et al.*, *J. Virol.* 67:4566 (1993)). This system, which utilizes transfer vectors, is sold in the BAC-to-BAC kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector, PFASTBAC (Life Technologies) containing a Tn7 transposon to move the DNA encoding the Zinf2 polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." See, Hill-Perkins and Possee, *J. Gen. Virol.* 71:971 (1990), Bonning, *et al.*, *J. Gen. Virol.* 75:1551 (1994), and Chazenbalk, and Rapoport, *J. Biol. Chem.* 270:1543 (1995). In addition, transfer vectors can include an in-frame 15 fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed Zinf2 polypeptide, for example, a Glu-Glu epitope tag (Grussenmeyer *et al.*, *Proc. Nat'l Acad. Sci.* 82:7952 (1985)). Using a technique known in the art, a transfer vector containing a Zinf2 gene is transformed into *E. coli*, and screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid 20 DNA containing the recombinant baculovirus genome is then isolated using common techniques.

The illustrative PFASTBAC vector can be modified to a considerable degree. For example, the polyhedrin promoter can be removed and substituted with the baculovirus basic protein promoter (also known as P_{cor}, p6.9 or MP promoter) which is 30 expressed earlier in the baculovirus infection, and has been shown to be advantageous for expressing secreted proteins (see, for example, Hill-Perkins and Possee, *J. Gen. Virol.* 71:971 (1990); Bonning, *et al.*, *J. Gen. Virol.* 75:1551 (1994), and Chazenbalk and Rapoport, *J. Biol. Chem.* 270:1543 (1995). In such transfer vector constructs, a short or long version of the basic protein promoter can be used. Moreover, transfer vectors can be constructed which replace the native Zinf2 secretory signal sequences 35 with secretory signal sequences derived from insect proteins. For example, a secretory signal sequence from Ecdysteroid Glucosyltransferase (EGT), honey bee Melittin

(Invitrogen Corporation; Carlsbad, CA), or baculovirus gp67 (PharMingen; San Diego, CA) can be used in constructs to replace the native Zinf2 secretory signal sequence.

The recombinant virus or bacmid is used to transfect host cells. Suitable insect host cells include cell lines derived from IPLB-Sf-21, a *Spodoptera frugiperda* pupal ovarian cell line, such as Sf9 (ATCC CRL 1711), Sf21AE, and Sf21 (Invitrogen Corporation; San Diego, CA), as well as *Drosophila* Schneider-2 cells, and the HIGH FIVEO cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent No. 5,300,435). Commercially available serum-free media can be used to grow and to maintain the cells. Suitable media are Sf900 II™ (Life Technologies) or ESF 921™ (Expression Systems) for the Sf9 cells; and Ex-cello405™ (JRH Biosciences, Lenexa, KS) or Express FiveO™ (Life Technologies) for the *T. ni* cells. When recombinant virus is used, the cells are typically grown up from an inoculation density of approximately 2.5×10^5 cells to a density of $1-2 \times 10^6$ cells at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3.

Established techniques for producing recombinant proteins in baculovirus systems are provided by Bailey *et al.*, "Manipulation of Baculovirus Vectors," in *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols*, Murray (ed.), pages 147-168 (The Humana Press, Inc. 1991), by Patel *et al.*, "The baculovirus expression system," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), pages 205-244 (Oxford University Press 1995), by Ausubel (1995) at pages 16-37 to 16-57, by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995), and by Lucknow, "Insect Cell Expression Technology," in *Protein Engineering: Principles and Practice*, Cleland *et al.* (eds.), pages 183-218 (John Wiley & Sons, Inc. 1996).

Fungal cells, including yeast cells, can also be used to express the genes described herein. Yeast species of particular interest in this regard include *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*. Suitable promoters for expression in yeast include promoters from *GALI* (galactose), *PGK* (phosphoglycerate kinase), *ADH* (alcohol dehydrogenase), *AOXI* (alcohol oxidase), *HIS4* (histidinol dehydrogenase), and the like. Many yeast cloning vectors have been designed and are readily available. These vectors include YIp-based vectors, such as YIp5, YRp vectors, such as YRp17, YEp vectors such as YEp13 and YCp vectors, such as YCp19. Methods for transforming *S. cerevisiae* cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311, Kawasaki *et al.*, U.S. Patent No. 4,931,373, Brake, U.S. Patent No. 4,870,008, Welch *et al.*, U.S. Patent No. 5,037,743, and Murray *et al.*, U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype

determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in *Saccharomyces cerevisiae* is the *POT1* vector system disclosed by Kawasaki *et al.* (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Additional suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311, Kingsman *et al.*, U.S. Patent No. 4,615,974, and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446, 5,063,154, 5,139,936, and 4,661,454.

Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson *et al.*, *J. Gen. Microbiol.* 132:3459 (1986), and Cregg, U.S. Patent No. 4,882,279. *Aspergillus* cells may be utilized according to the methods of McKnight *et al.*, U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino *et al.*, U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

For example, the use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed by Raymond, U.S. Patent No. 5,716,808, Raymond, U.S. Patent No. 5,736,383, Raymond *et al.*, *Yeast* 14:11-23 (1998), and in international publication Nos. WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, it is preferred that the promoter and terminator in the plasmid be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilization gene (*AUG1* or *AUG2*). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in *Pichia methanolica* is a *P. methanolica* *ADE2* gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), and which allows *ade2* host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol utilization genes (*AUG1* and *AUG2*) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (*PEP4* and *PRB1*) are preferred.

Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. *P. methanolica* cells can be transformed by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (τ) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

Expression vectors can also be introduced into plant protoplasts, intact plant tissues, or isolated plant cells. Methods for introducing expression vectors into plant tissue include the direct infection or co-cultivation of plant tissue with *Agrobacterium tumefaciens*, microprojectile-mediated delivery, DNA injection, electroporation, and the like. See, for example, Horsch *et al.*, *Science* 227:1229 (1985), Klein *et al.*, *Biotechnology* 10:268 (1992), and Miki *et al.*, "Procedures for Introducing Foreign DNA into Plants," in *Methods in Plant Molecular Biology and Biotechnology*, Glick *et al.* (eds.), pages 67-88 (CRC Press, 1993).

Alternatively, Zinf2 genes can be expressed in prokaryotic host cells. Suitable promoters that can be used to express Zinf2 polypeptides in a prokaryotic host are well-known to those of skill in the art and include promoters capable of recognizing the T4, T3, Sp6 and T7 polymerases, the P_R and P_L promoters of bacteriophage lambda, the *trp*, *recA*, heat shock, *lacUV5*, *tac*, *lpp-lacSpr*, *phoA*, and *lacZ* promoters of *E. coli*, promoters of *B. subtilis*, the promoters of the bacteriophages of *Bacillus*, *Streptomyces* promoters, the *int* promoter of bacteriophage lambda, the *bla* promoter of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene. Prokaryotic promoters have been reviewed by Glick, *J. Ind. Microbiol.* 1:277 (1987), Watson *et al.*, *Molecular Biology of the Gene*, 4th Ed. (Benjamin Cummins 1987), and by Ausubel *et al.* (1995).

Preferred prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Suitable strains of *E. coli* include BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, DH1, DH4I, DH5, DH5I, DH5IF', DH5IMCR, DH10B, DH10B/p3, DH11S, C600, HB101, JM101, JM105, JM109, JM110, K38, RR1, Y1088, Y1089, CSH18, ER1451, and ER1647 (see, for example, Brown (ed.), *Molecular Biology Labfax* (Academic Press 1991)). Suitable strains of *Bacillus subtilis* include BR151, YB886, MI119, MI120, and B170 (see, for example, Hardy, "Bacillus Cloning Methods," in *DNA Cloning: A Practical Approach*, Glover (ed.) (IRL Press 1985)).

When expressing a Zinf2 polypeptide in bacteria such as *E. coli*, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and

dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.

Methods for expressing proteins in prokaryotic hosts are well-known to those of skill in the art (see, for example, Williams *et al.*, "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), page 15 (Oxford University Press 1995), Ward *et al.*, "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, page 137 (Wiley-Liss, Inc. 1995), and Georgiou, "Expression of Proteins in Bacteria," in *Protein Engineering: Principles and Practice*, Cleland *et al.* (eds.), page 101 (John Wiley & Sons, Inc. 1996)).

Standard methods for introducing expression vectors into bacterial, yeast, insect, and plant cells are provided, for example, by Ausubel (1995).

General methods for expressing and recovering foreign protein produced by a mammalian cell system are provided by, for example, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland *et al.* (eds.), pages 163 (Wiley-Liss, Inc. 1996). Standard techniques for recovering protein produced by a bacterial system is provided by, for example, Grisshammer *et al.*, "Purification of over-produced proteins from *E. coli* cells," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), pages 59-92 (Oxford University Press 1995). Established methods for isolating recombinant proteins from a baculovirus system are described by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995).

In particular, the art of producing interferon polypeptides from cultured cells is well-established due to the great interest in interferon pharmaceuticals. For example, recombinant interferons have been produced by bacteria, yeasts, plant cells, insect cells, vertebrate cells, as well as in cell-free systems (Horisberger and Di Marco, *Pharmac. Ther.* 66:507 (1995)). Reviews of methods for producing recombinant interferon are provided, for example, by Edge and Camble, *Biotechnol. Genet. Eng. Rev.* 2:215 (1984), Langer and Pestka, *J. Invest. Dermatol* 83:128s (1984), Pestka, *Semin. Hematol.* 23:27 (1986), Baron and Narula, *Crit. Rev. Biotechnol.* 10:179 (1990), and Croughan *et al.*, *Bioprocess Technol* 21:377 (1995).

As an alternative, polypeptides of the present invention can be synthesized by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. These synthesis methods are well-known to those of skill in the art (see, for example, Merrifield, *J. Am. Chem. Soc.* 85:2149 (1963), Stewart *et al.*, "Solid Phase Peptide Synthesis" (2nd Edition), (Pierce Chemical Co. 1984), Bayer and Rapp, *Chem. Pept. Prot.* 3:3 (1986), Atherton *et al.*, *Solid Phase Peptide Synthesis: A Practical Approach* (IRL Press 1989), Fields and Colowick, "Solid-Phase Peptide Synthesis," *Methods in Enzymology Volume 289* (Academic Press 1997), and Lloyd-Williams *et al.*, *Chemical Approaches to the Synthesis of Peptides and Proteins* (CRC Press, Inc. 1997)). Variations in total chemical synthesis strategies, such as "native chemical ligation" and "expressed protein ligation" are also standard (see, for example, Dawson *et al.*, *Science* 266:776 (1994), Hackeng *et al.*, *Proc. Nat'l Acad. Sci. USA* 94:7845 (1997), Dawson, *Methods Enzymol.* 287: 34 (1997), Muir *et al.*, *Proc. Nat'l Acad. Sci. USA* 95:6705 (1998), Severinov and Muir, *J. Biol. Chem.* 273:16205 (1998), and Kochendoerfer and Kent, *Curr. Opin. Chem. Biol.* 3:665 (1999)).

7. Isolation of Zinf2 Polypeptides

The polypeptides of the present invention can be purified to at least about 80% purity, to at least about 90% purity, to at least about 95% purity, or even greater than 95% purity with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. The polypeptides of the present invention may also be purified to a pharmaceutically pure state, which is greater than 99.9% pure. In certain preparations, a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.

Expressed recombinant Zinf2 polypeptides, fusion Zinf2 polypeptides, or Zinf2 from natural sources can be purified from cultures of recombinant host cells using fractionation and/or conventional purification methods and media. In general, ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl

butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked
5 polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties.

Examples of coupling chemistries include cyanogen bromide activation,
10 N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Selection of a particular method for polypeptide isolation and purification is a matter of routine design and is determined in part by the
15 properties of the chosen support. See, for example, *Affinity Chromatography: Principles & Methods* (Pharmacia LKB Biotechnology 1988); and Doonan, *Protein Purification Protocols* (The Humana Press 1996).

Additional variations in Zinf2 isolation and purification can be devised by those of skill in the art. For example, anti-Zinf2 antibodies, obtained as described
20 below, can be used to isolate large quantities of protein by immunoaffinity purification. The use of monoclonal antibody columns to purify interferons from recombinant cells and from natural sources has been described, for example, by Staehelin *et al.*, *J. Biol. Chem.* 256:9750 (1981), and by Adolf *et al.*, *J. Biol. Chem.* 265:9290 (1990). Moreover, methods for binding ligands, such as Zinf2, to receptor polypeptides bound
25 to support media are well known in the art.

The polypeptides of the present invention can also be isolated by exploitation of particular properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to
30 form a chelate (Sulkowski, *Trends in Biochem.* 3:1 (1985)). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography (M. Deutscher, (ed.),
35 *Meth.Enzymol.* 182:529 (1990)). For example, the interferon- γ isolation method of Rinderknecht *et al.*, *J. Biol. Chem.* 259:6790 (1984), requires the binding of the interferon with concanavalin A-sepharose in one step. Within additional embodiments

of the invention, a fusion of the polypeptide of interest and an affinity tag (*e.g.*, maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification.

5 Zinf2 polypeptides or fragments thereof may also be prepared through chemical synthesis, as described below. Zinf2 polypeptides may be monomers or multimers; glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue.

8. Assays for Zinf2, Its Analogs, and the Zinf2 Receptor

10 As described above, the disclosed polypeptides can be used to construct Zinf2 variants. A Zinf2 variant will possess a Zinf2 biological activity, as determined by the *in vitro* assays described below. A polypeptide produced by a Zinf2 variant gene is considered to be a Zinf2 agonist if the polypeptide exhibits a biological activity (*e.g.*, anti-viral or anti-proliferative activity).

15 On the other hand, a Zinf2 variant gene product that lacks biological activity may be a Zinf2 antagonist. These biologically-inactive Zinf2 variants can be initially identified on the basis of hybridization analysis, sequence identity determination, or by the ability to specifically bind anti-Zinf2 antibody. A Zinf2 antagonist can be further characterized by its ability to inhibit the biological response induced by Zinf2 or by a Zinf2 agonist. This inhibitory effect may result, for example, 20 from the competitive or non-competitive binding of the antagonist to the Zinf2 receptor.

Zinf2, its agonists, and antagonists are valuable in both *in vivo* and *in vitro* uses. As an illustration, cytokines can be used as components of defined cell culture media, alone or in combination with other cytokines and hormones, to replace serum that is commonly used in cell culture. In particular, interferons have been shown 25 to stimulate the production of other biologically active polypeptides, such as interleukin-1, by cultured cells, which can be isolated from the culture (see, for example, Danis *et al.*, *Clin. Exp. Immunol.* 80:435 (1990)). Interferons have also been shown to induce the expression of antigens by cultured cells (see, for example, Auth *et al.*, *Hepatology* 18:546 (1993), Guadagni *et al.*, *Int. J. Biol. Markers* 9:53 (1994), Girolomoni *et al.*, *Eur. J. Immunol.* 25:2163 (1995), and Maciejewski *et al.*, *Blood* 85:3183 (1995). This activity enhances the ability to identify new tumor associated antigens *in vitro*. Moreover, the ability of interferons to augment the level of expression of human tumor antigens indicates that interferons can be useful in an 30 adjuvant setting for immunotherapy or immunoscintigraphy using anti-tumor antigen

antibodies (Guadagni *et al.*, *Cancer Immunol. Immunother.* 26:222 (1988); Guadagni *et al.*, *Int. J. Biol. Markers* 9:53 (1994)).

Antagonists are also useful as research reagents for characterizing sites of interaction between Zinf2 and its receptor. In a therapeutic setting, pharmaceutical compositions comprising Zinf2 antagonists can be used to inhibit Zinf2 activity.

One general class of Zinf2 analogs are agonists or antagonists having an amino acid sequence that is a mutation of the amino acid sequences disclosed herein. Another general class of Zinf2 analogs is provided by anti-idiotypic antibodies, and fragments thereof, as described below. Moreover, recombinant antibodies comprising anti-idiotypic variable domains can be used as analogs (see, for example, Monfardini *et al.*, *Proc. Assoc. Am. Physicians* 108:420 (1996)). Since the variable domains of anti-idiotypic Zinf2 antibodies mimic Zinf2, these domains can provide either Zinf2 agonist or antagonist activity. As an illustration, Lim and Langer, *J. Interferon Res.* 13:295 (1993), describe anti-idiotypic interferon- α antibodies that have the properties of either interferon- α agonists or antagonists.

A third approach to identifying Zinf2 analogs is provided by the use of combinatorial libraries. Methods for constructing and screening phage display and other combinatorial libraries are provided, for example, by Kay *et al.*, *Phage Display of Peptides and Proteins* (Academic Press 1996), Verdine, U.S. Patent No. 5,783,384, Kay, *et al.*, U.S. Patent No. 5,747,334, and Kauffman *et al.*, U.S. Patent No. 5,723,323.

One assay that can be used to measure Zinf2 biological activity is an interferon *in vitro* virus inhibition assay (see, for example, Familletti *et al.*, *Methods in Enzymol.* 78:83 (1981)). As an illustration, a test sample is diluted in culture medium in the first well of a row of a microtiter plate to a final volume of 0.2 ml. Two-fold dilutions of the test sample are made by transferring 0.1 ml serially to the end of the row. Several wells on the plate contain 0.1 ml of culture medium without Zinf2; these provide the virus and cell controls. Each well is seeded with about 3×10^4 cells/well of a cell line that forms a monolayer in culture and that is susceptible to the virus used in the assay. For example, the "WISH" human amnion cell line (ATCC No. CCL-25) would be suitable. The plate is incubated at 37°C for one hour. With the exception of the cell control wells, each well is challenged with 3000 plaque-forming units of vesicular stomatic virus. The plate is then incubated at 37°C for an additional 16 hours, or until a full cytopathic effect is noted in the virus control well that lacks Zinf2. The medium is aspirated from the wells, and the cells are immediately fixed and stained with 0.1 ml of 0.5% crystal violet in 70% methanol. The amount of Zinf2 is calculated as the reciprocal of the dilution represented in the well in which 50% of the cell monolayer is

protected by the Zinf2. One unit of Zinf2 may be defined as the concentration of Zinf2 required to inhibit virus plaque formation by 50%.

Those of skill in the art can devise variations of this viral assay. For example, the WISH cells can be substituted with Madin Darby bovine kidney (MDBK; ATCC No. CCL-22). Alternatively, an assay can be performed with A549 human lung carcinoma cells (ATCC No. CCL-185), or a human glioblastoma cell line 86HG39, and encephalomyocarditis virus. See, for example, Roberts and Liu, "Interferon- α ," in *Human Cytokines, Volume II*, Aggarwal and Gutterman (eds.), pages 168-177 (Blackwell Science 1996), and Daubener *et al.*, *J. Immunol. Methods* 168:39 (1994). In addition, Example 1 illustrates a viral assay with encephalomyocarditis virus and either mouse fibroblast cells (L929) and human cervical carcinoma cells (HeLa).

An alternative to the cytopathic effect assay is an assay that measures an inhibition of virus plaque formation in cultured cells infected with a virus, such as vesicular stomatitis virus (see, for example, Horisberger and de Startitzky, *J. Gen. Virol.* 68:945 (1987)). A third approach is to determine the reduction in virus yield by measuring the amount of virus released by infected cells, typically during a single growth cycle (see, for example, Stitz and Schellekens, *J. Gen. Virol.* 46:205 (1980)).

Another approach to evaluating Zinf2 activity is to use an assay that measures the inhibition of the proliferation of cultured human cells. An anti-proliferation assay is particularly useful to indicate the biological activity of an interferon in anti-tumor and immunomodulatory therapies. As an illustration, Mire-Sluis *et al.*, *J. Immunol. Methods* 195:55 (1996), have described an anti-cytokine bioassay based on the ability of interferons to inhibit granulocyte-macrophage-colony-stimulating factor (GM-CSF)-induced proliferation of the erythroleukemic cell line TF-1 (ATCC No. CRL-2003). The assay can be performed within 24 hours, and the assay is sensitive to as little as 100-200 fg interferon. The assay may be varied, for example, by using erythropoietin-induced proliferation of TF-1 cells, or erythropoietin-induced proliferation of UT-7-EPO cells.

Example 2 illustrates the use of a cell proliferation assay to characterize the effect of Zinf2 on a human B cell lymphoma cell line. In this test, samples containing the interferon are incubated with Daudi cells, a human B lymphoblast cell line derived from Burkitt's lymphoma (ATCC No. CCL-213). The inhibition of cell proliferation is determined by measuring incorporation of ^3H -thymidine by the Daudi cells.

Yet another general approach to measuring Zinf2 activity is based upon the interferon-mediated inhibition of the expression of *Eschericia coli* β -galactosidase in cells of genetically modified human glioblastoma cell line, as described by

Hammerling *et al.*, *J. Interferon Cytokine Res.* 18:451 (1998). These cells were stably transfected with a glial fibrillary acidic protein promoter sequence operatively linked with a *lacZ* promoter gene, and consequently, the recombinant cells produced β -galactosidase constitutively. However, human interferons selectively reduced β -galactosidase formation in a dose-dependent manner. This β -gal interferon assay is sensitive to picomolar concentrations of human interferon, and the assay can be used with both Type I and Type II interferons.

Additional methods for measuring interferon activity are known to those of skill in the art. For example, Uno *et al.*, U.S. Patent No. 5,766,864, describe a method of determining interferon activity by measuring the induction of 2'→5' oligoadenylate synthetase.

Alternatively, interferon activity can be detected by the induction of the expression of interferon-responsive genes using standard methods for mRNA detection, such as RT-PCR or an RNase protection assay. Various interferon-inducible proteins are described, for example, on pages 498 to 499 of De Maeyer and De Maeyer-Guignard, "Interferons," in *The Cytokine Handbook*, 3rd Edition, Thompson (ed.), pages 491-516 (Academic Press Ltd. 1998).

As a receptor ligand, the activity of Zinf2 can be measured by a silicon-based biosensor microphysiometer which measures the extracellular acidification rate or proton excretion associated with receptor binding and subsequent cellular responses. An exemplary device is the CYTOSENSOR Microphysiometer manufactured by Molecular Devices Corp. (Sunnyvale, CA). A variety of cellular responses, such as cell proliferation, ion transport, energy production, inflammatory response, regulatory and receptor activation, and the like, can be measured by this method (see, for example, McConnell *et al.*, *Science* 257:1906 (1992), Pitchford *et al.*, *Meth. Enzymol.* 228:84 (1997), Arimilli *et al.*, *J. Immunol. Meth.* 212:49 (1998), and Van Liefde *et al.*, *Eur. J. Pharmacol.* 346:87 (1998)). Moreover, the microphysiometer can be used for assaying adherent or non-adherent eukaryotic or prokaryotic cells.

Since energy metabolism is coupled with the use of cellular ATP, any event which alters cellular ATP levels, such as receptor activation and the initiation of signal transduction, will cause a change in cellular acid section. An early event in interferon signal transduction is protein phosphorylation, which requires ATP. By measuring extracellular acidification changes in cell media over time, therefore, the microphysiometer directly measures cellular responses to various stimuli, including Zinf2, its agonists, or antagonists. Preferably, the microphysiometer is used to measure responses of a Zinf2 responsive eukaryotic cell, compared to a control eukaryotic cell that does not respond to Zinf2 polypeptide. Zinf2-responsive eukaryotic cells comprise

cells into which a receptor for Zinf2 has been transfected to create a cell that is responsive to Zinf2, or cells that are naturally responsive to Zinf2. Suitable Zinf2 responsive cells include HeLa cells, Daudi cells, L929 cells (ATCC No. CCL-1), human lung carcinoma cells (e.g., A549 cells; ATCC No. CCL-185) cells, and normal
5 human diploid fibroblasts cells (e.g., FS-4 cells; Vilcek *et al.*, *J. Exp. Med.* 163:632 (1986)). Zinf2 modulated cellular responses are measured by a change (e.g., an increase or decrease in extracellular acidification) in the response of cells exposed to Zinf2, compared with control cells that have not been exposed to Zinf2.

Accordingly, a microphysiometer can be used to identify cells, tissues, or
10 cell lines which respond to a Zinf2 stimulated pathway, and which express a functional Zinf2 receptor. As an illustration, cells that express a functional Zinf2 receptor can be identified by (a) providing test cells, (b) incubating a first portion of the test cells in the absence of Zinf2, (c) incubating a second portion of the test cells in the presence of Zinf2, and (d) detecting a change (e.g., an increase or decrease in extracellular
15 acidification rate, as measured by a microphysiometer) in a cellular response of the second portion of the test cells, as compared to the first portion of the test cells, wherein such a change in cellular response indicates that the test cells express a functional Zinf2 receptor. An additional negative control may be included in which a portion of the test cells is incubated with Zinf2 and an anti-Zinf2 antibody to inhibit the binding of Zinf2
20 with its cognate receptor.

The microphysiometer also provides one means to identify Zinf2 agonists. For example, agonists of Zinf2 can be identified by a method, comprising the steps of (a) providing cells responsive to Zinf2, (b) incubating a first portion of the cells in the absence of a test compound, (c) incubating a second portion of the cells in the
25 presence of a test compound, and (d) detecting a change, for example, an increase or diminution, in a cellular response of the second portion of the cells as compared to the first portion of the cells, wherein such a change in cellular response indicates that the test compound is a Zinf2 agonist. An illustrative change in cellular response is a measurable change in extracellular acidification rate, as measured by a
30 microphysiometer. Moreover, incubating a third portion of the cells in the presence of Zinf2 and in the absence of a test compound can be used as a positive control for the Zinf2 responsive cells, and as a control to compare the agonist activity of a test compound with that of Zinf2. An additional control may be included in which a portion of the cells is incubated with a test compound (or Zinf2) and an anti-Zinf2 antibody to
35 inhibit the binding of the test compound (or Zinf2) with the Zinf2 receptor.

The microphysiometer also provides a means to identify Zinf2 antagonists. For example, Zinf2 antagonists can be identified by a method, comprising

the steps of (a) providing cells responsive to Zinf2, (b) incubating a first portion of the cells in the presence of Zinf2 and in the absence of a test compound, (c) incubating a second portion of the cells in the presence of both Zinf2 and the test compound, and (d) comparing the cellular responses of the first and second cell portions, wherein a decreased response by the second portion, compared with the response of the first portion, indicates that the test compound is a Zinf2 antagonist. An illustrative change in cellular response is a measurable change extracellular acidification rate, as measured by a microphysiometer.

Zinf2, its analogs, and anti-idiotypic Zinf2 antibodies can be used to identify and to isolate Zinf2 receptors. For example, proteins and peptides of the present invention can be immobilized on a column and used to bind receptor proteins from membrane preparations that are run over the column (Hermanson *et al.* (eds.), *Immobilized Affinity Ligand Techniques*, pages 195-202 (Academic Press 1992)). Radiolabeled or affinity labeled Zinf2 polypeptides can also be used to identify or to localize Zinf2 receptors in a biological sample (see, for example, Deutscher (ed.), *Methods in Enzymol.*, vol. 182, pages 721-37 (Academic Press 1990); Brunner *et al.*, *Ann. Rev. Biochem.* 62:483 (1993); Fedan *et al.*, *Biochem. Pharmacol.* 33:1167 (1984)). Also see, Varthakavi and Minocha, *J. Gen. Virol.* 77:1875 (1996), who describe the use of anti-idiotypic antibodies for receptor identification.

In addition, a solid phase system can be used to identify a Zinf2 receptor, or an agonist or antagonist of a Zinf2 receptor. For example, a Zinf2 polypeptide or Zinf2 fusion protein can be immobilized onto the surface of a receptor chip of a commercially available biosensor instrument (BIAcore, Biacore AB; Uppsala, Sweden). The use of this instrument is disclosed, for example, by Karlsson, *Immunol. Methods* 145:229 (1991), and Cunningham and Wells, *J. Mol. Biol.* 234:554 (1993).

As an illustration, a Zinf2 polypeptide or fusion protein is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within a flow cell. A test sample is then passed through the cell. If a receptor is present in the sample, it will bind to the immobilized polypeptide or fusion protein, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding. This system can also be used to examine antibody-antigen interactions, and the interactions of other complement/anti-complement pairs.

9. Production of Antibodies to Zinf2 Proteins

Antibodies to Zinf2 can be obtained, for example, using the product of a Zinf2 expression vector or Zinf2 isolated from a natural source as an antigen. Particularly useful anti-Zinf2 antibodies "bind specifically" with Zinf2. Antibodies are considered to be specifically binding if the antibodies exhibit at least one of the following two properties: (1) antibodies bind to Zinf2 with a threshold level of binding activity, and (2) antibodies do not significantly cross-react with polypeptides related to Zinf2.

With regard to the first characteristic, antibodies specifically bind if they bind to a Zinf2 polypeptide, peptide or epitope with a binding affinity (K_a) of $10^6 M^{-1}$ or greater, preferably $10^7 M^{-1}$ or greater, more preferably $10^8 M^{-1}$ or greater, and most preferably $10^9 M^{-1}$ or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, *Ann. NY Acad. Sci.* 51:660 (1949)). With regard to the second characteristic, antibodies do not significantly cross-react with related polypeptide molecules, for example, if they detect Zinf2, but not known related polypeptides using a standard Western blot analysis. Examples of known related polypeptides are orthologs and proteins from the same species that are members of a protein family. For example, specifically-binding anti-Zinf2 antibodies bind with Zinf2, but not with polypeptides such as interferon- α , interferon- β , interferon- γ , interferon- δ , interferon- ω , interferon- τ , or interferon- ϵ . Suitable antibodies include antibodies that bind with interferon-1 in regions having a low sequence similarity with other interferons.

Anti-Zinf2 antibodies can be produced using antigenic Zinf2 epitope-bearing peptides and polypeptides. Antigenic epitope-bearing peptides and polypeptides of the present invention contain a sequence of at least nine, preferably between 15 to about 30 amino acids contained within SEQ ID NO:2. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of the invention, containing from 30 to 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are useful for inducing antibodies that bind with Zinf2. It is desirable that the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (*i.e.*, the sequence includes relatively hydrophilic residues, while hydrophobic residues are preferably avoided). Moreover, amino acid sequences containing proline residues may be also be desirable for antibody production.

As an illustration, potential antigenic sites in Zinf2 were identified using the Jameson-Wolf method, Jameson and Wolf, *CABIOS* 4:181, (1988), as implemented

by the PROTEAN program (version 3.14) of LASERGENE (DNASTAR; Madison, WI). Default parameters were used in this analysis.

The Jameson-Wolf method predicts potential antigenic determinants by combining six major subroutines for protein structural prediction. Briefly, the Hopp-Woods method, Hopp *et al.*, *Proc. Nat'l Acad. Sci. USA* 78:3824 (1981), was first used to identify amino acid sequences representing areas of greatest local hydrophilicity (parameter: seven residues averaged). In the second step, Emini's method, Emini *et al.*, *J. Virology* 55:836 (1985), was used to calculate surface probabilities (parameter: surface decision threshold (0.6) = 1). Third, the Karplus-Schultz method, Karplus and Schultz, *Naturwissenschaften* 72:212 (1985), was used to predict backbone chain flexibility (parameter: flexibility threshold (0.2) = 1). In the fourth and fifth steps of the analysis, secondary structure predictions were applied to the data using the methods of Chou-Fasman, Chou, "Prediction of Protein Structural Classes from Amino Acid Composition," in *Prediction of Protein Structure and the Principles of Protein Conformation*, Fasman (ed.), pages 549-586 (Plenum Press 1990), and Garnier-Robson, Garnier *et al.*, *J. Mol. Biol.* 120:97 (1978) (Chou-Fasman parameters: conformation table = 64 proteins; α region threshold = 103; β region threshold = 105; Garnier-Robson parameters: α and β decision constants = 0). In the sixth subroutine, flexibility parameters and hydropathy/solvent accessibility factors were combined to determine a surface contour value, designated as the "antigenic index." Finally, a peak broadening function was applied to the antigenic index, which broadens major surface peaks by adding 20, 40, 60, or 80% of the respective peak value to account for additional free energy derived from the mobility of surface regions relative to interior regions. This calculation was not applied, however, to any major peak that resides in a helical region, since helical regions tend to be less flexible.

The results of this analysis indicated that the following illustrative amino acid sequences of SEQ ID NO:2 would provide suitable antigenic peptides: amino acids 28 to 36 ("antigenic peptide 1"), amino acids 41 to 47 ("antigenic peptide 2"), amino acids 49 to 56 ("antigenic peptide 3"), amino acids 62 to 74 ("antigenic peptide 4"), amino acids 90 to 96 ("antigenic peptide 5"), amino acids 110 to 120 ("antigenic peptide 6"), amino acids 138 to 144 ("antigenic peptide 7"), and amino acids 154 to 160 ("antigenic peptide 8"), and amino acids 169 to 185 ("antigenic peptide 9"). An additional antigenic peptide ("antigenic peptide 10") was determined from a surface probability plot as amino acids 130 to 145 of SEQ ID NO:2. The present invention contemplates the use of any one of antigenic peptides 1 to 10 to generate antibodies to Zinf2 proteins. The present invention also contemplates polypeptides comprising at least one of antigenic peptides 1 to 10.

Additional useful anti-Zinf2 antibodies bind to one of the following amino acid sequences: amino acid residues 30 to 40 of SEQ ID NO:2, amino acid residues 41 to 75 of SEQ ID NO:2, amino acid residues 76 to 92 of SEQ ID NO:2, amino acid residues 30 to 92 of SEQ ID NO:2, amino acid residues 100 to 110 of SEQ ID NO:2, amino acid residues 111 to 124 of SEQ ID NO:2, amino acid residues 125 to 139 of SEQ ID NO:2, amino acid residues 140 to 149 of SEQ ID NO:2, amino acid residues 150 to 169 of SEQ ID NO:2, amino acid residues 170 to 198 of SEQ ID NO:2, and amino acid residues 170 to 180 of SEQ ID NO:5.

Polyclonal antibodies to recombinant Zinf2 protein or to Zinf2 isolated from natural sources can be prepared using methods well-known to those of skill in the art. See, for example, Green *et al.*, "Production of Polyclonal Antisera," in *Immunochemical Protocols* (Manson, ed.), pages 1-5 (Humana Press 1992), and Williams *et al.*, "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), page 15 (Oxford University Press 1995). The immunogenicity of a Zinf2 polypeptide can be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zinf2 or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like," such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

Although polyclonal antibodies are typically raised in animals such as horses, cows, dogs, chicken, rats, mice, rabbits, goats, or sheep, an anti-Zinf2 antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in Goldenberg *et al.*, international patent publication No. WO 91/11465, and in Losman *et al.*, *Int. J. Cancer* 46:310 (1990).

Alternatively, monoclonal anti-Zinf2 antibodies can be generated. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler *et al.*, *Nature* 256:495 (1975), Coligan *et al.* (eds.), *Current Protocols in Immunology, Vol. 1*, pages 2.5.1-2.6.7 (John Wiley & Sons 1991) ["Coligan"], Picksley *et al.*, "Production of monoclonal antibodies against proteins expressed in *E. coli*," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover *et al.* (eds.), page 93 (Oxford University Press 1995)).

Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising a Zinf2 gene product, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

In addition, an anti-Zinf2 antibody of the present invention may be derived from a human monoclonal antibody. Human monoclonal antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, for example, by Green *et al.*, *Nature Genet.* 7:13 (1994), Lonberg *et al.*, *Nature* 368:856 (1994), and Taylor *et al.*, *Int. Immun.* 6:579 (1994).

Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines *et al.*, "Purification of Immunoglobulin G (IgG)," in *Methods in Molecular Biology*, Vol. 10, pages 79-104 (The Humana Press, Inc. 1992)).

For particular uses, it may be desirable to prepare fragments of anti-Zinf2 antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')₂. This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patent No. 4,331,647, Nisonoff *et al.*, *Arch Biochem. Biophys.* 89:230 (1960), Porter, *Biochem. J.* 73:119

(1959), Edelman *et al.*, in *Methods in Enzymology Vol. 1*, page 422 (Academic Press 1967), and by Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.

Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

For example, Fv fragments comprise an association of V_H and V_L chains. This association can be noncovalent, as described by Inbar *et al.*, *Proc. Nat'l Acad. Sci. USA* 69:2659 (1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde (see, for example, Sandhu, *Crit. Rev. Biotech.* 12:437 (1992)).

The Fv fragments may comprise V_H and V_L chains which are connected by a peptide linker. These single-chain antigen binding proteins (scFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains which are connected by an oligonucleotide. The structural gene is inserted into an expression vector which is subsequently introduced into a host cell, such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing scFvs are described, for example, by Whitlow *et al.*, *Methods: A Companion to Methods in Enzymology* 2:97 (1991) (also see, Bird *et al.*, *Science* 242:423 (1988), Ladner *et al.*, U.S. Patent No. 4,946,778, Pack *et al.*, *Bio/Technology* 11:1271 (1993), and Sandhu, *supra*).

As an illustration, a scFV can be obtained by exposing lymphocytes to Zinf2 polypeptide *in vitro*, and selecting antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled Zinf2 protein or peptide). Genes encoding polypeptides having potential Zinf2 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner *et al.*, U.S. Patent No. 5,223,409, Ladner *et al.*, U.S. Patent No. 4,946,778, Ladner *et al.*, U.S. Patent No. 5,403,484, Ladner *et al.*, U.S. Patent No. 5,571,698, and Kay *et al.*, *Phage Display of Peptides and Proteins* (Academic Press, Inc. 1996)) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from CLONTECH

Laboratories, Inc. (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA), and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the Zinf2 sequences disclosed herein to identify proteins which bind to Zinf2.

5 Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (see, for
10 example, Larrick *et al.*, *Methods: A Companion to Methods in Enzymology* 2:106 (1991), Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in *Monoclonal Antibodies: Production, Engineering and Clinical Application*, Ritter *et al.* (eds.), page 166 (Cambridge University Press 1995), and Ward *et al.*, "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, Birch *et al.*, (eds.), page 137 (Wiley-Liss, Inc. 1995)).

 Alternatively, an anti-Zinf2 antibody may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementary determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain. Typical residues
20 of human antibodies are then substituted in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi *et al.*, *Proc. Nat'l Acad. Sci. USA* 86:3833 (1989). Techniques for producing humanized monoclonal antibodies are
25 described, for example, by Jones *et al.*, *Nature* 321:522 (1986), Carter *et al.*, *Proc. Nat'l Acad. Sci. USA* 89:4285 (1992), Sandhu, *Crit. Rev. Biotech.* 12:437 (1992), Singer *et al.*, *J. Immun.* 150:2844 (1993), Sudhir (ed.), *Antibody Engineering Protocols* (Humana Press, Inc. 1995), Kelley, "Engineering Therapeutic Antibodies," in *Protein Engineering: Principles and Practice*, Cleland *et al.* (eds.), pages 399-434 (John Wiley & Sons, Inc. 1996), and by Queen *et al.*, U.S. Patent No. 5,693,762 (1997).

30 Polyclonal anti-idiotypic antibodies can be prepared by immunizing animals with anti-Zinf2 antibodies or antibody fragments, using standard techniques. See, for example, Green *et al.*, "Production of Polyclonal Antisera," in *Methods In Molecular Biology: Immunochemical Protocols*, Manson (ed.), pages 1-12 (Humana Press 1992). Also, see Coligan at pages 2.4.1-2.4.7. Alternatively, monoclonal anti-idiotypic antibodies can be prepared using anti-Zinf2 antibodies or antibody fragments

as immunogens with the techniques, described above. As another alternative, humanized anti-idiotypic antibodies or subhuman primate anti-idiotypic antibodies can be prepared using the above-described techniques. Methods for producing anti-idiotypic antibodies are described, for example, by Irie, U.S. Patent No. 5,208,146, Greene, *et al.*, U.S. Patent No. 5,637,677, and Varthakavi and Minocha, *J. Gen. Virol.* 77:1875 (1996).

10. Use of Zinf2 Nucleotide Sequences to Detect Zinf2 Gene Expression and to Examine Zinf2 Gene Structure

Nucleic acid molecules can be used to detect the expression of a Zinf2 gene in a biological sample. Such probe molecules include double-stranded nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO:1, or a portion thereof, as well as single-stranded nucleic acid molecules having the complement of the nucleotide sequence of SEQ ID NO:1, or a portion thereof. Probe molecules may be DNA, RNA, oligonucleotides, and the like. As used herein, the term "portion" refers to at least eight nucleotides to at least 20 or more nucleotides. Certain probes bind with regions of the Zinf2 gene that have a low sequence similarity to comparable regions in other interferons.

In a basic assay, a single-stranded probe molecule is incubated with RNA, isolated from a biological sample, under conditions of temperature and ionic strength that promote base pairing between the probe and target Zinf2 RNA species. After separating unbound probe from hybridized molecules, the amount of hybrids is detected.

Well-established hybridization methods of RNA detection include northern analysis and dot/slot blot hybridization (see, for example, Ausubel (1995) at pages 4-1 to 4-27, and Wu *et al.* (eds.), "Analysis of Gene Expression at the RNA Level," in *Methods in Gene Biotechnology*, pages 225-239 (CRC Press, Inc. 1997)). Nucleic acid probes can be detectably labeled with radioisotopes such as ³²P or ³⁵S. Alternatively, Zinf2 RNA can be detected with a nonradioactive hybridization method (see, for example, Isaac (ed.), *Protocols for Nucleic Acid Analysis by Nonradioactive Probes* (Humana Press, Inc. 1993)). Typically, nonradioactive detection is achieved by enzymatic conversion of chromogenic or chemiluminescent substrates. Illustrative nonradioactive moieties include biotin, fluorescein, and digoxigenin.

Zinf2 oligonucleotide probes are also useful for *in vivo* diagnosis. As an illustration, ¹⁸F-labeled oligonucleotides can be administered to a subject and visualized by positron emission tomography (Tavitian *et al.*, *Nature Medicine* 4:467 (1998)).

Numerous diagnostic procedures take advantage of the polymerase chain reaction (PCR) to increase sensitivity of detection methods. Standard techniques for performing PCR are well-known (see, generally, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), White (ed.), *PCR Protocols: Current Methods and Applications* (Humana Press, Inc. 1993), Cotter (ed.), *Molecular Diagnosis of Cancer* (Humana Press, Inc. 1996), Hanausek and Walaszek (eds.), *Tumor Marker Protocols* (Humana Press, Inc. 1998), Lo (ed.), *Clinical Applications of PCR* (Humana Press, Inc. 1998), and Meltzer (ed.), *PCR in Bioanalysis* (Humana Press, Inc. 1998)).

Preferably, PCR primers are designed to amplify a portion of the Zinf2 gene that has a low sequence similarity to a comparable region in other interferons.

One variation of PCR for diagnostic assays is reverse transcriptase-PCR (RT-PCR). In the RT-PCR technique, RNA is isolated from a biological sample, reverse transcribed to cDNA, and the cDNA is incubated with Zinf2 primers (see, for example, Wu *et al.* (eds.), "Rapid Isolation of Specific cDNAs or Genes by PCR," in *Methods in Gene Biotechnology*, pages 15-28 (CRC Press, Inc. 1997)). PCR is then performed and the products are analyzed using standard techniques.

As an illustration, RNA is isolated from biological sample using, for example, the guanidinium-thiocyanate cell lysis procedure described above. Alternatively, a solid-phase technique can be used to isolate mRNA from a cell lysate. A reverse transcription reaction can be primed with the isolated RNA using random oligonucleotides, short homopolymers of dT, or Zinf2 anti-sense oligomers. Oligo-dT primers offer the advantage that various mRNA nucleotide sequences are amplified that can provide control target sequences. Zinf2 sequences are amplified by the polymerase chain reaction using two flanking oligonucleotide primers that are typically 20 bases in length.

PCR amplification products can be detected using a variety of approaches. For example, PCR products can be fractionated by gel electrophoresis, and visualized by ethidium bromide staining. Alternatively, fractionated PCR products can be transferred to a membrane, hybridized with a detectably-labeled Zinf2 probe, and examined by autoradiography. Additional alternative approaches include the use of digoxigenin-labeled deoxyribonucleic acid triphosphates to provide chemiluminescence detection, and the C-TRAK colorimetric assay.

Another approach for detection of Zinf2 expression is cycling probe technology (CPT), in which a single-stranded DNA target binds with an excess of DNA-RNA-DNA chimeric probe to form a complex, the RNA portion is cleaved with RNAase H, and the presence of cleaved chimeric probe is detected (see, for example,

Beggs *et al.*, *J. Clin. Microbiol.* 34:2985 (1996), Bekkaoui *et al.*, *Biotechniques* 20:240 (1996)). Alternative methods for detection of *Zinf2* sequences can utilize approaches such as nucleic acid sequence-based amplification (NASBA), cooperative amplification of templates by cross-hybridization (CATCH), and the ligase chain reaction (LCR) (see, for example, Marshall *et al.*, U.S. Patent No. 5,686,272 (1997), Dyer *et al.*, *J. Virol. Methods* 60:161 (1996), Ehricht *et al.*, *Eur. J. Biochem.* 243:358 (1997), and Chadwick *et al.*, *J. Virol. Methods* 70:59 (1998)). Other standard methods are known to those of skill in the art.

Zinf2 probes and primers can also be used to detect and to localize *Zinf2* gene expression in tissue samples. Methods for such *in situ* hybridization are well-known to those of skill in the art (see, for example, Choo (ed.), *In Situ Hybridization Protocols* (Humana Press, Inc. 1994), Wu *et al.* (eds.), "Analysis of Cellular DNA or Abundance of mRNA by Radioactive *In Situ* Hybridization (RISH)," in *Methods in Gene Biotechnology*, pages 259-278 (CRC Press, Inc. 1997), and Wu *et al.* (eds.), "Localization of DNA or Abundance of mRNA by Fluorescence *In Situ* Hybridization (RISH)," in *Methods in Gene Biotechnology*, pages 279-289 (CRC Press, Inc. 1997)).

Various additional diagnostic approaches are well-known to those of skill in the art (see, for example, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), Coleman and Tsongalis, *Molecular Diagnostics* (Humana Press, Inc. 1996), and Elles, *Molecular Diagnosis of Genetic Diseases* (Humana Press, Inc., 1996)).

The present invention also includes the use of nucleic acid molecules comprising *Zinf2* nucleotide sequences to determine whether a subject's chromosomes contain a mutation in the *Zinf2* gene. Detectable chromosomal aberrations at the *Zinf2* gene locus include, but are not limited to, aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements. Of particular interest are genetic alterations that inactivate the *Zinf2* gene.

Aberrations associated with the *Zinf2* locus can be detected using nucleic acid molecules of the present invention by employing molecular genetic techniques, such as restriction fragment length polymorphism analysis, short tandem repeat analysis employing PCR techniques, amplification-refractory mutation system analysis, single-strand conformation polymorphism detection, RNase cleavage methods, denaturing gradient gel electrophoresis, fluorescence-assisted mismatch analysis, and other genetic analysis techniques known in the art (see, for example, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), Marian, *Chest* 108:255 (1995), Coleman and Tsongalis, *Molecular Diagnostics* (Human Press, Inc. 1996), Elles (ed.), *Molecular Diagnosis of Genetic Diseases* (Humana Press, Inc. 1996), Landegren (ed.),

Laboratory Protocols for Mutation Detection (Oxford University Press 1996), Birren *et al.* (eds.), *Genome Analysis, Vol. 2: Detecting Genes* (Cold Spring Harbor Laboratory Press 1998), Dracopoli *et al.* (eds.), *Current Protocols in Human Genetics* (John Wiley & Sons 1998), and Richards and Ward, "Molecular Diagnostic Testing," in *Principles of Molecular Medicine*, pages 83-88 (Humana Press, Inc. 1998)).

The protein truncation test is also useful for detecting the inactivation of a gene in which translation-terminating mutations produce only portions of the encoded protein (see, for example, Stoppa-Lyonnet *et al.*, *Blood* 91:3920 (1998)). According to this approach, RNA is isolated from a biological sample, and used to synthesize cDNA. PCR is then used to amplify the *Zinf2* target sequence and to introduce an RNA polymerase promoter, a translation initiation sequence, and an in-frame ATG triplet. PCR products are transcribed using an RNA polymerase, and the transcripts are translated *in vitro* with a T7-coupled reticulocyte lysate system. The translation products are then fractionated by SDS-PAGE to determine the lengths of the translation products. The protein truncation test is described, for example, by Dracopoli *et al.* (eds.), *Current Protocols in Human Genetics*, pages 9.11.1 - 9.11.18 (John Wiley & Sons 1998).

In a related approach, *Zinf2* protein is isolated from a subject, the molecular weight of the isolated *Zinf2* protein is determined, and then compared with the molecular weight a normal *Zinf2* protein, such as a protein having the amino acid sequence of SEQ ID NO:2. A substantially lower molecular weight for the isolated *Zinf2* protein is indicative that the protein is truncated. In this context, "substantially lower molecular weight" refers to at least about 10 percent lower, and preferably, at least about 25 percent lower. The *Zinf2* protein may be isolated by various procedures known in the art including immunoprecipitation, solid phase radioimmunoassay, enzyme-linked immunosorbent assay, or Western blotting. The molecular weight of the isolated *Zinf2* protein can be determined using standard techniques, such as SDS-polyacrylamide gel electrophoresis.

The chromosomal location of the *Zinf2* gene can be localized using radiation hybrid mapping, which is a somatic cell genetic technique developed for constructing high-resolution, contiguous maps of mammalian chromosomes (Cox *et al.*, *Science* 250:245 (1990)). Partial or full knowledge of a gene's sequence allows one to design PCR primers suitable for use with chromosomal radiation hybrid mapping panels. Radiation hybrid mapping panels are commercially available which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel (Research Genetics, Inc., Huntsville, AL). These panels enable rapid, PCR-based chromosomal localizations and ordering of genes, sequence-tagged sites (STSs), and

other nonpolymorphic and polymorphic markers within a region of interest. This includes establishing directly proportional physical distances between newly discovered genes of interest and previously mapped markers.

5 The present invention also contemplates kits for performing a diagnostic assay for *Zinf2* gene expression or to examine the *Zinf2* locus. Such kits comprise nucleic acid probes, such as double-stranded nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO:1, or a portion thereof, as well as single-stranded nucleic acid molecules having the complement of the nucleotide sequence of SEQ ID NO:1, or a portion thereof. Probe molecules may be DNA, RNA, oligonucleotides, and the like.
10 Kits may comprise nucleic acid primers for performing PCR.

Such a kit can contain all the necessary elements to perform a nucleic acid diagnostic assay described above. A kit will comprise at least one container comprising a *Zinf2* probe or primer. The kit may also comprise a second container comprising one or more reagents capable of indicating the presence of *Zinf2* sequences.
15 Examples of such indicator reagents include detectable labels such as radioactive labels, fluorochromes, chemiluminescent agents, and the like. A kit may also comprise a means for conveying to the user that the *Zinf2* probes and primers are used to detect *Zinf2* gene expression. For example, written instructions may state that the enclosed nucleic acid molecules can be used to detect either a nucleic acid molecule that encodes
20 *Zinf2*, or a nucleic acid molecule having a nucleotide sequence that is complementary to a *Zinf2*-encoding nucleotide sequence. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.

11. Use of Anti-*Zinf2* Antibodies to Detect *Zinf2* Protein

25 The present invention contemplates the use of anti-*Zinf2* antibodies to screen biological samples *in vitro* for the presence of *Zinf2*. In one type of *in vitro* assay, anti-*Zinf2* antibodies are used in liquid phase. For example, the presence of *Zinf2* in a biological sample can be tested by mixing the biological sample with a trace amount of labeled *Zinf2* and an anti-*Zinf2* antibody under conditions that promote binding between
30 *Zinf2* and its antibody. Complexes of *Zinf2* and anti-*Zinf2* in the sample can be separated from the reaction mixture by contacting the complex with an immobilized protein which binds with the antibody, such as an Fc antibody or *Staphylococcus* protein A. The concentration of *Zinf2* in the biological sample will be inversely proportional to the amount of labeled *Zinf2* bound to the antibody and directly related to the amount of free
35 labeled *Zinf2*.

Alternatively, *in vitro* assays can be performed in which anti-Zinf2 antibody is bound to a solid-phase carrier. For example, antibody can be attached to a polymer, such as aminodextran, in order to link the antibody to an insoluble support such as a polymer-coated bead, a plate or a tube. Other suitable *in vitro* assays will be readily apparent to those of skill in the art.

In another approach, anti-Zinf2 antibodies can be used to detect Zinf2 in tissue sections prepared from a biopsy specimen. Such immunochemical detection can be used to determine the relative abundance of Zinf2 and to determine the distribution of Zinf2 in the examined tissue. General immunochemistry techniques are well established (see, for example, Ponder, "Cell Marking Techniques and Their Application," in *Mammalian Development: A Practical Approach*, Monk (ed.), pages 115-38 (IRL Press 1987), Coligan at pages 5.8.1-5.8.8, Ausubel (1995) at pages 14.6.1 to 14.6.13 (Wiley Interscience 1990), and Manson (ed.), *Methods In Molecular Biology, Vol.10: Immunochemical Protocols* (The Humana Press, Inc. 1992)).

Immunochemical detection can be performed by contacting a biological sample with an anti-Zinf2 antibody, and then contacting the biological sample with a detectably labeled molecule which binds to the antibody. For example, the detectably labeled molecule can comprise an antibody moiety that binds to anti-Zinf2 antibody. Alternatively, the anti-Zinf2 antibody can be conjugated with avidin/streptavidin (or biotin) and the detectably labeled molecule can comprise biotin (or avidin/streptavidin). Numerous variations of this basic technique are well-known to those of skill in the art.

Alternatively, an anti-Zinf2 antibody can be conjugated with a detectable label to form an anti-Zinf2 immunoconjugate. Suitable detectable labels include, for example, a radioisotope, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label or colloidal gold. Methods of making and detecting such detectably-labeled immunoconjugates are well-known to those of ordinary skill in the art, and are described in more detail below.

The detectable label can be a radioisotope that is detected by autoradiography. Isotopes that are particularly useful for the purpose of the present invention are ^3H , ^{125}I , ^{131}I , ^{35}S and ^{14}C .

Anti-Zinf2 immunoconjugates can also be labeled with a fluorescent compound. The presence of a fluorescently-labeled antibody is determined by exposing the immunoconjugate to light of the proper wavelength and detecting the resultant fluorescence. Fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

Alternatively, anti-Zinf2 immunoconjugates can be detectably labeled by coupling an antibody component to a chemiluminescent compound. The presence of the

chemiluminescent-tagged immunoconjugate is determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of chemiluminescent labeling compounds include luminol, isoluminol, an aromatic acridinium ester, an imidazole, an acridinium salt and an oxalate ester.

5 Similarly, a bioluminescent compound can be used to label anti-Zinf2 immunoconjugates of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Bioluminescent compounds that
10 are useful for labeling include luciferin, luciferase and aequorin.

Alternatively, anti-Zinf2 immunoconjugates can be detectably labeled by linking an anti-Zinf2 antibody component to an enzyme. When the anti-Zinf2-enzyme conjugate is incubated in the presence of the appropriate substrate, the enzyme moiety reacts with the substrate to produce a chemical moiety which can be detected, for
15 example, by spectrophotometric, fluorometric or visual means. Examples of enzymes that can be used to detectably label polyspecific immunoconjugates include β -galactosidase, glucose oxidase, peroxidase and alkaline phosphatase.

Those of skill in the art will know of other suitable labels which can be employed in accordance with the present invention. The binding of marker moieties to
20 anti-Zinf2 antibodies can be accomplished using standard techniques known to the art. Typical methodology in this regard is described by Kennedy *et al.*, *Clin. Chim. Acta* 70:1 (1976), Schurs *et al.*, *Clin. Chim. Acta* 81:1 (1977), Shih *et al.*, *Int'l J. Cancer* 46:1101 (1990), Stein *et al.*, *Cancer Res.* 50:1330 (1990), and Coligan, *supra*.

Moreover, the convenience and versatility of immunochemical detection
25 can be enhanced by using anti-Zinf2 antibodies that have been conjugated with avidin, streptavidin, and biotin (see, for example, Wilchek *et al.* (eds.), "Avidin-Biotin Technology," *Methods In Enzymology*, Vol. 184 (Academic Press 1990), and Bayer *et al.*, "Immunochemical Applications of Avidin-Biotin Technology," in *Methods In Molecular Biology*, Vol. 10, Manson (ed.), pages 149-162 (The Humana Press, Inc. 1992).

30 Methods for performing immunoassays are well-established. See, for example, Cook and Self, "Monoclonal Antibodies in Diagnostic Immunoassays," in *Monoclonal Antibodies: Production, Engineering, and Clinical Application*, Ritter and Ladyman (eds.), pages 180-208, (Cambridge University Press, 1995), Perry, "The Role of Monoclonal Antibodies in the Advancement of Immunoassay Technology," in
35 *Monoclonal Antibodies: Principles and Applications*, Birch and Lennox (eds.), pages 107-120 (Wiley-Liss, Inc. 1995), and Diamandis, *Immunoassay* (Academic Press, Inc. 1996).

In a related approach, biotin- or FITC-labeled Zinf2 can be used to identify cells that bind Zinf2. Such can binding can be detected, for example, using flow cytometry.

5 The present invention also contemplates kits for performing an immunological diagnostic assay for Zinf2 gene expression. Such kits comprise at least one container comprising an anti-Zinf2 antibody, or antibody fragment. A kit may also
10 comprise a second container comprising one or more reagents capable of indicating the presence of Zinf2 antibody or antibody fragments. Examples of such indicator reagents include detectable labels such as a radioactive label, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label, colloidal gold, and the like. A kit may also comprise a means for conveying to the user that Zinf2 antibodies
15 or antibody fragments are used to detect Zinf2 protein. For example, written instructions may state that the enclosed antibody or antibody fragment can be used to detect Zinf2. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.

12. Therapeutic Uses of Polypeptides Having Zinf2 Activity

Interferons are known to be potent cytokines that possess antiviral, immunomodulating, and anti-proliferative activities. Therefore, the present invention
20 includes the use of proteins, polypeptides, and peptides having Zinf2 activity (such as Zinf2 polypeptides, Zinf2 analogs, and Zinf2 fusion proteins) to provide antiviral, immunomodulatory, or anti-proliferative activity. These molecules can be administered to any subject in need of treatment, and the present invention contemplates both veterinary and human therapeutic uses. Illustrative subjects include mammalian
25 subjects, such as farm animals, domestic animals, and human patients.

Both recombinant interferons and interferons isolated from natural sources have been approved in the United States for treatment of autoimmune diseases, condyloma acuminatum, chronic hepatitis C, bladder carcinoma, cervical carcinoma, laryngeal papillomatosis, fungoides mycosis, chronic hepatitis B, Kaposi's sarcoma in
30 patients infected with human immunodeficiency virus, malignant melanoma, hairy cell leukemia, and multiple sclerosis. In addition, Zinf2 may be used to treat forms of arteriosclerosis, such as atherosclerosis, by inhibiting cell proliferation. Accordingly, the present invention contemplates the use of proteins, polypeptides, and peptides having Zinf2 activity to treat such conditions, as well as to treat retinopathy. The
35 present invention also contemplates the use of proteins, polypeptides, and peptides

having Zinf2 activity to treat lymphoproliferative disorders, including B-cell lymphomas, chronic lymphatic leukemias, and acute lymphatic leukemias.

Interferons are also known to augment the presentation of human tumor antigens, as discussed above. Thus, the present invention includes the use of proteins, polypeptides and peptides having Zinf2 activity as an adjuvant for immunotherapy or immunoscintigraphy using anti-tumor antigen antibodies.

Members of the type I interferon family have also been shown to influence neural cell activity and growth (see, for example, Dafny *et al.*, *Brain Res.* 734:269 (1996); Pliopsys and Massimini, *Neuroimmunomodulation* 2:31 (1995)). In addition, intraventricular injection of neural growth factors has been shown to influence learning in animal models (see, for example, Fischer, *et al.*, *Nature* 329:65 (1987)). Accordingly, the present invention includes methods for using Zinf2 protein to treat disorders of the central nervous system, including anxiety, depression, schizophrenia, Parkinson's disease, stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and Huntington's disease.

Zinf2 can also be used to treat myocarditis, a disorder that arises when the heart is involved in an inflammatory process. The infiltration of lymphocytes and myocytolysis is thought to result after infection by virus, bacteria, fungi or parasites (see, for example, Brodison *et al.*, *J. Infection* 37:99 (1998)). Zinf2 can be injected intravenously to treat infections associated with myocarditis. Zinf2 can also be administered intravenously as an immunoregulatory cytokine in the treatment of autoimmune myocarditis. Interferon dosages can be extrapolated using a autoimmune model of myocarditis in the A/J mouse (Donermeyer, *et al.*, *J. Exp. Med.* 182:1291 (1995)).

Exogenous administration of interferon- τ in sheep increases the pregnancy rate (Aggarwal, *Human Cytokines III*, (Blackwell Science 1997)). As described herein, Zinf2 mRNA is expressed in placenta. Accordingly, the present invention includes the use of Zinf2, such as the disclosed human Zinf2, to promote and protect growth of the fetus. As an illustration, Zinf2 can be used to protect a developing fetus from viral infection (*e.g.*, human immunodeficiency virus, human papilloma virus, and the like). In addition, Zinf2 can be used to promote *in vitro* fertilization.

Generally, the dosage of administered Zinf2 (or Zinf2 analog or fusion protein) will vary depending upon such factors as the subject's age, weight, height, sex, general medical condition and previous medical history. Typically, it is desirable to provide the recipient with a dosage of Zinf2, which is in the range of from about 1

pg/kg to 10 mg/kg (amount of agent/body weight of subject), although a lower or higher dosage also may be administered as circumstances dictate.

Administration of a molecule having Zinf2 activity to a subject can be intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, by perfusion through a regional catheter, or by direct intralesional injection. When administering therapeutic proteins by injection, the administration may be by continuous infusion or by single or multiple boluses. Alternatively, Zinf2 can be administered as a controlled release formulation. For example, Cleland and Jones, *Pharm. Res.* 13:1464 (1996), describe a method for producing Zinf2 encapsulated in polylactic-coglycolic microspheres.

Additional routes of administration include oral, dermal, mucosal-membrane, pulmonary, and transcutaneous. Oral delivery is suitable for polyester microspheres, zein microspheres, proteinoid microspheres, polycyanoacrylate microspheres, and lipid-based systems (see, for example, DiBase and Morrel, "Oral Delivery of Microencapsulated Proteins," in *Protein Delivery: Physical Systems*, Sanders and Hendren (eds.), pages 255-288 (Plenum Press 1997)). The feasibility of an intranasal delivery is exemplified by such a mode of insulin administration (see, for example, Hinchcliffe and Illum, *Adv. Drug Deliv. Rev.* 35:199 (1999)). Dry or liquid particles comprising Zinf2 can be prepared and inhaled with the aid of dry-powder dispersers, liquid aerosol generators, or nebulizers (e.g., Pettit and Gombotz, *TIBTECH* 16:343 (1998); Patton *et al.*, *Adv. Drug Deliv. Rev.* 35:235 (1999)). This approach is illustrated by the AERX diabetes management system, which is a hand-held electronic inhaler that delivers aerosolized insulin into the lungs. Studies have shown that proteins as large as 48,000 kDa have been delivered across skin at therapeutic concentrations with the aid of low-frequency ultrasound, which illustrates the feasibility of transcutaneous administration (Mitragotri *et al.*, *Science* 269:850 (1995)). Transdermal delivery using electroporation provides another means to administer Zinf2 (Potts *et al.*, *Pharm. Biotechnol.* 10:213 (1997)).

A pharmaceutical composition comprising molecules having Zinf2 activity can be furnished in liquid form, in an aerosol, or in solid form. Proteins having Zinf2 activity can be administered as a conjugate with a pharmaceutically acceptable water-soluble polymer moiety, as described above. As an illustration, a Zinf2-polyethylene glycol conjugate is useful to increase the circulating half-life of the interferon, and to reduce the immunogenicity of the polypeptide. Liquid forms, including liposome-encapsulated formulations, are illustrated by injectable solutions and oral suspensions. Exemplary solid forms include capsules, tablets, and controlled-release forms, such as a miniosmotic pump or an implant. Other dosage forms can be

devised by those skilled in the art, as shown, for example, by Ansel and Popovich, *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 5th Edition (Lea & Febiger 1990), Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 19th Edition (Mack Publishing Company 1995), and by Ranade and Hollinger, *Drug Delivery Systems* (CRC Press 1996).

A pharmaceutical composition comprising a protein, polypeptide, or peptide having Zinf2 activity can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient subject. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers are well-known to those in the art. See, for example, Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 19th Edition (Mack Publishing Company 1995).

For purposes of therapy, molecules having Zinf2 activity and a pharmaceutically acceptable carrier are administered to a subject in a therapeutically effective amount. A combination of a protein, polypeptide, or peptide having Zinf2 activity and a pharmaceutically acceptable carrier is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient subject. In the present context, an agent is physiologically significant if its presence results in the inhibition of the growth of tumor cells or in the inhibition of a viral infection. An inhibition of tumor growth may be indicated, for example, by a decrease in the number of tumor cells, decreased metastasis, a decrease in the size of a solid tumor, or increased necrosis of a tumor. Indicators of viral infection inhibition include decreased viral titer, a decrease in detectable viral antigen, or an increase in anti-viral antibody titer.

Zinf2 pharmaceutical compositions may be supplied as a kit comprising a container that comprises Zinf2, a Zinf2 agonist, or a Zinf2 antagonist (e.g., an anti-Zinf2 antibody or antibody fragment). Zinf2 can be provided in the form of an injectable solution for single or multiple doses, or as a sterile powder that will be reconstituted before injection. Alternatively, such a kit can include a dry-powder disperser, liquid aerosol generator, or nebulizer for administration of a therapeutic polypeptide. Such a kit may further comprise written information on indications and usage of the pharmaceutical composition. Moreover, such information may include a statement that the Zinf2 composition is contraindicated in patients with known hypersensitivity to Zinf2.

13. Therapeutic Uses of Zinf2 Nucleotide Sequences

Immunomodulator genes can be introduced into a subject to enhance immunological responses. As an illustration "immunomodulator gene therapy" has been examined in model systems using vectors that express IL-2, IL-3, IL-4, IL-6, IL-10, IL-12, IL-15, interferon- γ , tumor necrosis factor- α , or granulocyte-macrophage colony-stimulating factor (see, for example, Cao *et al.*, *J. Gastroenterol. Hepatol.* 11:1053 (1996), Tahara *et al.*, *Ann. N. Y. Acad. Sci.* 795:275 (1996), Rakhmilevich *et al.*, *Hum. Gene Ther.* 8:1303 (1997), and Cao *et al.*, *Transplantation* 65:325 (1998)). The present invention includes the use of Zinf2 nucleotide sequences to augment an immunological response to a tumor or viral infection in a subject. In addition, a therapeutic expression vector can be provided that inhibits Zinf2 gene expression, such as an anti-sense molecule, a ribozyme, or an external guide sequence molecule.

There are numerous approaches to introduce a Zinf2 gene to a subject, including the use of recombinant host cells that express Zinf2, delivery of naked nucleic acid encoding Zinf2, use of a cationic lipid carrier with a nucleic acid molecule that encodes Zinf2, and the use of viruses that express Zinf2, such as recombinant retroviruses, recombinant adeno-associated viruses, recombinant adenoviruses, and recombinant Herpes simplex viruses [HSV] (see, for example, Mulligan, *Science* 260:926 (1993), Rosenberg *et al.*, *Science* 242:1575 (1988), LaSalle *et al.*, *Science* 259:988 (1993), Wolff *et al.*, *Science* 247:1465 (1990), Breakfield and Deluca, *The New Biologist* 3:203 (1991)). In an *ex vivo* approach, for example, cells are isolated from a subject, transfected with a vector that expresses a Zinf2 gene, and then transplanted into the subject.

In order to effect expression of a Zinf2 gene, an expression vector is constructed in which a nucleotide sequence encoding a Zinf2 gene is operably linked to a core promoter, and optionally a regulatory element, to control gene transcription. The general requirements of an expression vector are described above.

Alternatively, a Zinf2 gene can be delivered using recombinant viral vectors, including for example, adenoviral vectors (*e.g.*, Kass-Eisler *et al.*, *Proc. Nat'l Acad. Sci. USA* 90:11498 (1993), Kolls *et al.*, *Proc. Nat'l Acad. Sci. USA* 91:215 (1994), Li *et al.*, *Hum. Gene Ther.* 4:403 (1993), Vincent *et al.*, *Nat. Genet.* 5:130 (1993), and Zabner *et al.*, *Cell* 75:207 (1993)), adenovirus-associated viral vectors (Flotte *et al.*, *Proc. Nat'l Acad. Sci. USA* 90:10613 (1993)), alphaviruses such as Semliki Forest Virus and Sindbis Virus (Hertz and Huang, *J. Vir.* 66:857 (1992), Raju and Huang, *J. Vir.* 65:2501 (1991), and Xiong *et al.*, *Science* 243:1188 (1989)), herpes

viral vectors (e.g., U.S. Patent Nos. 4,769,331, 4,859,587, 5,288,641 and 5,328,688), parvovirus vectors (Koering *et al.*, *Hum. Gene Therap.* 5:457 (1994)), pox virus vectors (Ozaki *et al.*, *Biochem. Biophys. Res. Comm.* 193:653 (1993), Panicali and Paoletti, *Proc. Nat'l Acad. Sci. USA* 79:4927 (1982)), pox viruses, such as canary pox virus or vaccinia virus (Fisher-Hoch *et al.*, *Proc. Nat'l Acad. Sci. USA* 86:317 (1989), and Flexner *et al.*, *Ann. N.Y. Acad. Sci.* 569:86 (1989)), and retroviruses (e.g., Baba *et al.*, *J. Neurosurg* 79:729 (1993), Ram *et al.*, *Cancer Res.* 53:83 (1993), Takamiya *et al.*, *J. Neurosci. Res* 33:493 (1992), Vile and Hart, *Cancer Res.* 53:962 (1993), Vile and Hart, *Cancer Res.* 53:3860 (1993), and Anderson *et al.*, U.S. Patent No. 5,399,346). Within various embodiments, either the viral vector itself, or a viral particle which contains the viral vector may be utilized in the methods and compositions described below.

High titer stocks of recombinant viruses capable of expressing a therapeutic gene can be obtained from infected mammalian cells using standard methods. For example, recombinant HSV can be prepared in Vero cells, as described by Brandt *et al.*, *J. Gen. Virol.* 72:2043 (1991), Herold *et al.*, *J. Gen. Virol.* 75:1211 (1994), Visalli and Brandt, *Virology* 185:419 (1991), Grau *et al.*, *Invest. Ophthalmol. Vis. Sci.* 30:2474 (1989), Brandt *et al.*, *J. Virol. Meth.* 36:209 (1992), and by Brown and MacLean (eds.), *HSV Virus Protocols* (Humana Press 1997).

Alternatively, an expression vector comprising a Zinf2 gene can be introduced into a subject's cells by lipofection *in vivo* using liposomes. Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker (Felgner *et al.*, *Proc. Nat'l Acad. Sci. USA* 84:7413 (1987); Mackey *et al.*, *Proc. Nat'l Acad. Sci. USA* 85:8027 (1988)). The use of lipofection to introduce exogenous genes into specific organs *in vivo* has certain practical advantages. Liposomes can be used to direct transfection to particular cell types, which is particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules for the purpose of targeting. Targeted peptides (e.g., hormones or neurotransmitters), proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.

In an alternative approach to gene therapy, a therapeutic gene may encode a Zinf2 anti-sense RNA that inhibits the expression of Zinf2. Suitable sequences for anti-sense molecules can be derived from the nucleotide sequences of Zinf2 disclosed herein.

Alternatively, an expression vector can be constructed in which a regulatory element is operably linked to a nucleotide sequence that encodes a ribozyme. Ribozymes can be designed to express endonuclease activity that is directed to a certain target sequence in a mRNA molecule (see, for example, Draper and Macejak, U.S.

Patent No. 5,496,698, McSwiggen, U.S. Patent No. 5,525,468, Chowrira and McSwiggen, U.S. Patent No. 5,631,359, and Robertson and Goldberg, U.S. Patent No. 5,225,337). In the context of the present invention, ribozymes include nucleotide sequences that bind with Zinf2 mRNA.

5 In another approach, expression vectors can be constructed in which a regulatory element directs the production of RNA transcripts capable of promoting RNase P-mediated cleavage of mRNA molecules that encode a Zinf2 gene. According to this approach, an external guide sequence can be constructed for directing the endogenous
10 ribozyme, RNase P, to a particular species of intracellular mRNA, which is subsequently cleaved by the cellular ribozyme (see, for example, Altman *et al.*, U.S. Patent No. 5,168,053, Yuan *et al.*, *Science* 263:1269 (1994), Pace *et al.*, international publication No. WO 96/18733, George *et al.*, international publication No. WO 96/21731, and Werner *et al.*, international publication No. WO 97/33991). Preferably, the external
15 guide sequence comprises a ten to fifteen nucleotide sequence complementary to Zinf2 mRNA, and a 3'-NCCA nucleotide sequence, wherein N is preferably a purine. The external guide sequence transcripts bind to the targeted mRNA species by the formation of base pairs between the mRNA and the complementary external guide sequences, thus promoting cleavage of mRNA by RNase P at the nucleotide located at the 5'-side of the base-paired region.

20 In general, the dosage of a composition comprising a therapeutic vector having a Zinf2 nucleotide acid sequence, such as a recombinant virus, will vary depending upon such factors as the subject's age, weight, height, sex, general medical condition and previous medical history. Suitable routes of administration of therapeutic
25 vectors include intravenous injection, intraarterial injection, intraperitoneal injection, intramuscular injection, intratumoral injection, and injection into a cavity that contains a tumor.

A composition comprising viral vectors, non-viral vectors, or a combination of viral and non-viral vectors of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby
30 vectors or viruses are combined in a mixture with a pharmaceutically acceptable carrier. As noted above, a composition, such as phosphate-buffered saline is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient subject. Other suitable carriers are well-known to those in the art (see, for example, *Remington's Pharmaceutical Sciences*, 19th Ed. (Mack Publishing Co. 1995),
35 and *Gilman's the Pharmacological Basis of Therapeutics*, 7th Ed. (MacMillan Publishing Co. 1985)).

For purposes of therapy, a therapeutic gene expression vector, or a recombinant virus comprising such a vector, and a pharmaceutically acceptable carrier are administered to a subject in a therapeutically effective amount. A combination of an expression vector (or virus) and a pharmaceutically acceptable carrier is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient subject. In the present context, an agent is physiologically significant if its presence inhibits the growth of tumor cells or inhibits viral infection. An inhibition of tumor growth may be indicated, for example, by a decrease in the number of tumor cells, decreased metastasis, a decrease in the size of a solid tumor, or increased necrosis of a tumor. Indicators of viral infection inhibition include decreased viral titer, a decrease in detectable viral antigen, or an increase in anti-viral antibody titer.

When the subject treated with a therapeutic gene expression vector or a recombinant virus is a human, then the therapy is preferably somatic cell gene therapy. That is, the preferred treatment of a human with a therapeutic gene expression vector or a recombinant virus does not entail introducing into cells a nucleic acid molecule that can form part of a human germ line and be passed onto successive generations (*i.e.*, human germ line gene therapy).

14. Production of Transgenic Mice

Transgenic mice can be engineered to over-express the *Zinf2* gene in all tissues or under the control of a tissue-specific or tissue-preferred regulatory element. These over-producers of *Zinf2* can be used to characterize the phenotype that results from over-expression, and the transgenic animals can serve as models for human disease caused by excess *Zinf2*. Transgenic mice that over-express *Zinf2* also provide model bioreactors for production of *Zinf2* in the milk or blood of larger animals. Methods for producing transgenic mice are well-known to those of skill in the art (see, for example, Jacob, "Expression and Knockout of Interferons in Transgenic Mice," in *Overexpression and Knockout of Cytokines in Transgenic Mice*, Jacob (ed.), pages 111-124 (Academic Press, Ltd. 1994), Monastersky and Robl (eds.), *Strategies in Transgenic Animal Science* (ASM Press 1995), and Abbud and Nilson, "Recombinant Protein Expression in Transgenic Mice," in *Gene Expression Systems: Using Nature for the Art of Expression*, Fernandez and Hoeffler (eds.), pages 367-397 (Academic Press, Inc. 1999)).

For example, a method for producing a transgenic mouse that expresses a *Zinf2* gene can begin with adult, fertile males (studs) (B6C3f1, 2-8 months of age (Taconic Farms, Germantown, NY)), vasectomized males (duds) (B6D2f1, 2-8 months, (Taconic Farms)), prepubescent fertile females (donors) (B6C3f1, 4-5 weeks, (Taconic Farms)) and adult fertile females (recipients) (B6D2f1, 2-4 months, (Taconic Farms)). The donors are acclimated for one week and then injected with approximately 8 IU/mouse of Pregnant Mare's Serum gonadotrophin (Sigma Chemical Company; St. Louis, MO) I.P., and 46-47 hours later, 8 IU/mouse of human Chorionic Gonadotropin (hCG (Sigma)) I.P. to induce superovulation. Donors are mated with studs subsequent to hormone injections. Ovulation generally occurs within 13 hours of hCG injection. Copulation is confirmed by the presence of a vaginal plug the morning following mating.

Fertilized eggs are collected under a surgical scope. The oviducts are collected and eggs are released into urinalysis slides containing hyaluronidase (Sigma). Eggs are washed once in hyaluronidase, and twice in Whitten's W640 medium (described, for example, by Menino and O'Claray, *Biol. Reprod.* 77:159 (1986), and Dienhart and Downs, *Zygote* 4:129 (1996)) that has been incubated with 5% CO₂, 5% O₂, and 90% N₂ at 37°C. The eggs are then stored in a 37°C/5% CO₂ incubator until microinjection.

Ten to twenty micrograms of plasmid DNA containing a *Zinf2* encoding sequence is linearized, gel-purified, and resuspended in 10 mM Tris-HCl (pH 7.4), 0.25 mM EDTA (pH 8.0), at a final concentration of 5-10 nanograms per microliter for microinjection. For example, the *Zinf2* encoding sequences can encode a polypeptide comprising amino acid residues 28 to 207 of SEQ ID NO:2.

Plasmid DNA is microinjected into harvested eggs contained in a drop of W640 medium overlaid by warm, CO₂-equilibrated mineral oil. The DNA is drawn into an injection needle (pulled from a 0.75mm ID, 1mm OD borosilicate glass capillary), and injected into individual eggs. Each egg is penetrated with the injection needle, into one or both of the haploid pronuclei.

Picoliters of DNA are injected into the pronuclei, and the injection needle withdrawn without coming into contact with the nucleoli. The procedure is repeated until all the eggs are injected. Successfully microinjected eggs are transferred into an organ tissue-culture dish with pre-gassed W640 medium for storage overnight in a 37°C/5% CO₂ incubator.

The following day, two-cell embryos are transferred into pseudopregnant recipients. The recipients are identified by the presence of copulation plugs, after copulating with vasectomized duds. Recipients are anesthetized and shaved on the

dorsal left side and transferred to a surgical microscope. A small incision is made in the skin and through the muscle wall in the middle of the abdominal area outlined by the ribcage, the saddle, and the hind leg, midway between knee and spleen. The reproductive organs are exteriorized onto a small surgical drape. The fat pad is stretched out over the surgical drape, and a baby serrefine (Roboz, Rockville, MD) is attached to the fat pad and left hanging over the back of the mouse, preventing the organs from sliding back in.

With a fine transfer pipette containing mineral oil followed by alternating W640 and air bubbles, 12-17 healthy two-cell embryos from the previous day's injection are transferred into the recipient. The swollen ampulla is located and holding the oviduct between the ampulla and the bursa, a nick in the oviduct is made with a 28 g needle close to the bursa, making sure not to tear the ampulla or the bursa.

The pipette is transferred into the nick in the oviduct, and the embryos are blown in, allowing the first air bubble to escape the pipette. The fat pad is gently pushed into the peritoneum, and the reproductive organs allowed to slide in. The peritoneal wall is closed with one suture and the skin closed with a wound clip. The mice recuperate on a 37°C slide warmer for a minimum of four hours.

The recipients are returned to cages in pairs, and allowed 19-21 days gestation. After birth, 19-21 days postpartum is allowed before weaning. The weanlings are sexed and placed into separate sex cages, and a 0.5 cm biopsy (used for genotyping) is snipped off the tail with clean scissors.

Genomic DNA is prepared from the tail snips using, for example, a QIAGEN DNEASY kit following the manufacturer's instructions. Genomic DNA is analyzed by PCR using primers designed to amplify a *Zinf2* gene or a selectable marker gene that was introduced in the same plasmid. After animals are confirmed to be transgenic, they are back-crossed into an inbred strain by placing a transgenic female with a wild-type male, or a transgenic male with one or two wild-type female(s). As pups are born and weaned, the sexes are separated, and their tails snipped for genotyping.

To check for expression of a transgene in a live animal, a partial hepatectomy is performed. A surgical prep is made of the upper abdomen directly below the zyphoid process. Using sterile technique, a small 1.5-2 cm incision is made below the sternum and the left lateral lobe of the liver exteriorized. Using 4-0 silk, a tie is made around the lower lobe securing it outside the body cavity. An atraumatic clamp is used to hold the tie while a second loop of absorbable Dexon (American Cyanamid; Wayne, N.J.) is placed proximal to the first tie. A distal cut is made from the Dexon tie and approximately 100 mg of the excised liver tissue is placed in a sterile petri dish.

The excised liver section is transferred to a 14 ml polypropylene round bottom tube and snap frozen in liquid nitrogen and then stored on dry ice. The surgical site is closed with suture and wound clips, and the animal's cage placed on a 37°C heating pad for 24 hours post operatively. The animal is checked daily post operatively and the wound clips removed 7-10 days after surgery. The expression level of Zinf2 mRNA is examined for each transgenic mouse using an RNA solution hybridization assay or polymerase chain reaction.

In addition to producing transgenic mice that over-express Zinf2, it is useful to engineer transgenic mice with either abnormally low or no expression of the gene. Such transgenic mice provide useful models for diseases associated with a lack of Zinf2. As discussed above, *Zinf2* gene expression can be inhibited using anti-sense genes, ribozyme genes, or external guide sequence genes. To produce transgenic mice that under-express the *Zinf2* gene, such inhibitory sequences are targeted to *Zinf2* mRNA. Methods for producing transgenic mice that have abnormally low expression of a particular gene are known to those in the art (see, for example, Wu *et al.*, "Gene Underexpression in Cultured Cells and Animals by Antisense DNA and RNA Strategies," in *Methods in Gene Biotechnology*, pages 205-224 (CRC Press 1997)).

An alternative approach to producing transgenic mice that have little or no *Zinf2* gene expression is to generate mice having at least one normal *Zinf2* allele replaced by a nonfunctional *Zinf2* gene. One method of designing a nonfunctional *Zinf2* gene is to insert another gene, such as a selectable marker gene, within a nucleic acid molecule that encodes Zinf2. Standard methods for producing these so-called "knockout mice" are known to those skilled in the art (see, for example, Jacob, "Expression and Knockout of Interferons in Transgenic Mice," in *Overexpression and Knockout of Cytokines in Transgenic Mice*, Jacob (ed.), pages 111-124 (Academic Press, Ltd. 1994), and Wu *et al.*, "New Strategies for Gene Knockout," in *Methods in Gene Biotechnology*, pages 339-365 (CRC Press 1997)).

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

EXAMPLE 1

Anti-viral Activity of Zinf2

The anti-viral activity of Zinf2 is examined using mouse fibroblast cells (L929) and human cervical carcinoma cells (HeLa). On the first day, 50,000 cells and various concentrations of conditioned medium samples are distributed per well of a

multi-well plate. A sample comprising Zinf2 is tested with both L929 cells and HeLa cells. Following a 24 hour incubation at 37°C, the culture medium is removed, and replaced with medium containing encephalomyocarditis virus at a multiplicity of infection of 0.1. The cells are again incubated for 24 hours at 37°C. Culture wells are then scored visually for the presence of cytopathic effect.

EXAMPLE 2

Inhibition of the Proliferation of a Human Burkitt Lymphoma B Cell Line by Zinf2

A liposome-mediated transfection procedure is used to introduce Zinf2 expression vectors into baby hamster kidney cells (BHK-570; ATCC CRL 10314). These vectors comprise a *dihydrofolate reductase* gene, and nucleotide sequences that encode Zinf2. The Zinf2 gene is operably linked with a cytomegalovirus promoter. Transfected cells are selected by incubation with methotrexate to 3 μ M.

To prepare conditioned media samples, cells approaching confluent growth are incubated in base Dulbecco's Modified Eagle Medium (high glucose) containing L-glutamine, sodium pyruvate, and HEPES buffer. The cultures are incubated for 48 hours, and then conditioned medium samples were collected, filter-sterilized, and stored at 4°C. Millipore Ultrafree-15 Centrifugal Filter Devices (molecular weight cut-off of 5000) are used to concentrate conditioned medium samples. In brief, filter columns are centrifuged chilled at approximately 1300xG for 30 minutes to reduce the volume 50-fold, and 50x concentrated conditioned medium is then sterilized with a 0.2 μ M filter and stored at 4°C. The 50x concentrated conditioned medium is diluted in standard Daudi medium (RPMI 1640 with 2mM L-glutamine, 0.075% NaHCO₃, 20mM HEPES buffer, 1mM sodium pyruvate, 4.5g/L glucose) for cell proliferation studies.

The effect of Zinf2 on human B cell lymphoma cells is tested with a Daudi cell proliferation assay. Daudi cells are harvested and diluted to 100,000 cells/ml in standard Daudi medium with 10% fetal bovine serum. Conditioned medium samples are diluted in serum-free Daudi medium, and the samples are added in 100 μ l aliquots to the wells of a 96-well flat bottom plate in triplicate. Each well then receives 10,000 cells (100 μ l), and the cells and test samples are mixed with a multi-channel pipette. After a three-day incubation at 37°C, 1 μ Ci of ³H-thymidine is added per well, and the cells are incubated for six hours at 37°C. Daudi cells are harvested onto a filter mat, washed 10 times, and dried for one hour at 37°C. About 25 μ l of scintillation fluid are added to each sample, and the counts per minute for each mixture are measured with a scintillation counter. Inhibition of cell proliferation is indicated by a decrease in the incorporation of tritiated thymidine.

5 From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

I claim:

1. An isolated polypeptide, comprising an amino acid sequence selected from the group consisting of:
 - a) the amino acid sequence of SEQ ID NO:2;
 - b) amino acid residues 1 to 198 of SEQ ID NO:2;
 - c) amino acid residues 25 to 198 of SEQ ID NO:2;
 - d) the amino acid sequence of SEQ ID NO:5;
 - e) amino acid residues 1 to 180 of SEQ ID NO:5; and
 - f) amino acid residues 25 to 180 of SEQ ID NO:5.
2. An isolated nucleic acid molecule, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:6, (b) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:5, and (c) a nucleic acid molecule that remains hybridized following stringent wash conditions to a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: nucleotides 88 to 540 of SEQ ID NO:4, nucleotides 1 to 540 of SEQ ID NO:4, or the complement thereof.
3. The isolated nucleic acid molecule of claim 2, wherein any difference between the amino acid sequence encoded by the nucleic acid molecule and the corresponding amino acid sequence of SEQ ID NO:2, is due to a conservative amino acid substitution.
4. The isolated nucleic acid molecule of claim 2, comprising the nucleotide sequence of SEQ ID NO:1.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: nucleotides 88 to 594 of SEQ ID NO:1, or nucleotides 88 to 540 of SEQ ID NO:4.
6. A vector, comprising the isolated nucleic acid molecule of claim 5.
7. An expression vector, comprising the isolated nucleic acid molecule of claim 5, a transcription promoter, and a transcription terminator, wherein the promoter is

operably linked with the nucleic acid molecule, and wherein the nucleic acid molecule is operably linked with the transcription terminator.

8. The expression vector of claim 7 further encoding an affinity tag.
9. A recombinant host cell comprising the expression vector of claim 7, wherein the host cell is selected from the group consisting of bacterium, yeast cell, fungal cell, insect cell, mammalian cell, avian, and plant cell.
10. A method of using the expression vector of claim 7 to produce Zinf2 protein, comprising culturing recombinant host cells that comprise the expression vector and that produce the Zinf2 protein.
11. The protein produced by the method of claim 10.
12. The method of claim 10, further comprising isolating the Zinf2 protein from the cultured recombinant host cells.
13. An antibody or antibody fragment that specifically binds with the polypeptide of claim 1.
14. The antibody of claim 13, wherein the antibody is selected from the group consisting of: (a) polyclonal antibody, (b) murine monoclonal antibody, (c) humanized antibody derived from (b), and (d) human monoclonal antibody.
15. An anti-idiotypic antibody that specifically binds with the antibody or antibody fragment of claim 13.
16. A method of detecting the presence of Zinf2 gene expression in a biological sample, comprising:
 - (a) contacting a Zinf2 nucleic acid probe under hybridizing conditions with either (i) test RNA molecules isolated from the biological sample, or (ii) nucleic acid molecules synthesized from the isolated RNA molecules, wherein the probe consists of a nucleotide sequence comprising a portion of the nucleotide sequence of the nucleic acid molecule of claim 5, or complements thereof, and

(b) detecting the formation of hybrids of the nucleic acid probe and either the test RNA molecules or the synthesized nucleic acid molecules,

wherein the presence of the hybrids indicates the presence of Zinf2 RNA in the biological sample,

or,

(a') contacting the biological sample with an antibody, or an antibody fragment, of claim 13, wherein the contacting is performed under conditions that allow the binding of the antibody or antibody fragment to the biological sample, and

(b') detecting any of the bound antibody or bound antibody fragment.

17. An isolated polypeptide, comprising an amino acid sequence selected from the group consisting of: the amino acid sequence of amino acid residues 25 to 180 of SEQ ID NO:2, and the amino acid sequence of SEQ ID NO:2.

18. A composition, comprising a carrier and the polypeptide of claim 15.

INA1_HUMAN	MASPFALLMVLVVLSCKSSCSLGCDLPETHSLDN-RRTLMLLAQMSRISP
INA6_HUMAN	MALPFALLMALVVLSCKSSCSLDCDLPQTHSLGH-RRTMMLLAQMRRISL
INAA_HUMAN	MALSFSLLMAVLVLSYKSICSLGCDLPQTHSLGN-RRALILLGQMGRISP
INAG_HUMAN	MALSFSLLMAVLVLSYKSICSLGCDLPQTHSLGN-RRALILLAQMGRISP
INA4_HUMAN	MALSFSLLMAVLVLSYKSICSLGCDLPQTHSLGN-RRALILLAQMGRISH
INA7_HUMAN	MARSFSLLMVVLVLSYKSICSLGCDLPQTHSLRN-RRALILLAQMGRISP
INAK_HUMAN	MALSFSLLMAVLVLSYKSICSLGCDLPQTHSLGN-RRALILLAQMGRISP
INAF_HUMAN	MALSFSLLMAVLVLSYKSICSLGCDLPQTHSLGN-RRALILLAQMGRISH
INAD_HUMAN	MALPFALMMALVVLSCKSSCSLGCDLQTHSLNN-RRTLMLMAQMRRISP
INA8_HUMAN	MALTFYLLVALVVLVSFSSLGCDLPQTHSLGN-RRALILLAQMRRISP
SEQ ID NO:2	MALPTFSLVXLXMMFSSFLCTLSCDLAQPARS---RRTFTVLHQMEESSF
SEQ ID NO:5	MALPTFSLVXLXMMFSSFLCTLSCDLAQPARS---RRTFTVLHQMEESSF
PIR_A48772	MAQ-IYLMAGVMLCSISVCFLDQNL SAVHCEK-REIFKHLQEIKKIPS

INA1_HUMAN	SSCLMDRHDGFGFPQEEFDGNQFQKAP AISVLHELIQQIFNLFTTKDSSAA
INA6_HUMAN	FSCLKDRHDFRFPQEEFDGNQFQKAE AISVLHEVIQQTFNLFSTKDSSVA
INAA_HUMAN	FSCLKDRHDFRIPQEEFDGNQFQKAQ AISVLHEMIQQTFNLFSTEDSSAA
INAG_HUMAN	FSCLKDRHDFGLPQEEFDGNQFQKTQ AISVLHEMIQQTFNLFSTEDSSAA
INA4_HUMAN	FSCLKDRHDFGFPPEEFDGHQFQKTQ AISVLHEMIQQTFNLFSTEDSSAA
INA7_HUMAN	FSCLKDRHDFRFPPEEFDGHQFQKTQ AISVLHEMIQQTFNLFSTEDSSAA
INAK_HUMAN	FSCLKDRHDFGFPQEEFDGNQFQKAQ AISVLHEMIQQTFNLFSTKDSSAT
INAF_HUMAN	FSCLKDRYDFGFPQEVFDGNQFQKAQ AISAFHEMIQQTFNLFSTKDSSAA
INAD_HUMAN	FSCLKDRHDFEFPQEEFDGNQFQKAQ AISVLHEMMQQTFNLFSTKNSSAA
INA8_HUMAN	FSCLKDRHDFEFPQEEFDDKQFQKAQ AISVLHEMIQQTFNLFSTKDSSAA
SEQ ID NO:2	SSCLKDKNVFRFSWSQMDGTFQKAQATNILHEMIQQISNVFSTKGS---
SEQ ID NO:5	SSCLKDKNVFRFSWSQMDGTFQKAQATNILHEMIQQISNVFSTKGS---
PIR_A48772	QLCLKDRIDFKFPWKRESITQIQKTEGTCYCYLMLQQISSVFSKKDSRAA

INA1_HUMAN	WDEDLLDKFCTELYQQLNDLEACVMQEER-VGETPLMNADSI-----
INA6_HUMAN	WDERLLDKLYTELYQQLNDLEACVMQEVW-VGGTPLMNEDSI-----
INAA_HUMAN	WEQSLLEKFSTELYQQLNDLEACVIEVG-VEETPLMNEDSI-----
INAG_HUMAN	WEQSLLEKFSTELYQQLNNLEACVIEVG-MEETPLMNEDSI-----
INA4_HUMAN	WEQSLLEKFSTELYQQLNDLEACVIEVG-VEETPLMNVDSI-----
INA7_HUMAN	WEQSLLEKFSTELYQQLNDLEACVIEVG-VEETPLMNEDFI-----
INAK_HUMAN	WEQSLLEKFSTELNQQLNDEACVIEVG-VEETPLMNVDSI-----
INAF_HUMAN	WDETLLDKFYIELFQQLNDLEACVTQEVG-VEEIALMNEDSI-----
INAD_HUMAN	WDETLLDKFYIELFQQMNDLEACVIEVG-VEETPLMNEDSI-----
INA8_HUMAN	LDETLLDEFYIELDQQLNDLESCVMQEVG-VIESPLMYEDSI-----
SEQ ID NO:2	-----NSLTGLGQQLEFLENLEQE---MEET--LGRTPA-----
SEQ ID NO:5	-----NSLTGLGQQLEFLENLEQE---MEET--LGRTPA-----
PIR_A48772	WNNTLLDQLLSSLDLGLRRLEHMKKDN---MDCPHVG-S-----

FIGURE 1A

INA1_HUMAN	----LAVKKYFRRITLYLTEKKYSPCAWEVVRAEIMRS-----LSLSTNL
INA6_HUMAN	----LAVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRS-----FSSSRNL
INAA_HUMAN	----LAVRKYFQRITLYLIERKYSPCAWEVVRAEIMRS-----LSFSTNL
INAG_HUMAN	----LAVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRS-----LSFSTNL
INA4_HUMAN	----LAVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRS-----LSFSTNL
INA7_HUMAN	----LAVRKYFQRITLYLMEKKYSPCAWEVVRAEIMRS-----FSFSTNL
INAK_HUMAN	----LAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRS-----FSLSKIF
INAF_HUMAN	----LAVRKYFQRITLYLMGKKYSPCAWEVVRAEIMRS-----FSFSTNL
INAD_HUMAN	----LAVKKYFQRITLYLMEKKYSPCAWEVVRAEIMRS-----LSFSTNL
INA8_HUMAN	----LAVRKYFQRITLYLTEKKYSSCAWEVVRAEIMRS-----FSLSINL
SEQ ID NO:2	----LAVMGYSQRTSLYLKKKVHSCCAQDIVLPEIKKSKSVSYFSVLIGL
SEQ ID NO:5	----LAVMGYSQRTSLYLKKKVHSCCAQDIVLPEIKKSKSVSYFSVLIGL
PIR_A48772	----ALRKYFQGIQLYLKEKKYSPCAWEIVRVEIERC-----FSLT---

INA1_HUMAN	QER--LRRKE-----
INA6_HUMAN	QER--LRRKE-----
INAA_HUMAN	QKR--LRRKD-----
INAG_HUMAN	QKI--LRRKD-----
INA4_HUMAN	QKR--LRRKD-----
INA7_HUMAN	KKG--LRRKD-----
INAK_HUMAN	QER--LRRKE-----
INAF_HUMAN	QKG--LRRKD-----
INAD_HUMAN	QKR--LRRKD-----
INA8_HUMAN	QKR--LKSKE-----
SEQ ID NO:2	SENSEVWRRDLVDNLILVSWVSSINLLL
SEQ ID NO:2	SENSEVWRRD-----
PIR_A48772	-----

FIGURE 1B

1

SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> HUMAN INTERFERON, ZINF2

<130> 00-31PC

<150> 60/198,889

<151> 2000-04-14

<160> 9

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 594

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(594)

<221> mat_peptide

<222> (88)...(594)

<221> variation

<222> (28)...(28)

<223> n = a or g

<221> variation

<222> (35)...(35)

<223> n = g or t

<221> misc_feature

<222> (1)...(594)

<223> n = A,T,C or G

<400> 1

atg gcc ctg cca acc ttt tca cta gtg nca ctg ang atg atg ttc tcc
 Met Ala Leu Pro Thr Phe Ser Leu Val Xaa Leu Xaa Met Met Phe Ser
 1 5 10 15

48

agc ttt ctc tgt acc ctt agc tgt gac ctg gcc cag cct gcc aga agc	96
Ser Phe Leu Cys Thr Leu Ser Cys Asp Leu Ala Gln Pro Ala Arg Ser	
20 25 30	
agg aga acc ttc aca gtt ctt cac caa atg gaa gaa tct tcc ttt tct	144
Arg Arg Thr Phe Thr Val Leu His Gln Met Glu Glu Ser Ser Phe Ser	
35 40 45	
tcc tgt ctg aag gac aag aat gtt ttc agg ttc tcc tgg agc cag atg	192
Ser Cys Leu Lys Asp Lys Asn Val Phe Arg Phe Ser Trp Ser Gln Met	
50 55 60	
gat ggc acc aaa ttc caa aag gct cag gcc acc aat att ctc cat gag	240
Asp Gly Thr Lys Phe Gln Lys Ala Gln Ala Thr Asn Ile Leu His Glu	
65 70 75 80	
atg atc cag cag atc tcc aat gtt ttc agc aca aag ggc tca aat tcc	288
Met Ile Gln Gln Ile Ser Asn Val Phe Ser Thr Lys Gly Ser Asn Ser	
85 90 95	
ctc act ggg ctt ggt cag cag cta gaa ttt ctg gag aac tgt ttg gaa	336
Leu Thr Gly Leu Gly Gln Gln Leu Glu Phe Leu Glu Asn Cys Leu Glu	
100 105 110	
cag gaa atg gaa gag acc ttg ggt aga act cca gcc ctg gct gtg atg	384
Gln Glu Met Glu Glu Thr Leu Gly Arg Thr Pro Ala Leu Ala Val Met	
115 120 125	
ggt tat tcc caa agg acc agt ctc tac ctg aaa aag aaa gta cat agc	432
Gly Tyr Ser Gln Arg Thr Ser Leu Tyr Leu Lys Lys Lys Val His Ser	
130 135 140	
tgc tgt gcc cag gac att gtc cta cca gaa att aag aag tca aaa tca	480
Cys Cys Ala Gln Asp Ile Val Leu Pro Glu Ile Lys Lys Ser Lys Ser	
145 150 155 160	
gta agt tat ttc tct gtg cta ata ggc tta tca gaa aac tca gaa gtt	528
Val Ser Tyr Phe Ser Val Leu Ile Gly Leu Ser Glu Asn Ser Glu Val	
165 170 175	
tgg aga aga gac tta gac gta aac ctc att ttg gtc agt tgg gtc tca	576
Trp Arg Arg Asp Leu Asp Val Asn Leu Ile Leu Val Ser Trp Val Ser	
180 185 190	

tct att aat ttg ttg ctt
 Ser Ile Asn Leu Leu Leu
 195

594

<210> 2
 <211> 198
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> (10)...(10)
 <223> Xaa = Thr or Ala

<221> VARIANT
 <222> (12)...(12)
 <223> Xaa = Arg or Met

<221> VARIANT
 <222> (1)...(198)
 <223> Xaa = Any Amino Acid

<400> 2
 Met Ala Leu Pro Thr Phe Ser Leu Val Xaa Leu Xaa Met Met Phe Ser
 1 5 10 15
 Ser Phe Leu Cys Thr Leu Ser Cys Asp Leu Ala Gln Pro Ala Arg Ser
 20 25 30
 Arg Arg Thr Phe Thr Val Leu His Gln Met Glu Glu Ser Ser Phe Ser
 35 40 45
 Ser Cys Leu Lys Asp Lys Asn Val Phe Arg Phe Ser Trp Ser Gln Met
 50 55 60
 Asp Gly Thr Lys Phe Gln Lys Ala Gln Ala Thr Asn Ile Leu His Glu
 65 70 75 80
 Met Ile Gln Gln Ile Ser Asn Val Phe Ser Thr Lys Gly Ser Asn Ser
 85 90 95
 Leu Thr Gly Leu Gly Gln Gln Leu Glu Phe Leu Glu Asn Cys Leu Glu
 100 105 110
 Gln Glu Met Glu Glu Thr Leu Gly Arg Thr Pro Ala Leu Ala Val Met
 115 120 125
 Gly Tyr Ser Gln Arg Thr Ser Leu Tyr Leu Lys Lys Lys Val His Ser
 130 135 140

Cys Cys Ala Gln Asp Ile Val Leu Pro Glu Ile Lys Lys Ser Lys Ser
 145 150 155 160
 Val Ser Tyr Phe Ser Val Leu Ile Gly Leu Ser Glu Asn Ser Glu Val
 165 170 175
 Trp Arg Arg Asp Leu Asp Val Asn Leu Ile Leu Val Ser Trp Val Ser
 180 185 190
 Ser Ile Asn Leu Leu Leu
 195

<210> 3
 <211> 594
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> degenerate sequence

<221> misc_feature
 <222> (1)...(594)
 <223> n = A,T,C or G

<400> 3
 atggcnytn cnacltlyws nytnngtnnnn ytnnnnatga tglttywsnws nttyytntgy 60
 acnytnwsnt gygayytngc ncarccngcn mgnwsnmgnm gnacnttyac ngtnytnca 120
 caratggarg arwsnwsntt ywsnwsntgy ytnaargaya araaygtntt ymgnttywsn 180
 tggwsncara tggayggnac naarttycar aargcncarg cnaclnaayat hytnca 240
 atgathcarc arathwsnaa ygtnttywsn acnaarggnw snaaywsnyt nacnggnytn 300
 ggncarcary tngarttyyt ngaraaytgy ytngarcarg aratggarga racnytnngn 360
 mgnacnccng cnytnngcngt natgggntay wsncarmgna cnwsnytna yytnaaraar 420
 aargtncayw sntgytgygc ncargayath gtntnccng arathaaraa rwsnaarwsn 480
 gtnwsntayt tywsngtnyt nathggnytn wsngaraayw sngargtntg gmgnmgngay 540
 ytngaygtna ayytnathyt ngtnwsntgg gtnwsnwsna thaayytnyt nytn 594

<210> 4
 <211> 540
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(540)
 <221> mat_peptide

<222> (88)...(540)

<221> variation

<222> (28)...(28)

<223> n = a or g

<221> variation

<222> (35)...(35)

<223> n = g or t

<221> misc_feature

<222> (1)...(540)

<223> n = A,T,C or G

<400> 4

atg gcc ctg cca acc ttt tca cta gtg nca ctg ang atg atg ttc tcc	48
Met Ala Leu Pro Thr Phe Ser Leu Val Xaa Leu Xaa Met Met Phe Ser	
1 5 10 15	
agc ttt ctc tgt acc ctt agc tgt gac ctg gcc cag cct gcc aga agc	96
Ser Phe Leu Cys Thr Leu Ser Cys Asp Leu Ala Gln Pro Ala Arg Ser	
20 25 30	
agg aga acc ttc aca gtt ctt cac caa atg gaa gaa tct tcc ttt tct	144
Arg Arg Thr Phe Thr Val Leu His Gln Met Glu Glu Ser Ser Phe Ser	
35 40 45	
tcc tgt ctg aag gac aag aat gtt ttc agg ttc tcc tgg agc cag atg	192
Ser Cys Leu Lys Asp Lys Asn Val Phe Arg Phe Ser Trp Ser Gln Met	
50 55 60	
gat ggc acc aaa ttc caa aag gct cag gcc acc aat att ctc cat gag	240
Asp Gly Thr Lys Phe Gln Lys Ala Gln Ala Thr Asn Ile Leu His Glu	
65 70 75 80	
atg atc cag cag atc tcc aat gtt ttc agc aca aag ggc tca aat tcc	288
Met Ile Gln Gln Ile Ser Asn Val Phe Ser Thr Lys Gly Ser Asn Ser	
85 90 95	
ctc act ggg ctt ggt cag cag cta gaa ttt ctg gag aac tgt ttg gaa	336
Leu Thr Gly Leu Gly Gln Gln Leu Glu Phe Leu Glu Asn Cys Leu Glu	
100 105 110	

cag gaa atg gaa gag acc ttg ggt aga act cca gcc ctg gct gtg atg	384
Gln Glu Met Glu Glu Thr Leu Gly Arg Thr Pro Ala Leu Ala Val Met	
115 120 125	
ggg tat tcc caa agg acc agt ctc tac ctg aaa aag aaa gta cat agc	432
Gly Tyr Ser Gln Arg Thr Ser Leu Tyr Leu Lys Lys Lys Val His Ser	
130 135 140	
tgc tgt gcc cag gac att gtc cta cca gaa att aag aag tca aaa tca	480
Cys Cys Ala Gln Asp Ile Val Leu Pro Glu Ile Lys Lys Ser Lys Ser	
145 150 155 160	
gta agt tat ttc tct gtg cta ata ggc tta tca gaa aac tca gaa gtt	528
Val Ser Tyr Phe Ser Val Leu Ile Gly Leu Ser Glu Asn Ser Glu Val	
165 170 175	
tgg aga aga gac	540
Trp Arg Arg Asp	
180	

<210> 5
 <211> 180
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> (10)...(10)
 <223> Xaa = Thr or Ala

<221> VARIANT
 <222> (12)...(12)
 <223> Xaa = Arg or Met

<221> VARIANT
 <222> (1)...(180)
 <223> Xaa = Any Amino Acid

<400> 5

Met	Ala	Leu	Pro	Thr	Phe	Ser	Leu	Val	Xaa	Leu	Xaa	Met	Met	Phe	Ser
1							5		10					15	

Ser Phe Leu Cys Thr Leu Ser Cys Asp Leu Ala Gln Pro Ala Arg Ser
 20 25 30
 Arg Arg Thr Phe Thr Val Leu His Gln Met Glu Glu Ser Ser Phe Ser
 35 40 45
 Ser Cys Leu Lys Asp Lys Asn Val Phe Arg Phe Ser Trp Ser Gln Met
 50 55 60
 Asp Gly Thr Lys Phe Gln Lys Ala Gln Ala Thr Asn Ile Leu His Glu
 65 70 75 80
 Met Ile Gln Gln Ile Ser Asn Val Phe Ser Thr Lys Gly Ser Asn Ser
 85 90 95
 Leu Thr Gly Leu Gly Gln Gln Leu Glu Phe Leu Glu Asn Cys Leu Glu
 100 105 110
 Gln Glu Met Glu Glu Thr Leu Gly Arg Thr Pro Ala Leu Ala Val Met
 115 120 125
 Gly Tyr Ser Gln Arg Thr Ser Leu Tyr Leu Lys Lys Lys Val His Ser
 130 135 140
 Cys Cys Ala Gln Asp Ile Val Leu Pro Glu Ile Lys Lys Ser Lys Ser
 145 150 155 160
 Val Ser Tyr Phe Ser Val Leu Ile Gly Leu Ser Glu Asn Ser Glu Val
 165 170 175
 Trp Arg Arg Asp
 180

<210> 6

<211> 540

<212> DNA

<213> Artificial Sequence

<220>

<223> degenerate sequence

<221> misc_feature

<222> (1)...(540)

<223> n = A,T,C or G

<400> 6

atggcnytn cncanttyws nytngtnnnn ytnnnnatga tgattywsnws nttyytntgy 60
 acnytnwsnt gygayytngc ncarccngcn mgnwsnmgnm gnacnttyac ngtnytnca 120
 caratggarg arwsnwsntt ywsnwsntgy ytnaargaya araaygtntt ymgnttywsn 180
 tggwsncara tggayggnac naarttycar aargcncarg cncnaayat hytnca 240
 atgathcarc arathwsnaa ygtnttywsn acnaarggnw snaaywsnyt nacnggnytn 300
 ggncarcary tngarttyyt ngaraaytgy ytnargcarg aratggarga racnytnngn 360
 mgnacncng cnytnngnt natgggntay wsncarmgna cnwsnynta yytnaaraar 420

aargtncayw sntgytgygc ncargayath gtnytnccng arathaaraa rwsnaarwsn 480
 gtnwsntayt tywsngtnyt nathggnytn wsngaraayw sngargtntg gmgnmgngay 540

<210> 7

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker

<400> 7

Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

<210> 8

<211> 208

<212> PRT

<213> Homo sapiens

<400> 8

Met. Ile Ile Lys His Phe Phe Gly Thr Val Leu Val Leu Leu Ala Ser
 1 5 10 15
 Thr Thr Ile Phe Ser Leu Asp Leu Lys Leu Ile Ile Phe Gln Gln Arg
 20 25 30
 Gln Val Asn Gln Glu Ser Leu Lys Leu Leu Asn Lys Leu Gln Thr Leu
 35 40 45
 Ser Ile Gln Gln Cys Leu Pro His Arg Lys Asn Phe Leu Leu Pro Gln
 50 55 60
 Lys Ser Leu Ser Pro Gln Gln Tyr Gln Lys Gly His Thr Leu Ala Ile
 65 70 75 80
 Leu His Glu Met Leu Gln Gln Ile Phe Ser Leu Phe Arg Ala Asn Ile
 85 90 95
 Ser Leu Asp Gly Trp Glu Glu Asn His Thr Glu Lys Phe Leu Ile Gln
 100 105 110
 Leu His Gln Gln Leu Glu Tyr Leu Glu Ala Leu Met Gly Leu Glu Ala
 115 120 125
 Glu Lys Leu Ser Gly Thr Leu Gly Ser Asp Asn Leu Arg Leu Gln Val
 130 135 140
 Lys Met Tyr Phe Arg Arg Ile His Asp Tyr Leu Glu Asn Gln Asp Tyr
 145 150 155 160

Ser Thr Cys Ala Trp Ala Ile Val Gln Val Glu Ile Ser Arg Cys Leu
 165 170 175
 Phe Phe Val Phe Ser Leu Thr Glu Lys Leu Ser Lys Gln Gly Arg Pro
 180 185 190
 Leu Asn Asp Met Lys Gln Glu Leu Thr Thr Glu Phe Arg Ser Pro Arg
 195 200 205

<210> 9
 <211> 208
 <212> PRT
 <213> Homo sapiens

<400> 9
 Met Ile Ile Lys His Phe Phe Gly Thr Val Leu Val Leu Leu Ala Ser
 1 5 10 15
 Thr Thr Ile Phe Ser Leu Asp Leu Lys Leu Ile Ile Phe Gln Gln Arg
 20 25 30
 Gln Val Asn Gln Glu Ser Leu Lys Leu Leu Asn Lys Leu Gln Thr Leu
 35 40 45
 Ser Ile Gln Gln Cys Leu Pro His Arg Lys Asn Phe Leu Leu Pro Gln
 50 55 60
 Lys Ser Leu Ser Pro Gln Gln Tyr Gln Lys Gly His Ala Leu Ala Ile
 65 70 75 80
 Leu His Glu Met Leu Gln Gln Ile Phe Ser Leu Phe Arg Ala Asn Ile
 85 90 95
 Ser Leu Asp Gly Trp Glu Glu Asn His Thr Glu Lys Phe Leu Ile Gln
 100 105 110
 Leu His Gln Gln Leu Glu Tyr Leu Glu Ala Leu Met Gly Leu Glu Ala
 115 120 125
 Glu Lys Leu Ser Gly Thr Leu Gly Ser Asp Asn Leu Arg Leu Gln Val
 130 135 140
 Lys Met Tyr Phe Arg Arg Ile His Asp Tyr Leu Glu Asn Gln Asp Tyr
 145 150 155 160
 Ser Thr Cys Ala Trp Ala Ile Val Gln Val Glu Ile Ser Arg Cys Leu
 165 170 175
 Phe Phe Val Phe Ser Leu Thr Glu Lys Leu Ser Lys Gln Gly Arg Pro
 180 185 190
 Leu Asn Asp Met Lys Gln Glu Leu Thr Thr Glu Phe Arg Ser Pro Arg
 195 200 205